Original Article
Use of a Monoclonal Antibody Directed against the Platelet Glycoprotein IIb/IIIa Receptor in High-Risk Coronary Angioplasty
N Engl J Med 1994; 330:956-961April 7, 1994
- Abstract
Background
Platelets are believed to play a part in the ischemic complications of coronary angioplasty, such as abrupt closure of the coronary vessel during or soon after the procedure. Accordingly, we evaluated the effect of a chimeric monoclonal-antibody Fab fragment (c7E3 Fab) directed against the platelet glycoprotein IIb/IIIa receptor, in patients undergoing angioplasty who were at high risk for ischemic complications. This receptor is the final common pathway for platelet aggregation.
Methods
In a prospective, randomized, double-blind trial, 2099 patients treated at 56 centers received a bolus and an infusion of placebo, a bolus of c7E3 Fab and an infusion of placebo, or a bolus and an infusion of c7E3 Fab. They were scheduled to undergo coronary angioplasty or atherectomy in high-risk clinical situations involving severe unstable angina, evolving acute myocardial infarction, or high-risk coronary morphologic characteristics. The primary study end point consisted of any of the following: death, nonfatal myocardial infarction, unplanned surgical revascularization, unplanned repeat percutaneous procedure, unplanned implantation of a coronary stent, or insertion of an intraaortic balloon pump for refractory ischemia. The numbers of end-point events were tabulated for 30 days after randomization.
Results
As compared with placebo, the c7E3 Fab bolus and infusion resulted in a 35 percent reduction in the rate of the primary end point (12.8 vs. 8.3 percent, P = 0.008), whereas a 10 percent reduction was observed with the c7E3 Fab bolus alone (12.8 vs. 11.5 percent, P = 0.43). The reduction in the number of events with the c7E3 Fab bolus and infusion was consistent across the end points of unplanned revascularization procedures and nonfatal myocardial infarction. Bleeding episodes and transfusions were more frequent in the group given the c7E3 Fab bolus and infusion than in the other two groups.
Conclusions
Ischemic complications of coronary angioplasty and atherectomy were reduced with a monoclonal antibody directed against the platelet IIb/IIIa glycoprotein receptor, although the risk of bleeding was increased.
Media in This Article
Figure 1
Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots).Table 1
Base-Line Characteristics and Procedures Performed in 2099 Patients at High Risk for Ischemia during Coronary Surgery, According to Treatment Group.Article Activity
- Article
Percutaneous coronary angioplasty is associated with improvement in the symptoms of ischemia and the quality of life,1,2 but acute complications remain a major drawback. The treated vessel closes abruptly during or soon after the procedure in 4 to 9 percent of cases, causing considerable morbidity and an approximately 10-fold increase in mortality3-7. Characteristics that identify patients at high risk for acute complications include the presence of a clinical syndrome associated with coronary thrombus (such as unstable angina or recent myocardial infarction), diabetes, female sex, and complex coronary morphologic features (an angulated arterial segment, thrombus, or bifurcation lesion)3,7-10.
Although aspirin reduces the risk of abrupt vessel closure and acute myocardial infarction in patients undergoing angioplasty,11,12 its effects on platelet function are relatively weak, and ischemic events continue to occur in 10 to 20 percent of patients at high risk who have been treated with aspirin8. The integrin glycoprotein IIb/IIIa receptor on the surface of the platelet, the final common pathway of platelet aggregation,13 binds circulating adhesive macromolecules, particularly fibrinogen and von Willebrand factor, which can then cross-link receptors on adjacent platelets, leading to platelet aggregation.
In 1985 Coller produced a mouse monoclonal antibody, known as 7E3, against this platelet receptor,14 and its antithrombotic effects were demonstrated in animal models15. In pilot studies in patients16 this agent inhibited platelet aggregation by more than 80 percent, thus showing its promising biologic and clinical effects. The current study was designed to determine whether the biologic properties of c7E3 Fab would translate into clinical benefit in the setting of coronary angioplasty or atherectomy.
Methods
Study Population
Patients scheduled to undergo coronary angioplasty or directional atherectomy were eligible for enrollment if they were at high risk for abrupt vessel closure and were not at high risk for bleeding. They were considered to be at high risk for vessel closure if they had one of three clinical features: (1) acute evolving myocardial infarction within 12 hours after the onset of symptoms that necessitated direct or “rescue” percutaneous intervention; (2) early postinfarction angina or unstable angina with at least two episodes of angina at rest associated with changes on resting electrocardiography during the previous 24 hours, despite medical therapy; or (3) clinical or angiographic characteristics indicating high risk, according to the criteria of the American Heart Association and the American College of Cardiology17 as modified by Ellis et al.7. Patients were excluded if they were 80 years old or older, were known to have a bleeding diathesis, had undergone major surgery within the preceding six weeks, or had had a stroke within the preceding two years. Approval was obtained from the institutional review board of each study center, and informed consent from each patient. Patients were recruited between November 1991 and November 1992; 2099 patients were enrolled at 56 institutions in the United States (see the Appendix).
Study Protocol
All the patients were treated with aspirin and heparin. Aspirin was administered orally in a dose of 325 mg at least two hours before angioplasty or atherectomy and daily thereafter. Heparin was given intravenously in an initial bolus dose of 10,000 to 12,000 units followed by incremental bolus doses of up to 3000 units at 15-minute intervals, but no more than 20,000 units was given during the procedure; the goal was to keep the activated clotting time between 300 and 350 seconds during the operation18-20. Heparin was continued by constant infusion for at least 12 hours to maintain the activated partial-thromboplastin time at 1.5 to 2.5 times the control value. The only medication required at discharge was aspirin in a dose of 325 mg per day. The chimeric 7E3 Fab (Centocor, Malvern, Pa.) used in the study is a Fab fragment of a human-mouse genetic reconstruction of a murine monoclonal IgG molecule that binds selectively to the glycoprotein IIb/IIIa platelet receptor. It was supplied as a sterile, nonpyrogenic solution containing 2 mg of monoclonal Fab per milliliter of 0.15 M sodium chloride, 0.01 M sodium phosphate, and 0.001 percent polysorbate 80 (pH 7.2).
Patients were randomly assigned to one of the following three treatment groups according to a double-blind study design: c7E3 Fab in a bolus dose of 0.25 mg per kilogram of body weight, followed by an infusion of 10 μg per minute; c7E3 Fab in a bolus dose of 0.25 mg per kilogram, followed by a placebo infusion; or a placebo bolus and a placebo infusion. The bolus dose was started at least 10 minutes before the procedure and given over a 5-minute period, and the infusion was continued for 12 hours unless a clinical contraindication developed.
Blood samples were obtained 30 minutes and 2, 12, and 24 hours after treatment began and then daily until hospital discharge and were carefully examined for evidence of thrombocytopenia. A predesigned algorithm was used to evaluate and treat life-threatening bleeding and thrombocytopenia,21 although no specific hemoglobin value was used to determine whether red-cell transfusions should be given. Vascular sheaths were maintained for at least six hours after the end of the infusion of the study drug and were left in place at least four hours after the end of the heparin infusion and until an acceptable activated partial-thromboplastin time was achieved to maintain hemostasis.
Study End Points
The primary end point of the trial was a prespecified composite of any of the following events in the first 30 days after randomization: death from any cause, nonfatal myocardial infarction, coronary-artery bypass grafting or repeat percutaneous intervention for acute ischemia, and insertion of a coronary endovascular stent because of procedural failure or placement of an intraaortic counterpulsation balloon pump to relieve refractory ischemia. Events were classified by the consensus of at least two members of an independent clinical-end-points committee blinded to the patients' treatment groups throughout the study.
If a patient entered the trial within 24 hours after an acute evolving myocardial infarction, one of two enzymatic criteria was required for the diagnosis of a subsequent nonfatal infarction: the activity of creatine kinase or its MB isozyme had to be at least three times the upper limit of normal, representing an increase of at least 33 percent from the previous “valley” (defined as a 25 percent decrease from a previous peak value but remaining at least twice the upper limit of normal); or the activity of creatine kinase or the MB isozyme increased by at least 100 percent and remained three times the upper limit of normal after a 50 percent decrease from a previous peak level and a valley level less than twice the upper limit of normal. The MB isozyme value was used (in more than 95 percent of patients) unless it was not available, in which case the value for total creatine kinase was used.
If a patient entered the trial more than 24 hours after an acute infarction or without a recent infarction, one of two criteria had to be met for a diagnosis of in-hospital myocardial infarction: a new Q wave with a duration of at least 0.04 second or a depth of more than one fourth the amplitude of the corresponding R wave in two or more contiguous leads; or an MB isozyme level more than three times the upper limit of normal, representing an increase of 50 percent or more over the previous valley level. After hospital discharge, either a new Q wave with the same adverse characteristics or a creatine kinase or MB isozyme level more than twice the upper limit of normal was required.
Other components of the primary end point were an unplanned repeat angioplasty to treat recurrent ischemia, urgent coronary surgery to treat recurrent ischemia or failure of an angioplasty, placement of an intracoronary stent to treat imminent or complete abrupt closure of the vessel undergoing angioplasty, and placement of an intraaortic balloon pump for recurrent ischemia when a repeat revascularization procedure was contraindicated.
Bleeding events were classified as major, minor, or insignificant according to the criteria of the Thrombolysis in Myocardial Infarction Study Group22. To estimate the total number of units of blood lost in patients who received blood transfusions, the number of units transfused was added to the observed drop in the hematocrit divided by 323.
Data Management and Statistical Analysis
After randomization by telephone, the patients were stratified according to their study center and whether they were having an acute evolving myocardial infarction. On the basis of data from previous trials, this trial was planned to include 2100 patients to detect a reduction of 33 percent in the primary end point (the event rate in the placebo group was predicted to be 15 percent), with a power of 0.8 and an alpha level of 0.05.
Data were collected by study coordinators on case-report forms and monitored by blinded study monitors before data entry. The trial sponsor (Centocor) and the investigators remained blinded to the randomization code and study results until all end points had been agreed on by the clinical-end-points committee and all details of the analysis plan were finalized.
The primary end point of the trial was analyzed by evaluating the time to the first occurrence of any one of the components of the composite end point that occurred within the first 30 days after enrollment. The results in the three treatment groups were displayed as Kaplan-Meier survival curves24 and compared according to the intention-to-treat principle. For the primary end point, a log-rank test for trend was performed in which the group assigned to the bolus of c7E3 Fab ranked between the group assigned to both the bolus and infusion of c7E3 Fab and the group given only placebo25. The analysis plan then called for pairwise log-rank comparisons between the placebo group and each of the two c7E3 Fab groups if the result of the test for trend was significant. Interim analyses were performed when data were available for one third and approximately two thirds of the patients. The nominal alpha level used for judging the significance of the test for trend and the pairwise group comparisons at each interim analysis was prespecified to maintain an overall type I error rate of 0.05. In the final analysis, the level of significance used in comparisons of the primary end point was 0.036. Differences among the treatment groups with respect to each component of the composite end point were also examined in the final analysis, although these comparisons were made for explanatory purposes. The data were presented with nominal two-tailed P values (unadjusted for multiple comparisons); readers can therefore make appropriate adjustments for multiplicity when interpreting the results. The prespecified final analysis also compared the treatment groups with respect to measures of bleeding complications, using conventional chi-square testing. Odds ratios and confidence intervals for the treatment effect in major subgroups (classified according to sex, age, weight, and clinical features at entry) were calculated, with the primary outcome used as a binary end point.
Results
There were no substantial differences among the treatment groups in their base-line clinical characteristics (Table 1Table 1
Base-Line Characteristics and Procedures Performed in 2099 Patients at High Risk for Ischemia during Coronary Surgery, According to Treatment Group.). When the c7E3 Fab groups were compared with the placebo group, a graded effect of c7E3 Fab was found (P = 0.009), with a 10 percent reduction in the rate of the composite end point in the group given the c7E3 Fab bolus alone (P = 0.43) and a 35 percent reduction in the rate in the group given both this bolus and the infusion (P = 0.008) (Table 2Table 2
Primary Outcome Events in the Treatment Groups.). A similar graded effect was observed for each of the most important individual end points relating to ischemia, including the spectrum of nonfatal myocardial infarctions. Three of the deaths among the patients assigned to the c7E3 Fab bolus and infusion occurred after randomization but before drug administration; these deaths were included in the analysis according to the intention-to-treat principle.The times of nonfatal ischemic events differed among the three groups, as shown in Figure 1Figure 1
Probability of No Urgent Repeated Percutaneous Revascularization Procedures in the Three Treatment Groups (Kaplan-Meier Plots). for urgent repeat angioplasty, an event whose beginning and end could be determined accurately. In the placebo group, more ischemic events occurred during the first six hours after the procedure than later (P<0.03), whereas in the group given the c7E3 Fab bolus, events were delayed for several hours, corresponding to the time of maximal receptor blockade. There was a marked delay in the onset of ischemic events in the group given the c7E3 Fab bolus and infusion, as well as a marked reduction in their absolute frequency.The rates of bleeding complications during hospitalization are shown in Table 3Table 3
Bleeding Complications and Hematologic Values in the Treatment Groups.. The group given the c7E3 Fab bolus and infusion had a substantial increase in both the rate of major bleeding and that of transfusion, with a more moderate increase seen in the group given the bolus alone. The majority of bleeding episodes occurred during coronary-artery bypass grafting or at the site of vascular puncture in the groin. The rates of surgery for bleeding were similar (1.4 percent in the placebo group, 2.6 percent in the group given the c7E3 Fab bolus only, and 1.7 percent in the group given both the bolus and the infusion). Similarly, six patients had an intracranial hemorrhage -- two patients assigned to placebo only, one patient assigned to the c7E3 bolus, and three patients assigned to the bolus and infusion; one of these last three patients did not receive the drug because the hemorrhage occurred after randomization but before angioplasty.When the treatment effect was evaluated in subgroups defined according to whether patients were enrolled with an acute ischemic syndrome or unstable angina or with high-risk anatomical features, the odds ratio for the primary end point was less than 1.0 in all subgroups (Table 4Table 4
Event Rates of Primary End Point and Transfusion in Subgroups Defined before Entry.). Similarly, the treatment effect was homogeneous across the subgroups defined by age and sex.As a function of body weight, the hazard ratio for the primary end point was less than 1.0 across the study population, although the treatment effect was more pronounced in heavier patients. The risk of major bleeding was increased in lighter patients given c7E3 Fab (whether the bolus only or both the bolus and the infusion). In the lightest third of the patients, major bleeding occurred in 21 percent of those given both the bolus and the infusion of c7E3 Fab, 15 percent of those given the bolus only, and 7 percent of those given placebo, whereas in the heaviest third the corresponding rates of bleeding were 9, 7, and 6 percent.
Discussion
This study confirms the importance of platelet aggregation in the occurrence of acute ischemic events in patients undergoing percutaneous transluminal coronary angioplasty26. The administration of c7E3 Fab directed against the platelet glycoprotein IIb/IIIa receptor as a bolus and infusion resulted in a 35 percent reduction in the composite-event rate, primarily in the rate of nonfatal myocardial infarction and the need for emergency angioplasty or bypass surgery. This beneficial effect was achieved at the cost of a significant increase in bleeding complications and transfusions. Judgment about the clinical usefulness of this approach in patients at high risk for ischemic complications during or after percutaneous revascularization depends on the value of averting ischemic events relative to the value of reducing the need for blood products. In the high-risk patients enrolled in this trial, the balance appeared to be favorable.
The composite end point serves as an overall estimate of the effect of this therapeutic approach on ischemic events in the period encompassing angioplasty. One of the most important findings of this trial is the consistency in the reduction of events across the various end points. This consistency is further demonstrated by the closeness of the hazard ratios across the range of patient characteristics in many subgroups (Table 4). Nominal statistical significance for a treatment effect with regard to each end point or within each subgroup would not be expected in view of the size of the study population27. Together with the positive results of a recent pilot trial in which the same antibody was given to patients with refractory unstable angina,28 the beneficial effect of glycoprotein IIb/ IIIa-receptor blockade on clinical end points in the setting of high-risk angioplasty is convincing.
The classification of nonfatal myocardial infarction has become a major issue in the evaluation of percutaneous coronary interventions. Elevations of creatine kinase MB isozyme activity above the upper limit of normal commonly occur in 4 to 21 percent of patients,29-32 yet when they are not accompanied by discrete clinical events, their association with long-term adverse outcomes is not clear. Thus, preventing isolated enzyme elevations may not be prognostically meaningful. To ensure objectivity in this subtle area, we systematically collected enzyme values and electrocardiograms, set up a blinded end-point committee, and required at least a threefold increase in myocardium-specific enzyme activity to classify an event as a myocardial infarction. Treatment with c7E3 Fab reduced all types of myocardial infarctions, including those associated with moderate and large enzyme elevations and Q-wave development, and also reduced the need for emergency coronary revascularization.
The blood loss observed in this trial was substantial and resulted in a significant increase in the use of blood products. The doubling of the transfusion rate in patients who received both a bolus and an infusion of c7E3 Fab occurred primarily as a result of bleeding at the femoral puncture site and did not lead to a marked difference among the three treatment groups in nadir hematocrits or the rate of life-threatening complications. The trends remained the same whether or not surgically treated patients were included in the analysis. Our previous experience has demonstrated that a refined protocol for the management of bleeding and the administration of transfusions in patients given thrombolytic therapy can effectively reduce the need for blood products33.
The relation between treatment benefit and the risk of bleeding as a function of body weight was more complex than expected. Although the primary-event rate and the risk of major bleeding did not vary substantially with weight in the placebo group in our study, it was clear that weight was inversely related to the number of primary-outcome events and major episodes of bleeding in the group given the bolus and infusion of c7E3 Fab. Future studies and clinical practice using potent, parenterally administered antithrombotic agents in patients with indwelling tubes or catheters must focus on weight-adjusted dosing with antithrombotic drugs, more detailed evaluation of the mechanisms by which antithrombotic therapy prevents ischemic complications, and protocols that define approaches to reduce bleeding that will be applied consistently at all participating centers.
These findings have many implications for future scientific inquiry. The broad consistency of the treatment effect across the study population is strong evidence that platelet thrombosis plays an important part in the abrupt closure of coronary lesions treated by angioplasty. The apparent delay of adverse events by the bolus of c7E3 Fab and the prevention of events by the bolus and infusion imply that in most situations the surface of the disrupted artery has lost much of its thrombogenicity 18 to 24 hours after the procedure. This finding suggests that fu-ture therapies must take into account the need for sustaining an antithrombotic effect in patients at high risk for abrupt vessel closure.
In summary, this trial demonstrates a beneficial effect of substantial and sustained blockade of the glycoprotein IIb/IIIa receptor in patients undergoing high-risk percutaneous revascularization procedures, although this benefit was achieved at the risk of increased bleeding. The relative value of a reduction in ischemic events as compared with an increase in bleeding events is at the crux of the decision about the clinical usefulness of glycoprotein IIb/IIIa-receptor blockade. Previous surveys of cardiologists' attitudes and clinical practice have demonstrated that they generally regard the transfusion of blood products as a much less serious clinical event than either an acute myocardial infarction or emergency repeat revascularization34. The prognostic implications of either of the latter two adverse events are serious, and fortunately the risks associated with transfusion continue to decline35-37. Future efforts to employ practice algorithms to avert bleeding and transfusions and to determine doses of antithrombotic agents more effectively, including their antithrombin and antiplatelet effects, should further enhance the clinical benefits observed in this trial.
Supported by a grant from Centocor, Inc., Malvern, Pa.
Dr. Califf, as the corresponding author, assumes overall responsibility for the contents of the manuscript.
Source Information
From the Department of Medicine, Division of Cardiology, Duke University Medical Center, Durham, N.C.
Address reprint requests to Dr. Robert M. Califf at Box 31123, Duke University Medical Center, Durham, NC 27710.
The principal investigators and study coordinators of the EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Study Group are listed in the Appendix.
Appendix
The following are the principal investigators and study coordinators of the EPIC Study Group: Presbyterian Hospital, Albuquerque, N.M. -- N. Shadoff and N. Valett; University of Michigan Medical Center, Ann Arbor -- E. Bates and A. Galeana; St. Joseph Hospital, Atlanta -- W. Knopf, J. Shaftel, and M.J. Bender; Johns Hopkins Hospital, Baltimore -- T. Aversano and J. Raqueno; University of Maryland Hospital, Baltimore -- P. Gurbel and J. Cowfer; St. Francis Hospital, Beech Grove, Ind. -- M. Cohen and P. Cross; Brigham and Women's Hospital, Boston -- J. Bittl and K. Eddings; Deborah Heart Center, Brown Mill, N.J. -- M. Taylor and K. DeRosa; DePaul Hospital, Cheyenne, Wyo. -- L. Hattel, L. Cooper, and B. Eshelman; Northwestern University, Chicago -- D. Fintel and P. Niemyski; Rush-Presbyterian-St. Luke's Medical Center, Chicago -- L. Klein, H. Kennedy, and T. Thornton; Christ Hospital, Cincinnati -- D. Kereiakes, L. Martin, L. Anderson, and N. Higby; Cleveland Clinic, Cleveland -- S. Ellis and K. Brezina; Riverside Methodist Hospitals, Columbus, Ohio -- B. George, A. Chapekis, and D. Smith; Baylor University, Dallas -- A. Anwar, T.L. Gerber, and G.L. Pritchard; San Francisco Heart Institute, Daly City, Calif. -- R. Myler, R. Shaw, M. Murphy, and K. Ward; Geisinger Medical Center, Danville, Pa. -- N.P. Madigan, J. Blankenship, M. Halbert, and C. Flanagan; Iowa Heart Center Mercy Hospital, Des Moines -- M. Tannenbaum, M. Polich, and C. Stevenson; Duke University, Durham, N.C. -- J. Tcheng, S. Hoffman, and R.M. Moore; St. Vincent Health Center, Erie, Pa. -- J. Smith and P. Henry; Evanston Hospital, Evanston, Ill. -- T.J. McDonough and S. Weszt; Moses Cone Hospital, Greensboro, N.C. -- B. Brodie and D. Muncy; Baylor University Methodist/Ben Taub General Hospital, Houston -- N. Kleiman, K. Trainor, D. Rose, and S. Johnson; Texas Heart Institute, Houston -- J. Willerson, J.J. Ferguson, and M. Harlan; University of Florida Medical Center, Jacksonville -- T.A. Bass and G. Rohman; Lakeland General Hospital, Lakeland, Fla. -- K. Browne and C. Ciesla; Lancaster General Hospital, Lancaster, Pa. -- S. Worley and J. Tuzi; Dartmouth-Hitchcock Medical Center, Lebanon, N.H. -- B. Hettleman, W.C. Burke, G. Olsen, and S.J. Kennedy; University of Louisville, Louisville, Ky. -- J.D. Talley, Z.A. Yussman, and M. Rawert; Loyola University Hospital, Maywood, Ill. -- E.D. Grassman and L. Wrona; Baptist Memorial, Memphis, Tenn. -- J. Samaha and B. Ehemann; East Jefferson Hospital, Metairie, La. -- S.D. Bleich and R. Leonhard; St. Luke's Medical Center, Milwaukee -- F. Cummins and J. Nonnweiler; St. Patrick Hospital, Missoula, Mont. -- M. Sanz and D. Mayer; Yale University Medical Center, New Haven, Conn. -- M.W. Cleman, V.J. Pascale, and S. McConnell; Creighton University Cardiac Center, Omaha, Nebr. -- M. Del Core and L. Stengel; Florida Hospital, Orlando, Fla. -- R.J. Ivanhoe and N. Granger; Lutheran General Hospital, Park Ridge, Ill. -- M.J. Rosenberg and A. Schaechter; Sacred Heart, Pensacola, Fla. -- G. Aycock and T. Wilcox; Graduate Hospital, Philadelphia -- R. Gottlieb and H. Hunter; Philadelphia Heart Institute, Philadelphia -- W. Unterecker and B. Hart; Arizona Heart Institute and Foundation, Phoenix -- R. Heuser and S. Hoopmann; North Memorial Medical Center, Robbinsdale, Minn. -- G. Hanovich and A. Antolick; Rochester General Hospital, Rochester, N.Y. -- G. Gacioch, V. Chiodo, and K. Karski; William Beaumont Hospital, Royal Oak, Mich. -- G. Timmis and M. Safian; St. Louis University, St. Louis -- F. Aguirre and T. Stonner; St. John's Hospital, Springfield, Ill. -- G.J. Taylor, K. Womack, and B. Ruyle; South Miami Hospital, Miami -- D. Krauthamer and G. Welcom; Tampa General Hospital, Tampa, Fla. -- M. Weston and K. Dillon; Harbor-UCLA Medical Center, Torrance, Calif. -- W.J. French and G.T. Reynolds; Mother Frances Hospital, Tyler, Tex. -- F. Navetta, G. Murphy, R. LeBoeuf, and S. Spencer; and Washington Hospital Center, Washington, D.C. -- J.J. Popma and L. Sweet.
Executive Committee -- E.J. Topol, R.M. Califf, C.R. Smith, H. Weisman, and K.L. Lee; Coordinating Center -- J. Miller, K. Sigmon, R.M. Califf, J. Tcheng, K.L. Lee, M. Lui, A. Kosloff, and J. DiFulvio (Durham, N.C.); and A.L. Wang, K. Anderson, H. Weisman, R. Dann, W. Kingma, D. Norton, B. Myer, R. Masek, M. Lewandowski, S. Broderick, M. Musco, M. Schorr, P. Hartman, and L. McCardle (Malvern, Pa.); Safety Data Monitoring Committee -- D. Faxon (chairman), P. Armstrong, J. Gore, J. Loscalzo, L. McCullough, and J. Verter; Economics and Quality of Life -- D.B. Mark, L. Davidson-Ray, N. Clapp-Channing, and L.C. Lam; Clinical Events Committee -- R.A. Waugh (chairman), C.B. McCants, Jr., M.C. Hindman, G. Dehmer, W.B. Hillegass, D.J. Frid, D.F. Fortin, B.C. Brott, T.L. Forest, D.M. Unks, and M.E. Hamer; ECG Core Laboratory -- G.S. Wagner and K. Gates; and Thrombocytopenia Core Laboratory -- D. Sane.
- References
References
1
Gruentzig AR ,King SB III ,Schlumpf M ,Siegenthaler W . Long-term follow-up after percutaneous transluminal coronary angioplasty: the early Zurich experience. N Engl J Med 1987;316:1127-1132
Full Text | Web of Science | Medline2
Parisi AF ,Folland ED ,Hartigan P . A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 1992;326:10-16
Full Text | Web of Science | Medline3
Lincoff AM ,Popma JJ ,Ellis SG ,Hacker JA ,Topol EJ . Abrupt vessel closure complicating coronary angioplasty: clinical, angiographic and therapeutic profile. J Am Coll Cardiol 1992;19:926-935
CrossRef | Web of Science | Medline4
Tenaglia AN ,Fortin DF ,Frid DJ , et al. Long-term outcome following successful reopening of abrupt closure after coronary angioplasty. Am J Cardiol 1993;72:21-25
CrossRef | Web of Science | Medline5
Detre KM ,Holmes DR Jr ,Holubkov R , et al. Incidence and consequences of periprocedural occlusion: the 1985-1986 National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1990;82:739-750
CrossRef | Web of Science | Medline6
Ellis SG ,Roubin GS ,King SB III , et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-379
CrossRef | Web of Science | Medline7
Ellis SG ,Bates ER ,Schaible T ,Weisman HF ,Pitt B ,Topol EJ . Prospects for the use of antagonists to the platelet glycoprotein IIb/IIIa receptor to prevent post-angioplasty restenosis and thrombosis. J Am Coll Cardiol 1991;17:Suppl B:89B-95B
CrossRef | Web of Science | Medline8
Tenaglia AM, Fortin DF, Frid DJ, et al. Individualizing the risk of angioplasty abrupt vessel closure. J Am Coll Cardiol (in press).
9
Moushmoush B ,Kramer B ,Hsieh AM ,Klein LW . Does the AHA/ACC task force grading system predict outcome in multivessel coronary angioplasty? Cathet Cardiovasc Diagn 1992;27:97-105
CrossRef | Medline10
Myler RK ,Shaw RE ,Stertzer SH , et al. Unstable angina and coronary angioplasty. Circulation 1990;82:Suppl II:II-8811
Schwartz L ,Bourassa MG ,Lesperance J , et al. Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty. N Engl J Med 1988;318:1714-1719
Full Text | Web of Science | Medline12
Barnathan ES ,Schwartz JS ,Taylor L , et al. Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. Circulation 1987;76:125-134
CrossRef | Web of Science | Medline13
Harker LA . Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty. Am J Cardiol 1987;60:Suppl:20B-28B
CrossRef | Web of Science | Medline14
Coller BS . A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985;76:101-108
CrossRef | Web of Science | Medline15
Coller BS ,Scudder LR . Inhibition of dog platelet function by in vivo infusion of F(ab')2 fragments of a monoclonal antibody to the platelet glycoprotein IIb/IIIa receptor. Blood 1985;66:1456-1459
Web of Science | Medline16
Ellis SG ,Navetta FI ,Tcheng JT , et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty: an initial experience. Coron Artery Dis 1993;4:167-175
CrossRef | Web of Science | Medline17
Ryan TJ ,Faxon DP ,Gunnar RM , et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). Circulation 1988;78:486-502
CrossRef | Web of Science | Medline18
Dougherty KG ,Marsh KC ,Edelman SK ,Gaos CM ,Ferguson JJ ,Leachman DR . Relationship between procedural activated clotting time and in-hospital post-PTCA outcome. Circulation 1990;82:Suppl IV:IV-18919
Rath B ,Bennett DH . Monitoring the effect of heparin by measurement of activated clotting time during and after percutaneous transluminal coronary angioplasty. Br Heart J 1990;63:18-21
CrossRef | Web of Science | Medline20
Ogilby JD ,Kopelman HA ,Klein LW ,Agarwal JB . Adequate heparinization during PTCA: assessment using activated clotting times. Cathet Cardiovasc Diagn 1989;18:206-209
CrossRef | Medline21
Sane DC ,Califf RM ,Topol EJ ,Stump DC ,Mark DB ,Greenberg CS . Bleeding during thrombolytic therapy for acute myocardial infarction: mechanisms and management. Ann Intern Med 1989;111:1010-1022
Web of Science | Medline22
Rao AK ,Pratt C ,Berke A , et al. Thrombolysis in Myocardial Infarction (TIMI) Trial -- phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11
CrossRef | Web of Science | Medline23
Landefeld CS ,Cook EF ,Flatley M ,Weisberg M ,Goldman L . Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med 1987;82:703-713
CrossRef | Web of Science | Medline24
Kaplan EL ,Meier P . Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481
CrossRef | Web of Science25
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley, 1980.
26
Willerson JT ,Golino P ,Eidt J ,Campbell WB ,Buja LM . Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989;80:198-205
CrossRef | Web of Science | Medline27
Yusuf S ,Wittes J ,Probstfield J ,Tyroler HA . Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-98
CrossRef | Web of Science | Medline28
Simoons ML ,de Boer MJ ,van den Brand MJBM , et al. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603
Web of Science | Medline29
Klein LW ,Kramer BL ,Howard E ,Lesch M . Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. J Am Coll Cardiol 1991;17:621-626
CrossRef | Web of Science | Medline30
Hunt AC ,Chow SL ,Shiu MF ,Chilton DC ,Cummins B ,Cummins P . Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty. Eur Heart J 1991;12:690-693
Web of Science | Medline31
Pauletto P ,Piccolo D ,Scannapieco G , et al. Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. Am J Cardiol 1987;59:999-1000
CrossRef | Web of Science | Medline32
Spadaro JJ ,Ludbrook PA ,Tiefenbrunn AJ ,Kurnik PB ,Jaffe AS . Paucity of subtle myocardial injury after angioplasty delineated with MB CK. Cathet Cardiovasc Diagn 1986;12:230-234
CrossRef | Medline33
Wall TC ,Califf RM ,Ellis SG , et al. Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. J Am Coll Cardiol 1993;21:597-603
CrossRef | Web of Science | Medline34
Califf RM ,Harrelson-Woodlief L ,Topol EJ . Left ventricular ejection fraction may not be useful as an end point of thrombolytic therapy comparative trials. Circulation 1990;82:1847-1853
CrossRef | Web of Science | Medline35
Donahue JG ,Munoz A ,Ness PM , et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med 1992;327:369-373
Full Text | Web of Science | Medline36
Dodd RY . The risk of transfusion-transmitted infection. N Engl J Med 1992;327:419-421
Full Text | Web of Science | Medline37
Nelson KE ,Donahue JG ,Munoz A , et al. Transmission of retroviruses from seronegative donors by transfusion during cardiac surgery: a multicenter study of HIV-1 and HTLV-I/II infections. Ann Intern Med 1992;117:554-559
Web of Science | Medline
- Citing Articles (878)
Citing Articles
1
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2012) 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: Executive Summary. Catheterization and Cardiovascular Interventions 79:3, 453-495
CrossRef2
S. H. Lang, N. Manning, N. Armstrong, K. Misso, A. Allen, M. Di Nisio, J. Kleijnen. (2012) Treatment with tirofiban for acute coronary syndrome (ACS): a systematic review and network analysis. Current Medical Research and Opinion1-20
CrossRef3
Walter J. Janse Rensburg, Jan P. Roodt, Seb Lamprecht, S. Muriel Meiring, Philip N. Badenhorst. (2012) Tirofiban versus abciximab: tirofiban is administered at suboptimal dosages when evaluated in an arterial thrombosis model in non-human primates. Clinical and Experimental Medicine
CrossRef4
Erik Kjoller, Jorgen Hilden, Per Winkel, Niels J. Frandsen, Soren Galatius, Gorm Jensen, Jens Kastrup, Jorgen Fischer Hansen, Hans J. Kolmos, Christian M. Jespersen, Per Hildebrandt, Christian Gluud. (2012) Good interobserver agreement was attainable on outcome adjudication in patients with stable coronary heart disease. Journal of Clinical Epidemiology
CrossRef5
S. D. Kristensen, M. Würtz, E. L. Grove, R. De Caterina, K. Huber, D. J. Moliterno, F.-J. Neumann. (2012) Contemporary use of glycoprotein IIb/IIIa inhibitors. Thrombosis and Haemostasis 107:2,
CrossRef6
Yuichi J. Shimada, Navin C. Nakra, John T. Fox, Yumiko Kanei. (2011) Meta-Analysis of Prospective Randomized Controlled Trials Comparing Intracoronary Versus Intravenous Abciximab in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. The American Journal of Cardiology
CrossRef7
David Plitt, William J. Brady. 2011. Non-ST-Segment Elevations Myocardial Infarction. , 18-37.
CrossRef8
Luke Kim, Konstantinos Charitakis, Rajesh V. Swaminathan, Dmitriy N. Feldman. (2011) Novel Antiplatelet Therapies. Current Atherosclerosis Reports
CrossRef9
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: Executive Summary. Journal of the American College of Cardiology
CrossRef10
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Journal of the American College of Cardiology
CrossRef11
Vinai C. Bhagirath, Lauren O'Malley, Mark A. Crowther. (2011) Management of Bleeding Complications in the Anticoagulated Patient. Seminars in Hematology 48:4, 285-294
CrossRef12
H. Benjamin Starnes, Ankit A. Patel, George A. Stouffer. (2011) Optimal Use of Platelet Glycoprotein IIb/IIIa Receptor Antagonists in Patients Undergoing Percutaneous Coronary Interventions. Drugs 71:15, 2009-2030
CrossRef13
Michelle J. Butler, William Chan, Andrew J. Taylor, Anthony M. Dart, Stephen J. Duffy. (2011) Management of the no-reflow phenomenon. Pharmacology & Therapeutics 132:1, 72-85
CrossRef14
Robert J. Applegate. (2011) Long-Term Impact of Periprocedural Bleeding. Journal of the American College of Cardiology 58:17, 1757-1759
CrossRef15
(2011) Outcomes assessment in the SPRINT multicenter tibial fracture trial: Adjudication committee size has trivial effect on trial results. Journal of Clinical Epidemiology 64:9, 1023-1033
CrossRef16
Allison Burnett, Jason Cohen, David A. Garcia. 2011. Hemorrhagic Complications of Anticoagulants in Hospitalized Patients. , 291-330.
CrossRef17
Michael Kornfeld, Joseph R. Munsayac. 2011. Antiplatelet Medications. , 47-65.
CrossRef18
Shaun Bhatty, Richard Cooke, Ranjith Shetty, Ion S Jovin. (2011) Femoral vascular access-site complications in the cardiac catheterization laboratory: diagnosis and management. Interventional Cardiology 3:4, 503-514
CrossRef19
Ryan D. Walsh, Kevin M. Barrett, Maria I. Aguilar, Giuseppe Lanzino, Ricardo A. Hanel, David A. Miller, Brian W. Chong, W. David Freeman. (2011) Intracranial Hemorrhage Following Neuroendovascular Procedures with Abciximab is Associated with High Mortality: A Multicenter Series. Neurocritical Care 15:1, 85-95
CrossRef20
MICHAEL MAHMOUDI, CEDRIC DELHAYE, KOHEI WAKABAYASHI, REBECCA TORGUSON, ZHENYI XUE, WILLIAM O. SUDDATH, LOWELL F. SATLER, KENNETH M. KENT, AUGUSTO D. PICHARD, RON WAKSMAN. (2011) Integrilin in Patients Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Journal of Interventional Cardiology 24:4, 351-356
CrossRef21
Osmar Antonio Centurión. (2011) Bivalirudin in Contemporary Percutaneous Coronary Intervention for Non-ST-Segment Elevation Acute Coronary Syndromes. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 10:2, 87-92
CrossRef22
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 57:19, e215-e367
CrossRef23
R. Scott Wright, Jeffrey L. Anderson, Cynthia D. Adams, Charles R. Bridges, Donald E. Casey, Steven M. Ettinger, Francis M. Fesmire, Theodore G. Ganiats, Hani Jneid, A. Michael Lincoff, Eric D. Peterson, George J. Philippides, Pierre Theroux, Nanette K. Wenger, James Patrick Zidar. (2011) 2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction (Updating the 2007 Guideline). Journal of the American College of Cardiology 57:19, 1920-1959
CrossRef24
ALLAN IVERSEN, ULRIK ABILDGAARD, ANDERS GALLOE, PETER R. HANSEN, SOREN GALATIUS, JAN K. MADSEN, THOMAS ENGSTROEM, SUNE PEDERSEN, KURT S. JENSEN, JAN S. JENSEN. (2011) Intracoronary Compared to Intravenous Bolus Abciximab during Primary Percutaneous Coronary Intervention in ST-segment Elevation Myocardial Infarction (STEMI) Patients Reduces 30-day Mortality and Target Vessel Revascularization: A Randomized Trial. Journal of Interventional Cardiology 24:2, 105-111
CrossRef25
G. Ganesha Babu, J. Malcolm Walker, D. M. Yellon, D. J. Hausenloy. (2011) Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. European Heart Journal 32:1, 23-31
CrossRef26
Glenn N. Levine, Eric R. Bates, James C. Blankenship, Steven R. Bailey, John A. Bittl, Bojan Cercek, Charles E. Chambers, Stephen G. Ellis, Robert A. Guyton, Steven M. Hollenberg, Umesh N. Khot, Richard A. Lange, Laura Mauri, Roxana Mehran, Issam D. Moussa, Debabrata Mukherjee, Brahmajee K. Nallamothu, Henry H. Ting, Alice K. Jacobs, Jeffrey L. Anderson, Nancy Albert, Mark A. Creager, Steven M. Ettinger, Robert A. Guyton, Jonathan L. Halperin, Judith S. Hochman, Frederick G. Kushner, E. Magnus Ohman, William Stevenson, Clyde W. Yancy. (2011) 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Catheterization and Cardiovascular Interventionsn/a-n/a
CrossRef27
Gemma Vilahur, Teresa Padro, Lina Badimon. (2011) Atherosclerosis and Thrombosis: Insights from Large Animal Models. Journal of Biomedicine and Biotechnology 2011, 1-12
CrossRef28
Antonio Fernández-Ortiz, Iván Núñez-Gil, Borja Ruiz-Mateos, Borja Ibáñez. (2011) Propiedades de los diferentes inhibidores de la glucoproteína IIb/IIIa: ¿se puede aceptar el efecto de clase?. Revista Española de Cardiología Suplementos 11, 3-7
CrossRef29
Ian C. Gilchrist. (2011) Transradial pharmacology: Do we need access relevant dosing to maximize outcome?. Catheterization and Cardiovascular Interventions 77:1, 69-71
CrossRef30
J. E. van Loon, P. P. T. de Jaegere, H. Ulrichts, H. H. D. M. van Vliet, M. P. M. de Maat, P. G. de Groot, M. L. Simoons, F. W. G. Leebeek. (2011) The in vitro effect of the new antithrombotic drug candidate ALX-0081 on blood samples of patients undergoing percutaneous coronary intervention. Thrombosis and Haemostasis 106:1, 165-171
CrossRef31
Adam P. Silverman, Mihalis S. Kariolis, Jennifer R. Cochran. (2011) Cystine-knot peptides engineered with specificities for αIIbβ3 or αIIbβ3 and αvβ3 integrins are potent inhibitors of platelet aggregation. Journal of Molecular Recognition 24:1, 127-135
CrossRef32
Robert Chilton. (2011) IC bolus only versus IV with infusion 2b/3a inhibitors during STEMIs having PCI. Catheterization and Cardiovascular Interventions 79:1, 68-69
CrossRef33
David E. Winchester, William D. Brearley, Xuerong Wen, Ki E. Park, Anthony A. Bavry. (2011) Efficacy and Safety of Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors During Revascularization for an Acute Coronary Syndrome: A Meta-Analysis of Randomized Trials Performed With Stents and Thienopyridines. Clinical Cardiologyn/a-n/a
CrossRef34
Gordon L. Chen, Chunming Dong, Pascal J. Goldschmidt-Clermont. (2010) Journey in Antithrombotic Strategies for ST-Elevation Myocardial Infarction. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 9:4, 235-242
CrossRef35
Meltem Refiker Ege, Mehmet Birhan Yilmaz, Vedat Caldir. (2010) Hemorragia alveolar después del tratamiento con tirofibán. Un diagnóstico engañoso. Revista Española de Cardiología 63:12, 1511-1512
CrossRef36
Elias B. Hanna, Sunil V. Rao, Steven V. Manoukian, Jorge F. Saucedo. (2010) The Evolving Role of Glycoprotein IIb/IIIa Inhibitors in the Setting of Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 3:12, 1209-1219
CrossRef37
Mohamed Aggour, Laurent Pierot, Krisztof Kadziolka, Philippe Gomis, Jean-Pierre Graftieaux. (2010) Abciximab Treatment Modalities for Thromboembolic Events Related to Aneurysm Coiling. Neurosurgery 67, ons503-ons508
CrossRef38
David J. Schneider. (2010) Anti-platelet therapy: Glycoprotein IIb-IIIa Antagonists. British Journal of Clinical Pharmacologyno-no
CrossRef39
Guido Parodi, Giuseppe Luca, Guia Moschi, Benedetta Bellandi, Renato Valenti, Angela Migliorini, Nazario Carrabba, David Antoniucci. (2010) Safety of immediate reversal of anticoagulation by protamine to reduce bleeding complications after infarct artery stenting for acute myocardial infarction and adjunctive abciximab therapy. Journal of Thrombosis and Thrombolysis 30:4, 446-451
CrossRef40
Michael Koutouzis, Bo Lagerqvist, Jonas Oldgren, Axel Åkerblom, Magnus Wahlin, Thomas Karlsson, Per Albertsson, Göran Matejka, Lars Grip. (2010) Long-Term Results Following Switch From Abciximab to Eptifibatide During Percutaneous Coronary Intervention. Clinical Cardiology 33:11, 686-692
CrossRef41
Dinesh Kumar, George Dangas, Roxana Mehran, Ajay Kirtane, Michel Bertrand, Ramin Ebrahimi, Giulio Guagliumi, Somjot Brar, Martin Fahy, Eric Heller, Jeffrey Moses, Gregg Stone. (2010) Comparison of Bivalirudin Versus Bivalirudin Plus Glycoprotein IIb/IIIa Inhibitor Versus Heparin Plus Glycoprotein IIb/IIIa Inhibitor in Patients With Acute Coronary Syndromes Having Percutaneous Intervention for Narrowed Saphenous Vein Aorto-Coronary Grafts (the ACUITY Trial Investigators). The American Journal of Cardiology 106:7, 941-945
CrossRef42
Dermot Cox, Marian Brennan, Niamh Moran. (2010) Integrins as therapeutic targets: lessons and opportunities. Nature Reviews Drug Discovery 9:10, 804-820
CrossRef43
Xavier Bosch, Jaume Marrugat, Juan Sanchis, Xavier Bosch. 2010. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef44
Pitchaiah Mandava, William Dalmeida, Jane A. Anderson, Perumal Thiagarajan, Roderic H. Fabian, Raymond U. Weir, Thomas A. Kent. (2010) A Pilot Trial of Low-Dose Intravenous Abciximab and Unfractionated Heparin for Acute Ischemic Stroke: Translating GP IIb/IIIa Receptor Inhibition to Clinical Practice. Translational Stroke Research 1:3, 170-177
CrossRef45
M. Valgimigli. (2010) Balancing safety and efficacy: recent clinical evidence optimizing outcomes in patients with intermediate to high-risk non-ST-segment elevated acute coronary syndrome. European Heart Journal Supplements 12:Suppl D, D14-D23
CrossRef46
M. VALGIMIGLI, G. CAMPO, M. TEBALDI, M. MONTI, S. GAMBETTI, A. SCALONE, G. PARRINELLO, R. FERRARI, . (2010) Randomized, double-blind comparison of effects of abiciximab bolus only vs. on-label regimen on ex vivo inhibition of platelet aggregation in responders to clopidogrel undergoing coronary stenting. Journal of Thrombosis and Haemostasis 8:9, 1903-1911
CrossRef47
Fabio Mangiacapra, Emanuele Barbato. (2010) Individual Variability of Response to Antiplatelet Therapy is an Important Determinant of Adverse Clinical Outcome. High Blood Pressure & Cardiovascular Prevention 17:3, 121-130
CrossRef48
Manivannan Srinivasan, Charanjit S. Rihal, Mandeep Singh, Ryan J. Lennon, David R. Holmes, Abhiram Prasad. (2010) Percutaneous Coronary Intervention in Native Vessels With Angiographically Visible Thrombus. JACC: Cardiovascular Interventions 3:9, 937-946
CrossRef49
Axel Åkerblom, Stefan K. James, Michail Koutouzis, Bo Lagerqvist, Ulf Stenestrand, Bodil Svennblad, Jonas Oldgren. (2010) Eptifibatide Is Noninferior to Abciximab in Primary Percutaneous Coronary Intervention. Journal of the American College of Cardiology 56:6, 470-475
CrossRef50
Clare E. Appleby, Karen Mackie, Vladimír Džavík, Joan Ivanov. (2010) Late outcomes following percutaneous coronary interventions: Results from a large, observational registry. Canadian Journal of Cardiology 26:7, e218-e224
CrossRef51
Jorge F. Saucedo. (2010) Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 30:2, 200-209
CrossRef52
Billal Patel, Michael Fisher. (2010) Therapeutic advances in myocardial microvascular resistance: Unravelling the enigma. Pharmacology & Therapeutics 127:2, 131-147
CrossRef53
Ajay J. Kirtane, Helen Parise, Roxana Mehran, Jeffrey W. Moses, Martin Fahy, Michel E. Bertrand, E. Magnus Ohman, Harvey D. White, Frederick Feit, Antonio Colombo, Brent T. McLaurin, David A. Cox, James H. Ware, Stuart J. Pocock, Alexandra J. Lansky, Gregg W. Stone. (2010) Comparison of Catheterization Laboratory Initiated Abciximab and Eptifibatide During Percutaneous Coronary Intervention in Acute Coronary Syndromes (an ACUITY Substudy). The American Journal of Cardiology 106:2, 180-186
CrossRef54
Fabio Mangiacapra, Emanuele Barbato. (2010) Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization. Biomarkers in Medicine 4:3, 421-434
CrossRef55
Michael Koutouzis, Lars Grip. (2010) Glycoprotein IIb/IIIa inhibitors during percutaneous coronary interventions. Interventional Cardiology 2:3, 301-318
CrossRef56
Guido Parodi, Angela Migliorini, Renato Valenti, Benedetta Bellandi, Umberto Signorini, Guia Moschi, Piergiovanni Buonamici, Giampaolo Cerisano, David Antoniucci. (2010) Comparison of Bivalirudin and Unfractionated Heparin Plus Protamine in Patients With Coronary Heart Disease Undergoing Percutaneous Coronary Intervention (from the Antithrombotic Regimens aNd Outcome [ARNO] Trial). The American Journal of Cardiology 105:8, 1053-1059
CrossRef57
Nicholas J. Schork, Eric J. Topol. (2010) Genotype-Based Risk and Pharmacogenetic Sampling in Clinical Trials. Journal of Biopharmaceutical Statistics 20:2, 315-333
CrossRef58
Michel R Hoenig, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2010. Early invasive versus conservative strategies for unstable angina and non-ST elevation myocardial infarction in the stent era. .
CrossRef59
Akhil Kapur, Roger J. Hall, Iqbal S. Malik, Ayesha C. Qureshi, Jeremy Butts, Mark de Belder, Andreas Baumbach, Gianni Angelini, Adam de Belder, Keith G. Oldroyd, Marcus Flather, Michael Roughton, Petros Nihoyannopoulos, Jens Peder Bagger, Kenneth Morgan, Kevin J. Beatt. (2010) Randomized Comparison of Percutaneous Coronary Intervention With Coronary Artery Bypass Grafting in Diabetic Patients. Journal of the American College of Cardiology 55:5, 432-440
CrossRef60
Davide Capodanno, Francesco Prati, Tomasz Pawlowsky, Vito Ramazzotti, Jeanny Albertucci, Alessio La Manna, Gil Robert, Corrado Tamburino. (2010) ClearWayRX System to reduce intracoronary thrombus in patients with acute coronary syndromes according to Optical Coherence Tomography after Abciximab Intracoronary Local infusion trial (COCTAIL): study rationale and design. Journal of Cardiovascular Medicine 11:2, 130-136
CrossRef61
Francesco Viola, F. William Mauldin, Xiefan Lin-Schmidt, Doris M. Haverstick, Michael B. Lawrence, William F. Walker. (2010) A novel ultrasound-based method to evaluate hemostatic function of whole blood. Clinica Chimica Acta 411:1-2, 106-113
CrossRef62
Esam Elbarasi, Shaun G. Goodman, Raymond T. Yan, Robert C. Welsh, Jan Kornder, Graham C. Wong, Jean-Pierre Déry, Fred Anderson, Joel M. Gore, Keith A.A. Fox, Andrew T. Yan. (2010) Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. American Heart Journal 159:1, 40-46
CrossRef63
M. Feuring, A. Ruf, A. Schultz, M. Wehling. (2010) The PFA-100® cannot detect blood group-dependent inhibition of platelet function by eptifibatide or abciximab at therapeutic plasma concentrations. Platelets 21:3, 176-182
CrossRef64
Jean-Etienne Fabre, Mark E. Gurney. (2010) Limitations of current therapies to prevent thrombosis: a need for novel strategies. Molecular BioSystems 6:2, 305
CrossRef65
Rodrigo Bagur, Olivier F. Bertrand, Josep Rodés-Cabau, Ãric Larose, Stéphane Rinfret, Can M. Nguyen, Bernard Noel, Robert De Larochellière, Paul Poirier, Olivier Costerousse, Louis Roy. (2009) Long term efficacy of abciximab bolus-only compared to abciximab bolus and infusion after transradial coronary stenting. Catheterization and Cardiovascular Interventions 74:7, 1010-1016
CrossRef66
Behnam Banihashemi, Shaun G. Goodman, Raymond T. Yan, Robert C. Welsh, Shamir R. Mehta, Gilles Montalescot, Jan M. Kornder, Graham C. Wong, Gabor Gyenes, Ph. Gabriel Steg, Andrew T. Yan. (2009) Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. American Heart Journal 158:6, 917-924
CrossRef67
Claudia DʼAndrea, Giovanni Esposito, Federico Piscione, Massimo Chiariello. (2009) Tirofiban administration and percutaneous coronary intervention with stenting of saphenous vein graft thrombosis. Journal of Cardiovascular Medicine 10:11, 875-878
CrossRef68
Stephen L. Nishimura. (2009) Integrin-Mediated Transforming Growth Factor-β Activation, a Potential Therapeutic Target in Fibrogenic Disorders. The American Journal of Pathology 175:4, 1362-1370
CrossRef69
John P Vavalle, Sunil V Rao. (2009) Impact of bleeding complications on outcomes after percutaneous coronary interventions. Interventional Cardiology 1:1, 51-62
CrossRef70
(2009) Acute Coronary Syndromes. New England Journal of Medicine 361:9, 925-927
Full Text71
Dong-Hyun Choi, Jung-Won Suh, Kyung-Woo Park, Hyun-Jae Kang, Hyo-Soo Kim. (2009) Assessment of the bioequivalence of brand and biogeneric formulations of abciximab for the treatment of acute coronary syndrome: A prospective, open-label, randomized, controlled study in Korean patients. Clinical Therapeutics 31:8, 1804-1811
CrossRef72
Farzan Irani, Sachin Kumar, William R Colyer. (2009) Common femoral artery access techniques: a review. Journal of Cardiovascular Medicine 10:7, 517-522
CrossRef73
Renato Valenti, Guido Parodi, Angela Migliorini. 2009. Platelet Glycoprotein IIb-IIIa Inhibitors. , 67-76.
CrossRef74
Shaker A. Mousa, James T. Willerson, Robert P. Giugliano. 2009. Overview of Antiplatelet Therapy. , 399-408.
CrossRef75
Jason N. Katz and, Robert A. Harrington. 2009. Intravenous Glycoprotein IIb/IIIa Antagonists. , 429-456.
CrossRef76
S. Honda, H. Shirotani-Ikejima, S. Tadokoro, Y. Maeda, T. Kinoshita, Y. Tomiyama, T. Miyata. (2009) Integrin-linked kinase associated with integrin activation. Blood 113:21, 5304-5313
CrossRef77
Magnus Wahlin, Per Albertsson, Thomas Karlsson, Göran Matejka, Annika Odell, Farshad Tahmasebiepour, Christina Wolmeryd, Lars Grip. (2009) Switch from abciximab to eptifibatide during percutaneous coronary intervention. International Journal of Cardiology 134:3, 393-400
CrossRef78
Scott J. Denardo. (2009) Exclusive Antiplatelet Therapy for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 53:20, 1921-1922
CrossRef79
Shiny Mathewkutty, Darren K McGuire. (2009) Platelet perturbations in diabetes: implications for cardiovascular disease risk and treatment. Expert Review of Cardiovascular Therapy 7:5, 541-549
CrossRef80
A. Siddique, M. Butt, E. Shantsila, G. Y. H. Lip. (2009) New antiplatelet drugs: beyond aspirin and clopidogrel. International Journal of Clinical Practice 63:5, 776-789
CrossRef81
Ayman A El-Menyar, Jassim Al Suwaidi. (2009) Impact of gender in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy 7:4, 411-421
CrossRef82
J. Hoekstra, M. Cohen. (2009) Management of patients with unstable angina / non-ST-elevation myocardial infarction: a critical review of the 2007 ACC /AHA guidelines. International Journal of Clinical Practice 63:4, 642-655
CrossRef83
Anthony Y. Fung, Jacqueline Saw, Andrew Starovoytov, Cameron Densem, Percy Jokhi, Simon J. Walsh, Rebecca S. Fox, Karin H. Humphries, Eve Aymong, Donald R. Ricci, John G. Webb, Jaap N. Hamburger, Ronald G. Carere, Christopher E. Buller. (2009) Abbreviated Infusion of Eptifibatide After Successful Coronary Intervention. Journal of the American College of Cardiology 53:10, 837-845
CrossRef84
Ehtisham Mahmud, Anand Prasad. (2009) Optimal Antiplatelet Therapy During Percutaneous Coronary Interventions Includes Glycoprotein IIb/IIIa Inhibitors. Journal of the American College of Cardiology 53:10, 846-848
CrossRef85
Cedric W. Lefebvre, James W. Hoekstra, Marc Bonaca, Robert Giugliano. (2009) Glycoprotein IIb-IIIa Inhibitors in the Emergency Department for Patients with Non-ST-Elevation Acute Coronary Syndromes: Principles and Practices. The Journal of Emergency Medicine 36:2, 162-170
CrossRef86
D. Varon, G. Spectre. (2009) Antiplatelet agents. Hematology 2009:1, 267-272
CrossRef87
Nanting Ni, Minyong Li, Junfeng Wang, Binghe Wang. (2009) Inhibitors and antagonists of bacterial quorum sensing. Medicinal Research Reviews 29:1, 65-124
CrossRef88
Sun-Jung Song, Kyoung Seok Kim, Yu Jeong Park, Myung Ho Jeong, Yeong-Mu Ko, Dong Lyun Cho. (2009) Preparation of a dual-drug-eluting stent by grafting of ALA with abciximab on a bare metal stent. Journal of Materials Chemistry 19:43, 8135
CrossRef89
You-Jeong Oh, Tae-Ho Park, Yun-Jung Choi, Su-Hyun Cho, Jae-Hyuk Choi, Dong-Hyun Lee, Sun-Yi Park, Kwang-Soo Cha, Moo-Hyun Kim, Young-Dae Kim. (2009) Abciximab (ReoPro)-Induced Thrombocytopenia Diagnosed Through Measurement of Heparin-Dependent Antibody. Korean Circulation Journal 39:2, 75
CrossRef90
Enrico Vizzardi, Antonio D’Aloia, Gregoriana Zanini, Elena Antonioli, Claudio Pedrinazzi, Riccardo Raddino, Livio Dei Cas. (2008) A case report of alveolar haemorrhage associated with severe thrombocytopenia induced by abciximab infusion in a patient with an acute coronary syndrome. Internal and Emergency Medicine 3:4, 345-347
CrossRef91
Refat Jabara, Radhika Gadesam, Lakshmana Pendyala, Nicolas Chronos, Larry V. Crisco, Spencer B. King, Jack P. Chen. (2008) Ambulatory discharge after transradial coronary intervention: Preliminary US single-center experience (Same-day TransRadial Intervention and Discharge Evaluation, the STRIDE Study). American Heart Journal 156:6, 1141-1146
CrossRef92
Umesh U Tamhane, Hitinder S Gurm. (2008) The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice. Expert Opinion on Drug Safety 7:6, 809-819
CrossRef93
Gennaro Galasso, Federico Piscione, Fulvio Furbatto, Dario Leosco, Adele Pierri, Roberta De Rosa, Plinio Cirillo, Antonio Rapacciuolo, Giovanni Esposito, Massimo Chiariello. (2008) Abciximab in elderly with Acute Coronary Syndrome invasively treated: Effect on outcome. International Journal of Cardiology 130:3, 380-385
CrossRef94
Barry F. Uretsky, Yochai Birnbaum, Abdulfatah Osman, Rajiv Gupta, Oscar Paniagua, Antonio Chamoun, Amir Pohwani, Charles Lui, Eli Lev, Todd McGehee, Darren Kumar, Asif Akhtar, Angelo Anzuini, Ernst R. Schwarz, Fen Wei Wang. (2008) Distal myocardial protection with intracoronary beta blocker when added to a Gp IIb/IIIa platelet receptor blocker during percutaneous coronary intervention improves clinical outcome. Catheterization and Cardiovascular Interventions 72:4, 488-497
CrossRef95
Jeffrey B. Washam, George L. Adams. (2008) Risks and Benefits of Antiplatelet Therapy in Uremic Patients. Advances in Chronic Kidney Disease 15:4, 370-377
CrossRef96
Jae-Sik Jang, Myeong-Ki Hong, Duk-Woo Park, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Jae-Joong Kim, Seong-Wook Park, Seung-Jung Park. (2008) Impact of periprocedural myonecrosis on clinical events after implantation of drug-eluting stents. International Journal of Cardiology 129:3, 368-372
CrossRef97
Barry S. Coller. (2008) Translational research: forging a new cultural identity. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 75:5, 478-487
CrossRef98
R. Iijima, G. Ndrepepa, J. Mehilli, R. A. Byrne, S. Schulz, F.-J. Neumann, G. Richardt, P. B. Berger, A. Schomig, A. Kastrati. (2008) Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. European Heart Journal 30:3, 290-296
CrossRef99
R. J. Gumina, E. H. Yang, G. S. Sandhu, A. Prasad, J. F. Bresnahan, R. J. Lennon, C. S. Rihal, D. R. Holmes, M. Singh. (2008) Survival Benefit With Concomitant Clopidogrel and Glycoprotein IIb/IIIa Inhibitor Therapy at Ad Hoc Percutaneous Coronary Intervention. Mayo Clinic Proceedings 83:9, 995-1001
CrossRef100
Caroline Johnson Girardeau, Deborah Montague. (2008) Implementing Consultant Recommendations in Percutaneous Coronary Interventions: Look Before You Leap. Hospital Pharmacy 43:8, 635-642
CrossRef101
Olivier F. Bertrand, Josep Rodés-Cabau, Éric Larose, Can Manh Nguyen, Louis Roy, Jean-Pierre Déry, Javier Courtis, Isabelle Nault, Paul Poirier, Olivier Costerousse, Robert De Larochellière. (2008) One-year clinical outcome after abciximab bolus-only compared with abciximab bolus and 12-hour infusion in the Randomized EArly Discharge after Transradial Stenting of CoronarY Arteries (EASY) Study. American Heart Journal 156:1, 135-140
CrossRef102
Daniel H. Steinberg, Palak Shah, Tim Kinnaird, Tina L. Pinto Slottow, Probal K. Roy, Teruo Okabe, Laurent Bonello, Axel de Labriolle, Kimberly A. Smith, Rebecca Torguson, Zhenyi Xue, William O. Suddath, Kenneth M. Kent, Lowell F. Satler, Augusto D. Pichard, Joseph Lindsay, Ron Waksman. (2008) Bleeding Risk and Outcomes of Bivalirudin Versus Glycoprotein IIb/IIIa Inhibitors With Targeted Low-Dose Unfractionated Heparin in Patients Having Percutaneous Coronary Intervention for Either Stable or Unstable Angina Pectoris. The American Journal of Cardiology 102:2, 160-164
CrossRef103
Jarred Thomas, William J. Brady. (2008) Antiplatelet Therapy in Acute Coronary Syndrome: Not as Confusing as You Think. The Journal of Emergency Medicine 35:1, 87-90
CrossRef104
Ernest L Mazzaferri Jr, John J Young. (2008) Abciximab: a review and update for clinicians. Expert Review of Cardiovascular Therapy 6:5, 609-618
CrossRef105
Dean J. Kereiakes, Paul A. Gurbel. (2008) Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 1:2, 111-121
CrossRef106
Frederick Feit, Steven V. Manoukian, Ramin Ebrahimi, Charles V. Pollack, E. Magnus Ohman, Michael J. Attubato, Roxana Mehran, Gregg W. Stone. (2008) Safety and Efficacy of Bivalirudin Monotherapy in Patients With Diabetes Mellitus and Acute Coronary Syndromes. Journal of the American College of Cardiology 51:17, 1645-1652
CrossRef107
ANDREW T. KWA, JASON H. ROGERS. (2008) Current Update on Glycoprotein IIb-IIIa and Direct Thrombin Inhibition in Percutaneous Coronary Intervention for Non-ST Elevation Acute Coronary Syndromes: Balancing Bleeding Risk and Antiplatelet Efficacy. Journal of Interventional Cardiology 21:2, 107-117
CrossRef108
Jae Hyo Park, Jeong Eun Kim, Seung Hun Sheen, Cheol Kyu Jung, Bae Ju Kwon, O-Ki Kwon, Chang Wan Oh, Moon Hee Han, Dae Hee Han. (2008) Intraarterial abciximab for treatment of thromboembolism during coil embolization of intracranial aneurysms: outcome and fatal hemorrhagic complications. Journal of Neurosurgery 108:3, 450-457
CrossRef109
M. Cattaneo. (2008) Haemorrhagic stroke during anti-platelet therapy. European Journal of Anaesthesiology 25:Supplement 42, 12-15
CrossRef110
Ramez R Fares, Lawrence S Lansing, Christine A Gallati, Shaker A Mousa. (2008) Antiplatelet therapy with clopidogrel and aspirin in vascular diseases: clinical evidence for and against the combination. Expert Opinion on Pharmacotherapy 9:3, 377-386
CrossRef111
KRIS NOWAKOWSKI, JAMES ROGERS, GREGORY NELSON, BRENDAN GUNALINGAM. (2008) Abciximab-Induced Thrombocytopenia: Management of Bleeding in the Setting of Recent Coronary Stents. Journal of Interventional Cardiology 21:1, 100-105
CrossRef112
Gjin Ndrepepa, Peter B. Berger, Julinda Mehilli, Melchior Seyfarth, Franz-Josef Neumann, Albert Schömig, Adnan Kastrati. (2008) Periprocedural Bleeding and 1-Year Outcome After Percutaneous Coronary Interventions. Journal of the American College of Cardiology 51:7, 690-697
CrossRef113
Jae-Youn Moon, Weon Kim, Ju Han Kim, Youngkeun Ahn, Myung Ho Jeong, Young-Hak Kim, Myeong-Ki Hong, Seong-Wook Park, Seung-Jung Park, Sungha Park, Young-Guk Ko, Donghoon Choi, Yangsoo Jang. (2008) A Multicenter, Randomized, Open-Label, Therapeutic, and Exploratory Trial to Evaluate the Tolerability and Efficacy of Platelet Glycoprotein IIb/IIIa Receptor Blocker (Clotinab?? in High-Risk Patients with Percutaneous Coronary Intervention. Yonsei Medical Journal 49:3, 389
CrossRef114
AZFAR G. ZAMAN, JAGATH HERATH. 2008. Percutaneous coronary intervention in saphenous vein graft disease. , 309-318.
CrossRef115
Shaker A. Mousa. (2008) Cell Adhesion Molecules: Potential Therapeutic & Diagnostic Implications. Molecular Biotechnology 38:1, 33-40
CrossRef116
Jochem W van Werkum, Christian M Hackeng, Jaap-Jan J Smit, Arnoud WJ van’t Hof, Freek WA Verheugt, Jurriën M ten Berg. (2008) Monitoring antiplatelet therapy with point-of-care platelet function assays: a review of the evidence. Future Cardiology 4:1, 33-55
CrossRef117
Michele Romano, Francesca Buffoli, Luca Tomasi, Marco Aroldi, Corrado Lettieri, Maria Rosa Ferrari, Roberto Zanini. (2008) The no-reflow phenomenon in acute myocardial infarction after primary angioplasty: incidence, predictive factors, and long-term outcomes. Journal of Cardiovascular Medicine 9:1, 59-63
CrossRef118
JOHN M. GALLA, A. MICHAEL LINCOFF. 2008. Adjunctive pharmacotherapy during PCI. , 53-64.
CrossRef119
Ernesto Oqueli, Leonie Baker, Aaron Carroll, Martin Hiscock, Ronald Dick. (2008) Percutaneous Coronary Intervention in Women: In-Hospital Clinical Outcome. Heart, Lung and Circulation 17, S55-S62
CrossRef120
Tae Jin Song, Kee Oog Lee, Dong Joon Kim, Kyung-Yul Lee. (2008) Rescue Treatment with Intra-arterial Tirofiban Infusion and Emergent Carotid Stenting. Yonsei Medical Journal 49:5, 857
CrossRef121
Young Joon Hong, Myung Ho Jeong, Sun Ho Hwang, Nam Sik Yun, Sang Yup Lim, Sang Rok Lee, Seo Na Hong, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Weon Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2007) Impact of postprocedure minimum stent area on long-term results following abciximab-coated stent implantation: An intravascular ultrasound analysis. International Journal of Cardiology 123:1, 23-28
CrossRef122
Arnoud van ‘t Hof, Christian Hamm, Saman Rasoul, Soneil Guptha, John Paolini, Jurriën ten Berg. (2007) Ongoing tirofiban in myocardial infarction evaluation (On-TIME) 2 trial: rationale and study design. EuroIntervention 3:3, 371-380
CrossRef123
Frederick Feit, Michele D. Voeltz, Michael J. Attubato, A. Michael Lincoff, Derek P. Chew, John A. Bittl, Eric J. Topol, Steven V. Manoukian. (2007) Predictors and Impact of Major Hemorrhage on Mortality Following Percutaneous Coronary Intervention from the REPLACE-2 Trial. The American Journal of Cardiology 100:9, 1364-1369
CrossRef124
Catherine Kim, Rita F. Redberg, Tiana Pavlic, Kim A. Eagle. (2007) A Systematic Review of Gender Differences in Mortality after Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Interventions. Clinical Cardiology 30:10, 491-495
CrossRef125
Ralf Zahn, Thomas Ischinger, Matthias Hochadel, Bernd Mark, Uwe Zeymer, Jens Jung, Alexander Schramm, Karl-Eugen Hauptmann, Hubert Seggewiß, Ilse Janicke, Harald Mudra, Jochen Senges, . (2007) Glycoprotein IIb/IIIa antagonists during carotid artery stenting:. Clinical Research in Cardiology 96:10, 730-737
CrossRef126
Thomas W. Wallace, Sunil V. Rao. (2007) The Challenge of Defining Bleeding Among Patients with Acute Coronary Syndromes. Clinical Cardiology 30:S2, II16-II23
CrossRef127
Robert K. Winn, Sam R. Sharar, Nicholas B. Vedder, John M. Harlan. 2007. Leukocyte and Endothelial Adhesion Molecules in Ischaemia/Reperfusion Injuries. , 63-78.
CrossRef128
Rajeev Garg, Barry F. Uretsky, Eli I. Lev. (2007) Anti-platelet and anti-thrombotic approaches in patients undergoing percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 70:3, 388-406
CrossRef129
Walid Hassan, Hani Al-Sergani, Jehad Al Buraiki, Bruce Dunn, Fawaz Al Turki, Nathem Akhras, Fayez ElShaer, Mahboob Nawaz, Suliman Kharabsheh, Naser ElKum. (2007) Immediate and intermediate results of intracoronary stand-alone bolus administration of eptifibatide during coronary intervention (ICE) study. American Heart Journal 154:2, 345-351
CrossRef130
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliott M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction. Journal of the American College of Cardiology 50:7, e1-e157
CrossRef131
Jeffrey L. Anderson, Cynthia D. Adams, Elliott M. Antman, Charles R. Bridges, Robert M. Califf, Donald E. Casey, William E. Chavey, Francis M. Fesmire, Judith S. Hochman, Thomas N. Levin, A. Michael Lincoff, Eric D. Peterson, Pierre Theroux, Nanette Kass Wenger, R. Scott Wright, Sidney C. Smith, Alice K. Jacobs, Cynthia D. Adams, Jeffrey L. Anderson, Elliot M. Antman, Jonathan L. Halperin, Sharon A. Hunt, Harlan M. Krumholz, Frederick G. Kushner, Bruce W. Lytle, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2007) ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction—Executive Summary. Journal of the American College of Cardiology 50:7, 652-726
CrossRef132
Kagari Murasaki, Masatoshi Kawana, Satoshi Murasaki, Yukio Tsurumi, Kenjiro Tanoue, Nobuhisa Hagiwara, Hiroshi Kasanuki. (2007) High P-selectin expression and low CD36 occupancy on circulating platelets are strong predictors of restenosis after coronary stenting in patients with coronary artery disease. Heart and Vessels 22:4, 229-236
CrossRef133
Jean-Pierre Dery, Mark E. Campbell, Jasmine Mathias, Karen S. Pieper, Robert A. Harrington, Mina Madan, C. Michael Gibson, Thaddeus R. Tolleson, J. Conor O'Shea, James E. Tcheng, . (2007) Complementary effects of thienopyridine pretreatment and platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention; Results from the ESPRIT trial. Catheterization and Cardiovascular Interventions 70:1, 44-51
CrossRef134
William J van Gaal, Adrian P Banning. (2007) Percutaneous coronary intervention and the no-reflow phenomenon. Expert Review of Cardiovascular Therapy 5:4, 715-731
CrossRef135
M. U. Zafar, G. VILAHUR, B. G. CHOI, B. IBANEZ, J. F. VILES-GONZALEZ, E. SALAS, J. J. BADIMON. (2007) A novel anti-ischemic nitric oxide donor (LA419) reduces thrombogenesis in healthy human subjects. Journal of Thrombosis and Haemostasis 5:6, 1195-1200
CrossRef136
HITINDER S. GURM, DEAN E. SMITH, STAN J. CHETCUTI, DAVID SHARE, SANJAYA KHANAL, ARTHUR RIBA, ANDREW J. CARTER, THOMAS LALONDE, EVA KLINE-ROGERS, MICHAEL O'DONNELL, WILLIAM O'NEILL, ROBERT SAFIAN, MAURO MOSCUCCI. (2007) Temporal Trends, Safety, and Efficacy of Bivalirudin in Elective Percutaneous Coronary Intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium. Journal of Interventional Cardiology 20:3, 197-203
CrossRef137
Taku Kokubo, Hisashi Uchida, Eric T. Choi. (2007) Integrin αvβ3 as a target in the prevention of neointimal hyperplasia. Journal of Vascular Surgery 45:6, A33-A38
CrossRef138
Kjell S Sakariassen, Lars Örning. (2007) Validation of the human tissue factor/FVIIa complex as an antithrombotic target and the discovery of a synthetic peptide. Future Cardiology 3:3, 249-262
CrossRef139
Pierluigi Tricoci, L Kristin Newby, David E Kandzari, Robert A Harrington. (2007) Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. Expert Review of Cardiovascular Therapy 5:3, 401-412
CrossRef140
Eric Sauvageau, Rodney M. Samuelson, Elad I. Levy, Alison M. Jeziorski, Ricky A. Mehta, L. Nelson Hopkins. (2007) MIDDLE CEREBRAL ARTERY STENTING FOR ACUTE ISCHEMIC STROKE AFTER UNSUCCESSFUL MERCI RETRIEVAL. Neurosurgery 60:4, 701???706
CrossRef141
Arun Kalyanasundaram, James C. Blankenship, Peter Berger, Howard Herrmann, Rick McClure, David Moliterno. (2007) Thrombus predicts ischemic complications during percutaneous coronary intervention in saphenous vein grafts: Results from TARGET (do tirofiban and reopro give similar efficacy trial?). Catheterization and Cardiovascular Interventions 69:5, 623-629
CrossRef142
Nadine Gauthier, Michel R Le May. (2007) Percutaneous coronary intervention for left main coronary artery disease. Expert Review of Cardiovascular Therapy 5:2, 213-220
CrossRef143
Enrico Romagnoli, Francesco Burzotta, Carlo Trani, Giuseppe G. L. Biondi-Zoccai, Floriana Giannico, Filippo Crea. (2007) Rationale for intracoronary administration of abciximab. Journal of Thrombosis and Thrombolysis 23:1, 57-63
CrossRef144
Ganesh Raveendran, Henry H. Ting, Patricia J. Best, David R. Holmes, Ryan J. Lennon, Mandeep Singh, Malcolm R. Bell, Kirsten Hall Long, Charanjit S. Rihal. (2007) Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Mayo Clinic Proceedings 82:2, 196-202
CrossRef145
G. Raveendran, H. H. Ting, P. J. Best, D. R. Holmes, R. J. Lennon, M. Singh, M. R. Bell, K. H. Long, C. S. Rihal. (2007) Eptifibatide vs Abciximab as Adjunctive Therapy During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction. Mayo Clinic Proceedings 82:2, 196-202
CrossRef146
Min Hwan Kim, Eun Sook Jung, Sang Goo Yoon, Joon Hyung Doh, June Namgung, Sung Yun Lee, Sung Uk Kwon, Won Ro Lee, Tae Hyun Um. (2007) A Case of Abciximab Induced Acute Profound Thrombocytopenia Resulting in Compartment Syndrome of the Forearm from Massive Bleeding at the Brachial Artery Access Site. Korean Circulation Journal 37:11, 594
CrossRef147
Yutaka Matsumoto, Hisao Takizawa, Xiaoqi Gong, Sang Le, Simon Lockyer, Keiji Okuyama, Michinori Tanaka, Masuhiro Yoshitake, Narendra N. Tandon, Junichi Kambayashi. (2007) Highly potent anti-human GPVI monoclonal antibodies derived from GPVI knockout mouse immunization. Thrombosis Research 119:3, 319-329
CrossRef148
Young Joon Hong, Myung Ho Jeong, Sang Rok Lee, Seo Na Hong, Kye Hun Kim, Hyung Wook Park, Ju Han Kim, Weon Kim, Youngkeun Ahn, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2007) Anti-inflammatory Effect of Abciximab-Coated Stent in a Porcine Coronary Restenosis Model. Journal of Korean Medical Science 22:5, 802
CrossRef149
Jakub Przyluski, Maciej Karcz, Łukasz Kalińczuk, Mariusz Kruk, Jerzy Prȩgowski, Edyta Kaczmarska, Joanna Petryka, Paweł Bekta, Tomasz Deptuch, Cezary Kȩpka, Adam Witkowski, Witold Rużyłło, . (2007) Comparison of Different Methods of ST Segment Resolution Analysis for Prediction of 1-Year Mortality after Primary Angioplasty for Acute Myocardial Infarction. Annals of Noninvasive Electrocardiology 12:1, 5-14
CrossRef150
Vijay S Ramanath, Kim A Eagle. (2007) Evidence-Based Medical Therapy of Patients with Acute Coronary Syndromes. American Journal of Cardiovascular Drugs 7:2, 95-116
CrossRef151
Cagdas Ozdol, Sadi Gulec, Uzeyir Rahimov, Yusuf Atmaca, Sibel Turhan, Cetin Erol. (2007) Naproxen treatment prevents periprocedural inflammatory response but not myocardial injury after percutaneous coronary intervention. Thrombosis Research 119:4, 453-459
CrossRef152
Jan K. Madsen, Torsten T. Nielsen, Peer Grande, Ulrik H. Eriksen, Kari Saunamäki, Per Thayssen, Eli Kassis, Klaus Rasmussen, Stig Haunsø, Torben Haghfelt, Per Fritz-Hansen, Erik Hjelms, Peter K. Paulsen, Poul Alstrup, Henrik Arendrup, Uffe Niebuhr-Jørgensen, Lars I. Andersen. (2007) Revascularization Compared to Medical Treatment in Patients with Silent vs. Symptomatic Residual Ischemia after Thrombolyzed Myocardial Infarction – The DANAMI Study. Cardiology 108:4, 243-251
CrossRef153
Richard C. Becker. 2007. Hemostatic Aspects of Cardiovascular Medicine. , 339-369.
CrossRef154
Shawn Jobe, Jorge Di Paola. 2007. Congenital and Acquired Disorders of Platelet Function and Number. , 139-157.
CrossRef155
Cinzia Capuano, Marco Sesana, Ornella Leonzi, Claudio Cuccia. (2006) Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results. Journal of Cardiovascular Medicine 7:12, 866-871
CrossRef156
Glenn N Levine, Peter B Berger, David J Cohen, Andrew O Maree, Kenneth Rosenfield, Barbara S Wiggins, Sarah A Spinler. (2006) Newer Pharmacotherapy in Patients Undergoing Percutaneous Coronary Interventions: A Guide for Pharmacists and Other Health Care Professionals. Pharmacotherapy 26:11, 1537-1556
CrossRef157
Kyle A Weant, Jeremy F Flynn, Wendell S Akers. (2006) Management of Antiplatelet Therapy for Minimization of Bleeding Risk Before Cardiac Surgery. Pharmacotherapy 26:11, 1616-1625
CrossRef158
Sixten Borg, Ulf Persson, Kristina Allikmets, Karin Ericsson. (2006) Comparative cost-effectiveness of anticoagulation with bivalirudin or heparin with and without a glycoprotein IIb/IIIa-Receptor inhibitor in patients undergoing percutaneous coronary intervention in Sweden: A decision-analytic model. Clinical Therapeutics 28:11, 1947-1959
CrossRef159
Adnan I. Qureshi, Pansy Harris-Lane, Jawad F. Kirmani, Nazli Janjua, Afshin A. Divani, Yousef M. Mohammad, Jose I. Suarez, Michael O. Montgomery. (2006) Intra-arterial Reteplase and Intravenous Abciximab in Patients with Acute Ischemic Stroke: An Open-label, Dose-ranging, Phase I Study. Neurosurgery 59:4, 789-797
CrossRef160
LORAN YEHUDAI, FREDERICK FEIT. (2006) Debate of Adjunctive Pharmacology for Percutaneous Coronary Intervention: Thrombin Inhibitors and Clopidogrel Are Enough. Journal of Interventional Cardiology 19:5, 464-469
CrossRef161
PIERLUIGI TRICOCI, ERIC D. PETERSON. (2006) The Evolving Role of Glycoprotein IIb/IIIa Inhibitor Therapy in Contemporary Care of Acute Coronary Syndrome Patients. Journal of Interventional Cardiology 19:5, 449-455
CrossRef162
Adnan K. Chhatriwalla, Deepak L. Bhatt. 2006. Anticoagulation and Antiplatelet Agents. , 501-524.
CrossRef163
Jacqueline Saw, Deepak L. Bhatt, David J. Moliterno, Sorin J. Brener, Steven R. Steinhubl, A. Michael Lincoff, James E. Tcheng, Robert A. Harrington, Maarten Simoons, TingFei Hu, Mobeen A. Sheikh, Dean J. Kereiakes, Eric J. Topol. (2006) The Influence of Peripheral Arterial Disease on Outcomes. Journal of the American College of Cardiology 48:8, 1567-1572
CrossRef164
James T. Willerson, Paul W Armstrong. 2006. Acute Myocardial Infarction. , 611-646.
CrossRef165
Florian B. Mayr, Bernd Jilma. (2006) Current developments in anti-platelet therapy. Wiener Medizinische Wochenschrift 156:17-18, 472-480
CrossRef166
SAID B. ISKANDAR, EHAB S. KASASBEH, BASSAM K. MECHLEB, ISRAEL GARCIA, ANN JACKSON, STEPHEN FAHRIG, KAISS ALBALBISSI, PHILLIP D. HENRY. (2006) Alveolar Hemorrhage: An Underdiagnosed Complication of Treatment with Glycoprotein IIb/IIIa Inhibitors. Journal of Interventional Cardiology 19:4, 356-363
CrossRef167
Geoff Hale. (2006) Therapeutic antibodies — Delivering the promise?. Advanced Drug Delivery Reviews 58:5-6, 633-639
CrossRef168
David J. Schneider, Friederike Keating, Burton E. Sobel. (2006) Greater inhibitory effects of bivalirudin compared with unfractionated heparin plus eptifibitide on thrombin-induced platelet activation. Coronary Artery Disease 17:5, 471-476
CrossRef169
Michel R Hoenig, Jenny Doust, Constantine N Aroney, Ian A Scott, Michel R Hoenig. 2006. Early invasive versus conservative strategies for unstable angina & non-ST-elevation myocardial infarction in the stent era. .
CrossRef170
K. J. Mishra, P. R. Sage, A. C. Philpott, C. J. Zeitz, J. D. Horowitz. (2006) Temporal trends in major angioplasty complications: technical issues and the case for on-site coronary surgery. Internal Medicine Journal 36:7, 458-461
CrossRef171
C. Michael Gibson, David A. Morrow, Sabina A. Murphy, Theresa M. Palabrica, Lisa K. Jennings, Peter H. Stone, Henry H. Lui, Thomas Bulle, Nasser Lakkis, Richard Kovach, David J. Cohen, Polly Fish, Carolyn H. McCabe, Eugene Braunwald. (2006) A Randomized Trial to Evaluate the Relative Protection Against Post-Percutaneous Coronary Intervention Microvascular Dysfunction, Ischemia, and Inflammation Among Antiplatelet and Antithrombotic Agents. Journal of the American College of Cardiology 47:12, 2364-2373
CrossRef172
Shen Wong, Michael Appleberg, David R. Lewis. (2006) ANTIPLATELET THERAPY IN PERIPHERAL OCCLUSIVE ARTERIAL DISEASE. ANZ Journal of Surgery 76:5, 364-372
CrossRef173
Karl Isaaz, Christophe Robin, Alexis Cerisier, Michel Lamaud, Laure Richard, Antoine Da Costa, Mohamed Hassan Sabry, Claude Gerenton, Jean Louis Blanc. (2006) A new approach of primary angioplasty for ST-elevation acute myocardial infarction based on minimalist immediate mechanical intervention. Coronary Artery Disease 17:3, 261-269
CrossRef174
Udaya S Tantry, Amena Etherington, Kevin P Bliden, Paul A Gurbel. (2006) Antiplatelet therapy: current strategies and future trends. Future Cardiology 2:3, 343-366
CrossRef175
M. Yazici, S. Demircan, E. Aygul, M. Sahin, F. Albayrak, E. Aksakal, B. Durupinar, A. Zimmo, O. Sagkan. (2006) Effect of sedation on soluble P-selectin levels, coagulation and myocardial damage following a coronary intervention. International Journal of Clinical Practice 60:5, 526-532
CrossRef176
E. M. L. Wong, E. B. Wu, W. W. M. Chan, C. M. Yu. (2006) A review of the management of patients after percutaneous coronary intervention. International Journal of Clinical Practice 60:5, 582-589
CrossRef177
G. W. Stone, H. D. Aronow. (2006) Long-term Care After Percutaneous Coronary Intervention: Focus on the Role of Antiplatelet Therapy. Mayo Clinic Proceedings 81:5, 641-652
CrossRef178
Rakesh P. Mehta, Matthew S. Johnson. (2006) Update on Anticoagulant Medications for the Interventional Radiologist. Journal of Vascular and Interventional Radiology 17:4, 597-612
CrossRef179
Weon Kim, Myung Ho Jeong, Kye Hun Kim, Il Suk Sohn, Young Joon Hong, Hyung Wook Park, Ju Han Kim, Young Keun Ahn, Jeong Gwan Cho, Jong Chun Park, Dong Lyun Cho, Jung Chae Kang. (2006) The Clinical Results of a Platelet Glycoprotein IIb/IIIa Receptor Blocker (Abciximab: ReoPro)-Coated Stent in Acute Myocardial Infarction. Journal of the American College of Cardiology 47:5, 933-938
CrossRef180
Michael P Dorsch, Debbie Montague, Jo E Rodgers, Cam Patterson. (2006) Abciximab-Associated Thrombocytopenia After Previous Tirofiban-Related Thrombocytopenia. Pharmacotherapy 26:3, 423-427
CrossRef181
Antonio Colombo, Goran Stankovic. (2006) The Value of Selectivity
Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 47:4, 719-720
CrossRef182
Gary M. Ansel, Mitchell J. Silver, Charles F. Botti, Krishna Rocha-Singh, Mark C. Bates, Kenneth Rosenfield, Robert M. Schainfeld, Steven B. Laster, Carol Zander. (2006) Functional and clinical outcomes of nitinol stenting with and without abciximab for complex superficial femoral artery disease: A randomized trial. Catheterization and Cardiovascular Interventions 67:2, 288-297
CrossRef183
Joseph A. Puma, Lesan T. Banko, Karen S. Pieper, Terrence J. Sacchi, J. Conor O’Shea, Jean Pierre Dery, James E. Tcheng. (2006) Clinical Characteristics Predict Benefits From Eptifibatide Therapy During Coronary Stenting. Journal of the American College of Cardiology 47:4, 715-718
CrossRef184
Sunil V. Rao, Kristi O’Grady, Karen S. Pieper, Christopher B. Granger, L. Kristin Newby, Kenneth W. Mahaffey, David J. Moliterno, A. Michael Lincoff, Paul W. Armstrong, Frans Van de Werf, Robert M. Califf, Robert A. Harrington. (2006) A Comparison of the Clinical Impact of Bleeding Measured by Two Different Classifications Among Patients With Acute Coronary Syndromes. Journal of the American College of Cardiology 47:4, 809-816
CrossRef185
Ruchira Glaser, Henry A. Glick, Howard C. Herrmann, Stephen E. Kimmel. (2006) The Role of Risk Stratification in the Decision to Provide Upstream Versus Selective Glycoprotein IIb/IIIa Inhibitors for Acute Coronary Syndromes. Journal of the American College of Cardiology 47:3, 529-537
CrossRef186
Weon Kim, Myung Ho Jeong, Sun Ho Hwang, Kye Hun Kim, Young Joon Hong, Young Keun Ahn, Wan Kim, Jeong Gwan Cho, Jong Chun Park, Jung Chaee Kang. (2006) Comparison of Abciximab Combined With Dalteparin or Unfractionated Heparin in High-Risk Percutaneous Coronary Intervention in Acute Myocardial Infarction Patients. International Heart Journal 47:6, 821-831
CrossRef187
Sidney C. Smith, Ted E. Feldman, John W. Hirshfeld, Alice K. Jacobs, Morton J. Kern, Spencer B. King, Douglass A. Morrison, William W. O’Neill, Hartzell V. Schaff, Patrick L. Whitlow, David O. Williams, Elliott M. Antman, Sidney C. Smith, Cynthia D. Adams, Jeffrey L. Anderson, David P. Faxon, Valentin Fuster, Jonathan L. Halperin, Loren F. Hiratzka, Sharon Ann Hunt, Alice K. Jacobs, Rick Nishimura, Joseph P. Ornato, Richard L. Page, Barbara Riegel. (2006) ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention. Journal of the American College of Cardiology 47:1, e1-e121
CrossRef188
Shyh-Ming Chen, Yuan-Kai Hsieh, Gary Bih-Fang Guo, Chi-Yan Fang, Hon-Kan Yip, Chiung-Jen Wu, Morgan Fu. (2006) Angiographic and Clinical Outcome in ST-Segment Elevation Myocardial Infarction Patients Receiving an Adjunctive Double Bolus Regimen of Tirofiban for Primary Percutaneous Coronary Intervention. Circulation Journal 70:5, 536-541
CrossRef189
2006. Abciximab. , 4-8.
CrossRef190
Friederike K. Keating, Harold L. Dauerman, Deborah A. Whitaker, Burton E. Sobel, David J. Schneider. (2006) Increased expression of platelet P-selectin and formation of platelet–leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thrombosis Research 118:3, 361-369
CrossRef191
John A. Bittl. (2005) Reducing the Risk of Emergency Bypass Surgery for Failed Percutaneous Coronary Interventions* *Editorials published in the Journal of American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.. Journal of the American College of Cardiology 46:11, 2010-2012
CrossRef192
A. Arhan, P. Ecollan, B. Madonna-Py, J. Kergueno, M. Bennaceur, M.-O. Josse, G. Montalescot, B. Riou. (2005) Assessment of early administration of abciximab in acute ST-segment elevation myocardial infarction in the emergency department. Journal Européen des Urgences 18:4, 193-198
CrossRef193
Eric Van Belle, Christophe Bauters, Eug??ne McFadden, Michel E. Bertrand. (2005) Nature of coronary disease in patients with insulin resistance and its impact on revascularization strategies. Coronary Artery Disease 16:8, 481-487
CrossRef194
George Y.H. Chi. (2005) Some issues with composite endpoints in clinical trials. Fundamental and Clinical Pharmacology 19:6, 609-619
CrossRef195
Lisa K Jennings. (2005) Current strategies with eptifibatide and other antiplatelet agents in percutaneous coronary intervention and acute coronary syndromes. Expert Opinion on Drug Metabolism & Toxicology 1:4, 727-737
CrossRef196
Jon G. Ryckman, Scott Hall, Jorge Serra. (2005) Coronary Artery Bypass Grafting in a Patient with Glanzmann's Thrombasthenia. Journal of Cardiac Surgery 20:6, 555-556
CrossRef197
Francesco Prati, Piotr Kwiatkowski, Constantino Caroselli, Fabrizio Imola, Alessandro Manzoli, Tamer Fouad, Pierfrancesco Corvo, Vito Ramazzotti. (2005) Use of abciximab prevents microcirculatory impairment in patients treated with coronary angioplasty for unstable angina: Results of a prospective randomized study. Catheterization and Cardiovascular Interventions 66:2, 165-169
CrossRef198
Deanne J Crosbie. (2005) Use of glycoprotein IIb/IIIa inhibitors in unstable angina and non-ST-elevation myocardial infarction. Emergency Medicine Australasia 17:5-6, 500-510
CrossRef199
T. AOKI, Y. TOMIYAMA, S. HONDA, K. MIHARA, T. YAMANAKA, M. OKUBO, A. MORIGUCHI, S. MUTOH. (2005) Association of the antagonism of von Willebrand factor but not fibrinogen by platelet αIIbβ3 antagonists with prolongation of bleeding time. Journal of Thrombosis and Haemostasis 3:10, 2307-2314
CrossRef200
Harjot K. Saini, Yan-Jun Xu, Amarjit S. Arneja, Paramjit S. Tappia, Naranjan S. Dhalla. (2005) Pharmacological basis of different targets for the treatment of atherosclerosis. Journal of Cellular and Molecular Medicine 9:4, 818-839
CrossRef201
Friederike K. Keating, Harold L. Dauerman, Deborah A. Whitaker, Burton E. Sobel, David J. Schneider. (2005) The effects of bivalirudin compared with those of unfractionated heparin plus eptifibatide on inflammation and thrombin generation and activity during coronary intervention. Coronary Artery Disease 16:6, 401-405
CrossRef202
D. R. PHILLIPS, P. B. CONLEY, U. SINHA, P. ANDRE. (2005) Therapeutic approaches in arterial thrombosis. Journal of Thrombosis and Haemostasis 3:8, 1577-1589
CrossRef203
ADRIAN F. LOW, YEAN-TENG LIM, SWEE-GUAN TEO, BAMBANG BUDIONO, ANTONO SUTANDAR, HUAY-CHEEM TAN. (2005) Comparison of the X-SIZER Thrombectomy Device with Adjunct Abciximab During Primary Angioplasty and Stenting for ST-Segment Elevation Myocardial Infarction. Journal of Interventional Cardiology 18:4, 267-273
CrossRef204
Saskia L.M.A. Beeres, Pranobe V. Oemrawsingh, Hazem M. Warda, Ratna Bechan, Douwe E. Atsma, J. Wouter Jukema, Ernst E. van der Wall, Martin J. Schalij. (2005) Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty. Catheterization and Cardiovascular Interventions 65:4, 478-483
CrossRef205
Toshio Yamanaka, Mitsuru Ohkubo, Satoru Kuroda, Hideko Nakamura, Fumie Takahashi, Toshiaki Aoki, Kayoko Mihara, Jiro Seki, Masayuki Kato. (2005) Design, synthesis, and structure–activity relationships of potent GPIIb/IIIa antagonists: discovery of FK419. Bioorganic & Medicinal Chemistry 13:13, 4343-4352
CrossRef206
D FIORELLA, L THIABOLT, F ALBUQUERQUE, V DESHMUKH, C MCDOUGALL, P RASMUSSEN. (2005) Antiplatelet Therapy in Neuroendovascular Therapeutics. Neurosurgery Clinics of North America 16:3, 517-540
CrossRef207
Efthymios N. Deliargyris, Bharathi Upadhya, Robert J. Applegate, Jimmy L. Kontos, Michael A. Kutcher, Jeffrey S. Riesmeyer, David C. Sane. (2005) Safety of Abciximab Administration During PCI of Patients with Previous Stroke. Journal of Thrombosis and Thrombolysis 19:3, 147-153
CrossRef208
(2005) Guías de Práctica Clínica sobre intervencionismo coronario percutáneo. Revista Española de Cardiología 58:6, 679-728
CrossRef209
Begoña Benito, Mónica Masotti, Amadeo Betriu. (2005) Avances en el tratamiento farmacológico coadyuvante en la intervención coronaria. Revista Española de Cardiología 58:6, 729-743
CrossRef210
Reza Jahan. (2005) Hyperacute Therapy of Ischemic Stroke: Intravenous Thrombolysis. Techniques in Vascular and Interventional Radiology 8:2, 81-86
CrossRef211
Dimitri A. Sherev, Richard E. Shaw, Bruce N. Brent,. (2005) Angiographic predictors of femoral access site complications: Implication for planned percutaneous coronary intervention. Catheterization and Cardiovascular Interventions 65:2, 196-202
CrossRef212
Rory O'Hanlon, Donal N. Reddan. (2005) Treatment of Acute Coronary Syndromes in Patients Who Have Chronic Kidney Disease. Medical Clinics of North America 89:3, 563-585
CrossRef213
Rosemarie A Reiter, Bernd Jilma. (2005) Platelets and new antiplatelet drugs. Therapy 2:3, 465-502
CrossRef214
Hani Jneid, Massoud Leessar, Roberto Bolli. (2005) Cardiac Preconditioning during Percutaneous Coronary Interventions. Cardiovascular Drugs and Therapy 19:3, 211-217
CrossRef215
Prabir Lahiri, Utpal Chaudhuri, Arnab Chattopadhyay, Prantar Chakraborty, Dipes Mandal, Anjan Kr Dasgupta. (2005) Structural insights in platelet receptor synergism-antiplatelet therapy in post-ischemic cerebrovascular events. Blood Cells, Molecules, and Diseases 34:3, 248-256
CrossRef216
Francisco J. Rodríguez-Gómez, Ángel Sánchez, Francisco J. Martínez, Juan Andreu, Alejandra Álvarez, Emilio Pujol. (2005) Hemorragia pulmonar por abciximab. Factores de riesgo y papel de la protamina. Revista Española de Cardiología 58:4, 453-455
CrossRef217
Miriam Galbusera, Simona Buelli, Sara Gastoldi, Daniela Macconi, Stefania Angioletti, Cristian Testa, Giuseppe Remuzzi, Marina Morigi. (2005) Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. Xenotransplantation 12:2, 110-120
CrossRef218
Hratch Karmanoukian, Bashir Attuwabi, Nader D. Nader. (2005) Antithrombotic controversies in off-pump coronary bypass. Seminars in Thoracic and Cardiovascular Surgery 17:1, 59-65
CrossRef219
Lloyd W. Klein. (2005) Coronary complications of percutaneous coronary intervention: A practical approach to the management of abrupt closure. Catheterization and Cardiovascular Interventions 64:3, 395-401
CrossRef220
Y. Joseph Woo. (2005) Cardiac surgery in patients on antiplatelet and antithrombotic agents. Seminars in Thoracic and Cardiovascular Surgery 17:1, 66-72
CrossRef221
Soumaya El Rouby, Marc Cohen, Andrea Gonzales, Debra Hoppensteadt, Marcia L Zucker, Ted Lee, Khaula Khalid, Jawed Fareed, Frank M LaDuca. (2005) Point-of-Care Monitoring of Enoxaparin in the Presence of GpIIb/IIIa Combined Therapy During Percutaneous Coronary Interventions. Point of Care: The Journal of Near-Patient Testing & Technology 4:1, 30-35
CrossRef222
Rosemarie Reiter, Petra Jilma-Stohlawetz, Michaela Horvath, Bernd Jilma. (2005) Additive effects between platelet concentrates and desmopressin in antagonizing the platelet glycoprotein IIb/IIIa inhibitor eptifibatide. Transfusion 45:3, 420-426
CrossRef223
Harry L. Messmore, Walter P. Jeske, William Wehrmacher, Erwin Coyne, Sohrab Mobarhan, Leslie Cho, Fred S. Leya, John F. Moran. (2005) Antiplatelet Agents: Current Drugs and Future Trends. Hematology/Oncology Clinics of North America 19:1, 87-117
CrossRef224
Jeffrey S. Berger, James N. Slater, Warren Sherman, Stephen J. Green, Timothy A. Sanborn, David L. Brown. (2005) Impact of Platelet Glycoprotein IIb/IIIa Inhibitor Therapy on In-Hospital Outcomes and Long-Term Survival Following Percutaneous Coronary Rotational Atherectomy. Journal of Thrombosis and Thrombolysis 19:1, 47-54
CrossRef225
OMAR ABDUL RAZAKJR, HUAY CHEEM TAN, WEI LUEN YIP, YEAN TENG LIM. (2005) Predictors of Bleeding Complications and Thrombocytopenia with the Use of Abciximab during Percutaneous Coronary Intervention. Journal of Interventional Cardiology 18:1, 33-37
CrossRef226
D. H. Lee, K. D. Jo. (2005) Adjuvant Use of Abciximab for Balloon Angioplasty of Symptomatic Middle Cerebral Artery Stenosis. Acta Radiologica 46:5, 534-538
CrossRef227
Abdallah G Rebeiz, Joseph Adams, Robert A Harrington. (2005) Interventional Cardiovascular Pharmacotherapy. American Journal of Cardiovascular Drugs 5:2, 93-102
CrossRef228
Ju Han Kim, Myung Ho Jeong, Jay Young Rhew, Ji Hyun Lim, Kyung Ho Yun, Kye Hun Kim, Dong Koo Kang, Seo Na Hong, Sang Yup Lim, Sang Hyun Lee, Yeon Sang Lee, Young Joon Hong, Hyung Wook Park, Weon Kim, Young Keun Ahn, Yong Moon, Jeong Gwang Cho, Jong Chun Park, Jung Chaee Kang. (2005) Long-Term Clinical Outcomes of Platelet Glycoprotein IIb/IIIa Inhibitor Combined With Low Molecular Weight Heparin in Patients With Acute Coronary Syndrome. Circulation Journal 69:2, 159-164
CrossRef229
Carey Kimmelstiel, Jehangir Badar, Lidija Covic, Sergio Waxman, Andrew Weintraub, Suzanne Jacques, Athan Kuliopulos. (2005) Pharmacodynamics and pharmacokinetics of the platelet GPIIb/IIIa inhibitor tirofiban in patients undergoing percutaneous coronary intervention: implications for adjustment of tirofiban and clopidogrel dosage. Thrombosis Research 116:1, 55-66
CrossRef230
Joon Hoon Jeong, Kook-Jin Chun, Yong Hyun Park, June Hong Kim, Taek Jong Hong, Yung Woo Shin. (2005) Safety of Tirofiban Therapy in Korean Patients With Acute Coronary Syndrome. Circulation Journal 69:6, 650-653
CrossRef231
Yulri Park, Hong Gee Roh, Sung Wook Choo, Sung Hoon Lee, Sung Wook Shin, Young Soo Do, Hong Sik Byun, Kwang Bo Park, Pyoung Jeon. (2005) Prospective Comparison of Collagen Plug (Angio-Seal?? and Suture-Mediated (the Closer S?? Closure Devices at Femoral Access Sites. Korean Journal of Radiology 6:4, 248
CrossRef232
Omar Badawi, Lance J. Oyen, Stuart T. Haines. (2004) Dosing of Unfractionated Heparin in Acute Coronary Syndromes. Pharmacotherapy 24:12, 1681-1691
CrossRef233
J. HIRSH, S. BATES. (2004) The multiple faces of the partial thromboplastin time APTT. Journal of Thrombosis and Haemostasis 2:12, 2254-2256
CrossRef234
Melanie M. White, Rajini Krishnan, Teddi J. Kueter, Mary V. Jacoski, Lisa K. Jennings. (2004) The Use of the Point of Care Helena ICHOR/Plateletworks® and the Accumetrics Ultegra® RPFA for Assessment of Platelet Function with GPIIb-IIIa Antagonists. Journal of Thrombosis and Thrombolysis 18:3, 163-169
CrossRef235
David J Schneider, Atul Aggarwal. (2004) Development of glycoprotein IIb–IIIa antagonists: translation of pharmacodynamic effects into clinical benefit. Expert Review of Cardiovascular Therapy 2:6, 903-913
CrossRef236
J. Hausleiter, A. Kastrati, J. Mehilli, H. Schuhlen, J. Pache, F. Dotzer, C. Glatthor, S. Siebert, J. Dirschinger, A. Schomig, . (2004) A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. Journal of Internal Medicine 256:5, 388-397
CrossRef237
Maud B. Gorbet, Michael V. Sefton. (2004) Biomaterial-associated thrombosis: roles of coagulation factors, complement, platelets and leukocytes. Biomaterials 25:26, 5681-5703
CrossRef238
&NA;. (2004) The use of glycoprotein IIb/IIIa receptor antagonists in percutaneous coronary intervention results in both short- and long-term benefits. Drugs & Therapy Perspectives 20:10, 7-10
CrossRef239
Mark A. Perazella, Ari Mosenkis, Jeffrey S. Berns. (2004) Use of Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Inhibitors in Patients with Chronic Kidney Disease. Seminars in Dialysis 17:5, 411-416
CrossRef240
Peter A. Heppner, Stephen J. Monteith, Andrew J. J. Law. (2004) Spontaneous spinal hematomas and low-molecular-weight heparin. Journal of Neurosurgery: Spine 1:2, 232-236
CrossRef241
Nicolette M.S.K.J. Ernst, Harry Suryapranata, Kor Miedema, Robbert J. Slingerland, Jan Paul Ottervanger, Jan C.A. Hoorntje, A.T.Marcel Gosselink, Jan-Henk E. Dambrink, Menko-Jan de Boer, Felix Zijlstra, Arnoud W.J. van’t Hof. (2004) Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 44:6, 1187-1193
CrossRef242
Ganesan Karthikeyan, Balram Bhargava. (2004) Prevention of restenosis after coronary angioplasty. Current Opinion in Cardiology 19:5, 500-509
CrossRef243
Mehmet Akbulut, Yilmaz Ozbay, Ilgin Karaca, Erdogan Ilkay, Ozlem Gundogdu, Nadi Arslan. (2004) The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention. Coronary Artery Disease 15:6, 347-352
CrossRef244
Michael S Lee, Eric M David, Raj R Makkar, James R Wilentz. (2004) Molecular and cellular basis of restenosis after percutaneous coronary intervention: the intertwining roles of platelets, leukocytes, and the coagulation–fibrinolysis system. The Journal of Pathology 203:4, 861-870
CrossRef245
Francis Q. Almeda, Gary L. Schaer. (2004) Noncardiac applications of glycoprotein IIb/IIIa inhibitors. Catheterization and Cardiovascular Interventions 62:4, 530-538
CrossRef246
Thomas L. Rihn, José Díez, The Heparin Consensus Group. (2004) Unfractionated Heparin in Cardiology: Redefining the Standard of Practice. Pharmacotherapy 24:8 Part 2, 132S-141S
CrossRef247
Michael L Stadius. (2004) Diminishing returns …and too many choices …the saga of pharmacologic therapy to reduce the complications of percutaneous coronary intervention. Journal of the American College of Cardiology 44:1, 25-27
CrossRef248
Ganesh Manoharan, A. A. Jennifer Adgey. (2004) Considerations in combination therapy: Fibrinolytics plus glycoprotein IIb/IIIa receptor inhibitors in acute myocardial infarction. Clinical Cardiology 27:7, 381-386
CrossRef249
Paul A Gurbel, Kevin P Bliden, Kevin M Hayes, Udaya Tantry. (2004) Platelet activation in myocardial ischemic syndromes. Expert Review of Cardiovascular Therapy 2:4, 535-545
CrossRef250
Brian D. Guth, Hans Narjes, Hans-Dieter Schubert, Paul Tanswell, Axel Riedel, Gerhard Nehmiz. (2004) Pharmacokinetics and pharmacodynamics of terbogrel, a combined thromboxane A2 receptor and synthase inhibitor, in healthy subjects. British Journal of Clinical Pharmacology 58:1, 40-51
CrossRef251
Cindy L Kaiser, David G. M Carville, Kirk E Guyer, C Ty Walker, George R Aycock. (2004) Evaluation of Platelet Count and Function in Patients Administered Tirofiban or Eptifibatide Undergoing Percutaneous Coronary Intervention. Point of Care: The Journal of Near-Patient Testing & Technology 3:2, 66-70
CrossRef252
Raymond L. Benza, Gilbert J. Zoghbi, Jose Tallaj, Robert Brown, James K. Kirklin, Meloneysa Hubbard, Barry Rayburn, Brian Foley, David C. McGiffin, Laura J. Pinderski, Vijay Misra, Robert C. Bourge. (2004) Palliation of allograft vasculopathy with transluminal angioplasty. Journal of the American College of Cardiology 43:11, 1973-1981
CrossRef253
MR Hoenig, JA Doust, CN Aroney, IA Scott, Michel Hoenig. 2004. Early invasive versus ischemia-guided strategies for unstable angina & non-ST-elevation myocardial infarction. .
CrossRef254
Kayoko Mihara, Toshiaki Aoki, Akira Moriguchi, Hiroko Yamamoto, Masashi Maeda, Nobuteru Tojo, Toshio Yamanaka, Mitsuru Ohkubo, Nobuya Matsuoka, Jiro Seki, Seitaro Mutoh. (2004) Characterization of the anti-platelet actions of FK419, a novel non-peptide antagonist of platelet GPIIb/IIIa. Drug Development Research 61:4, 233-241
CrossRef255
Victor J Marder, Michael H Rosove, Dena M Minning. (2004) Foundation and sites of action of antithrombotic agents. Best Practice & Research Clinical Haematology 17:1, 3-22
CrossRef256
Marco Zimarino, Raffaele De Caterina. (2004) Glycoprotein IIb-IIIa Antagonists in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Interventions: from Pharmacology to Individual Patient's Therapy. Journal of Cardiovascular Pharmacology 43:3, 325-332
CrossRef257
Wai-Hong Chen, Pui-Yin Lee, William Ng, Hung-Fat Tse, Chu-Pak Lau. (2004) Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. Journal of the American College of Cardiology 43:6, 1122-1126
CrossRef258
J. Niemetz, J. T. Fallon, E. Harrington, J. Hathcock. (2004) Rapid generation of thrombin by atheroma and platelets. Journal of Thrombosis and Haemostasis 2:2, 321-326
CrossRef259
Miles Dalby, Gilles Montalescot, Claire Bal dit Sollier, Eric Vicaut, Thierry Soulat, Jean-Philippe Collet, Rémi Choussat, Vanessa Gallois, Gérard Drobinski, Ludovic Drouet, Daniel Thomas. (2004) Eptifibatide provides additional platelet inhibition in Non–ST-Elevation myocardial infarction patients already treated with aspirin and clopidogrel. Journal of the American College of Cardiology 43:2, 162-168
CrossRef260
Sherwin K B Sy, Aaron L Levenstadt. (2004) A Perspective on the Toxicological Mechanisms Possibly Contributing to the Failure of Oral Glycoprotein IIb/IIIa Antagonists in the Clinic. American Journal of Cardiovascular Drugs 4:1, 1-10
CrossRef261
Ramesh M Gowda, Ijaz A Khan, Balendu C Vasavada, Terrence J Sacchi. (2004) Therapeutics of Platelet Glycoprotein IIb/IIIa Receptor Antagonism. American Journal of Therapeutics 11:4, 302-307
CrossRef262
Hideki Kunichika, Ori Ben-Yehuda, Stephane Lafitte, Naomi Kunichika, Barry Peters, Anthony N. DeMaria. (2004) Effects of glycoprotein iib/iiia inhibition on microvascular flow after coronary reperfusion. Journal of the American College of Cardiology 43:2, 276-283
CrossRef263
Stefan James. (2004) Coagulation, inflammation and myocardial dysfunction in unstable coronary artery disease and the influence of glycoprotein IIb/IIIa inhibition and low molecular weight heparin. Upsala Journal of Medical Sciences 109:2, 71-122
CrossRef264
Francois Philippe, Fabrice Larrazet, Tarek Meziane, Alain Dibie. (2004) Comparison of transradial vs. transfemoral approach in the treatment of acute myocardial infarction with primary angioplasty and abciximab. Catheterization and Cardiovascular Interventions 61:1, 67-73
CrossRef265
Aman K. Kakkar, Ali Moustapha, Henry G. Hanley, Mitchell Weiss, Gloria Caldito, Praphul Misra, Pratap C. Reddy, Neeraj Tandon. (2004) Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheterization and Cardiovascular Interventions 61:1, 31-34
CrossRef266
M. Ragosta, I. J. Sarembock. (2004) Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? No. Journal of Thrombosis and Haemostasis 2:1, 10-12
CrossRef267
Myung Ho Jeong. (2004) Percutaneous Coronary Intervention for Coronary Artery Disease. Journal of the Korean Medical Association 47:8, 736
CrossRef268
Juan F Granada, Neal S Kleiman. (2004) Therapeutic Use of Intravenous Eptifibatide in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiovascular Drugs 4:1, 31-41
CrossRef269
J. E. Exaire, A. M. Lincoff. (2004) Should glycoprotein IIb/IIIa inhibitors be used during all percutaneous coronary interventions? Yes. Journal of Thrombosis and Haemostasis 2:1, 7-9
CrossRef270
R Choussat, J.P Collet, F Beygui, M Borentain, G Montalescot. (2003) Intérêt de la prise en charge précoce des syndromes coronaires aigus par les anti-GPIIb/IIIa. Annales de Cardiologie et d'Angéiologie 52, S1-S9
CrossRef271
Mansoor A Qureshi, Robert D Safian, Cindy L Grines, James A Goldstein, Douglas C Westveer, Susan Glazier, Mamtha Balasubramanian, William W O'Neill. (2003) Simplified scoring system for predicting mortality after percutaneous coronary intervention. Journal of the American College of Cardiology 42:11, 1890-1895
CrossRef272
Sunil V. Rao. (2003) Controversies Surrounding the Use of Glycoprotein IIb/IIIa Inhibitors. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 2:4, 231-238
CrossRef273
Hani Jneid, Deepak L Bhatt. (2003) Advances in antiplatelet therapy. Expert Opinion on Emerging Drugs 8:2, 349-363
CrossRef274
Jasper S. Wijpkema, Gillian A.J. Jessurun, Ad J. Van Boven, Dik I.K. Versteeg, Raymond W.M. Hautvast, Ren
A. Tio. (2003) Clinical impact of abciximab on long-term outcome after complex coronary angioplasty. Catheterization and Cardiovascular Interventions 60:3, 339-343
CrossRef275
Christophe L Dubois, Ann Belmans, Christopher B Granger, Paul W Armstrong, Lars Wallentin, Paolo M Fioretti, José L López-Sendón, Freek W Verheugt, Jürgen Meyer, Frans Van de Werf. (2003) Outcome of urgent and elective percutaneous coronary interventions after pharmacologic reperfusion with tenecteplase combined with unfractionated heparin, enoxaparin, or abciximab. Journal of the American College of Cardiology 42:7, 1178-1185
CrossRef276
S. Dunkley, R. Lindeman, S. Evans, R. Casten, N. Jepson. (2003) Evidence of platelet activation due to tirofiban-dependent platelet antibodies: double trouble. Journal of Thrombosis and Haemostasis 1:10, 2248-2250
CrossRef277
Mitchell J Ross, Howard C Herrmann, David J Moliterno, James C Blankenship, Laura Demopoulos, Peter M DiBattiste, Stephen G Ellis, Ziyad Ghazzal, Jack L Martin, Jennifer White, Eric J Topol. (2003) Angiographic variables predict increased riskfor adverse ischemic events after coronarystenting with glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology 42:6, 981-988
CrossRef278
Jocelyn S Fernandez, Betty T Sadaniantz, Ara Sadaniantz. (2003) Review of antithrombotic agents used for acute coronary syndromes in renal patients. American Journal of Kidney Diseases 42:3, 446-455
CrossRef279
Christopher P. Cannon. (2003) Oral platelet glycoprotein IIb/IIIa receptor inhibitors-part I. Clinical Cardiology 26:8, 358-364
CrossRef280
Steven R. Steinhubl. (2003) Assessing platelet function during treatment with glycoprotein IIb/IIIa antagonists. Coronary Artery Disease 14:5, 381-386
CrossRef281
Anna M. Wodlinger, John A. Pieper. (2003) The role of clopidogrel in the management of acute coronary syndromes. Clinical Therapeutics 25:8, 2155-2181
CrossRef282
Michael Ragosta. (2003) Percutaneous coronary intervention in octogenarians and the safety of glycoprotein IIb/IIIa inhibitors. Journal of the American College of Cardiology 42:3, 433-436
CrossRef283
Jacqueline Saw, David J. Moliterno. (2003) Contemporary use of antiplatelet therapies in percutaneous coronary interventions. Coronary Artery Disease 14:5, 373-380
CrossRef284
KEITH ELLIS, JAMES E. TCHENG, SHELLY SAPP, ERIC J. TOPOL, A. MICHAEL LINCOFF. (2003) Mortality Benefit of Beta Blockade in Patients with Acute Coronary Syndromes Undergoing Coronary Intervention:. The Journal of Interventional Cardiology 16:4, 299-305
CrossRef285
Ingo Ahrens, Karlheinz Peter, Christoph Bode. (2003) Use of GPIIb/IIIa inhibitors in cardiovascular medicine. Expert Review of Cardiovascular Therapy 1:2, 233-242
CrossRef286
Julien Hanson, Xavier de Leval, Philippe Kolh, Claudiu Supuran, Bernard Pirotte, Jean-Michel Dogné. (2003) Update on GPIIb/IIIa antagonists. Expert Opinion on Therapeutic Patents 13:8, 1173-1188
CrossRef287
C. Hawkins, P. Gatenby, D. McGill. (2003) Severe hypotension complicating primary angioplasty: allergy to abciximab. Allergy 58:7, 688-689
CrossRef288
Shim Ching, Achilleas Thoma, Shelly Monkman, John G. Kelton. (2003) Inhibition of Microsurgical Thrombosis by the Platelet Glycoprotein IIb/IIIa Antagonist SR121566A. Plastic and Reconstructive Surgery 112:1, 177-185
CrossRef289
Rosaire P. Gray, John S. Yudkin. 2003. Clinical Features and Treatment of Coronary Heart Disease in Diabetes. .
CrossRef290
Chidambaram Rammohan, Dan Fintel. (2003) Dosing considerations and monitoring of low molecular weight heparins and glycoprotein IIb/IIIa antagonists in patients with renal insufficiency. Current Cardiology Reports 5:4, 303-309
CrossRef291
Mark Kozak, David R. Adams, Michael D. Ioffreda, Michelle J. Nickolaus, Thomas J. Seery, Charles E. Chambers, Steven M. Ettinger, Patrick H. McNulty, Ian C. Gilchrist. (2003) Sterile inflammation associated with transradial catheterization and hydrophilic sheaths. Catheterization and Cardiovascular Interventions 59:2, 207-213
CrossRef292
JAMES E. TCHENG, MINA MADAN, J. CONOR O'SHEA, ERIC A. COHEN, CHRISTOPHER E. BULLER, A. MICHAEL LINCOFF, JEFFREY J. POPMA, PAUL S. TEIRSTEIN, MICHAEL M. KITT, TODD J. LORENZ, SALLY GREENBERG, NORMAN FOST, ROBERT M. CALIFF. (2003) Ethics and Equipoise: Rationale for a Placebo-Controlled Study Design of Platelet Glycoprotein IIb/IIIa Inhibition in Coronary Intervention. Journal of Interventional Cardiology 16:2, 97-105
CrossRef293
Vladimir Rukshin, Babak Azarbal, Ariel Finkelstein, Prediman K. Shah, Bojan Cercek, Vivian Tsang, Sanjay Kaul. (2003) Effects of GP IIb/IIIa Receptor Inhibitor Tirofiban (Aggrastat) in Ex Vivo Canine Arteriovenous Shunt Model of Stent Thrombosis. Journal of Cardiovascular Pharmacology 41:4, 615-624
CrossRef294
Tift Mann, Roberto J. Cubeddu, Laura Raynor, Josie Bowen, Joel E. Schneider, Gregory Rose, Gabriela Cubeddu, Jaffar Ali Raza, Robert Lee Jobe, William Newman, Micheal Zellinger. (2003) Coronary stenting in stable patients: Identification of a low-risk subgroup that may not require adjunctive antiplatelet therapy. Catheterization and Cardiovascular Interventions 58:4, 459-466
CrossRef295
Martin Moser, Ulf Bertram, Karlheinz Peter, Christoph Bode, Johannes Ruef. (2003) Abciximab, Eptifibatide, and Tirofiban Exhibit Dose-dependent Potencies to Dissolve Platelet Aggregates. Journal of Cardiovascular Pharmacology 41:4, 586-592
CrossRef296
Holger Eggebrecht, Christoph Naber, Uta Woertgen, Sonia Ringe, Thomas F.M. Konorza, Axel Schmermund, Clemens von Birgelen, Michael Haude, Knut Kroeger, Raimund Erbel, Dietrich Baumgart. (2003) Percutaneous suture-mediated closure of femoral access sites deployed through the procedure sheath: Initial clinical experience with a novel vascular closure device. Catheterization and Cardiovascular Interventions 58:3, 313-321
CrossRef297
Jason H. Haga, Steven M. Slack, Lisa K. Jennings. (2003) Comparison of Shear Stress–Induced Platelet Microparticle Formation and Phosphatidylserine Expression in Presence of αIIbβ3 Antagonists. Journal of Cardiovascular Pharmacology 41:3, 363-371
CrossRef298
Waiel M. Samara, Paul A. Gurbel. (2003) The role of platelet receptors and adhesion molecules in coronary artery disease. Coronary Artery Disease 14:1, 65-79
CrossRef299
Thaddeus R Tolleson, J.Conor O’Shea, John A Bittl, William B Hillegass, Kathryn A Williams, Glenn Levine, Robert A Harrington, James E Tcheng. (2003) Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention. Journal of the American College of Cardiology 41:3, 386-393
CrossRef300
Raymond G. McKay. (2003) “Ischemia-guided” versus “early invasive” strategies in the management of acute coronary syndrome/non–ST-segment elevation myocardial infarction. Journal of the American College of Cardiology 41:4, S96-S102
CrossRef301
John Eikelboom, Harvey White, Salim Yusuf. (2003) The evolving role of direct thrombin inhibitors in acute coronary syndromes. Journal of the American College of Cardiology 41:4, S70-S78
CrossRef302
Sheldon Goldstein, David Amar. (2003) Pharmacotherapeutic Considerations in Anesthesia. Heart Disease 5:1, 34-48
CrossRef303
Christophe Caussin, Abdelhamid Fsihi, Alice Ohanessian, Laurent Jacq, Saliha Rahal, Bernard Lancelin. (2003) Direct stenting with 3000 iu heparin. Acute Cardiac Care 5:4, 206-210
CrossRef304
Jose A. Silva, Christopher J. White, Stephen R. Ramee, Tyrone J. Collins, J. Stephen Jenkins, Kalon Ho, Donald S. Baim, Joseph P. Carrozza, Stephane Rinfret, Cindy M. Setum, Jeffrey J. Popma, Richard E. Kuntz. (2003) Treatment of coronary stent thrombosis with rheolytic thrombectomy: Results from a multicenter experience. Catheterization and Cardiovascular Interventions 58:1, 11-17
CrossRef305
Ian C Gilchrist. (2003) Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Intervention. Clinical Pharmacokinetics 42:8, 703-720
CrossRef306
Can M Nguyen, Robert A Harrington. (2003) Glycoprotein IIb/IIIa Receptor Antagonists. American Journal of Cardiovascular Drugs 3:6, 423-436
CrossRef307
Luis Gruberg, Shlomo Amikam. (2003) Prolonged systemic delivery of tirofiban in a thrombus-laden saphenous vein graft. Acute Cardiac Care 5:2, 92-94
CrossRef308
Archibald McNicol, Sara J. Israels. (2003) Platelets and Anti-platelet Therapy. Journal of Pharmacological Sciences 93:4, 381-396
CrossRef309
Marc J Schweiger, Hameem U Changezi, Deborah Naglieri-Prescod, James R Cook. (2003) Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clinical Therapeutics 25:1, 225-234
CrossRef310
Nick Bosanquet, Bengt J??nsson, Keith A A Fox. (2003) Costs and Cost Effectiveness of Low Molecular Weight Heparins and Platelet Glycoprotein IIb/IIIa Inhibitors. PharmacoEconomics 21:16, 1135-1152
CrossRef311
Marc G Van der Planken, Marc J Claeys, Francine J Vertessen, Dagmara Dilling, Johan M Bosmans, Zwi N Berneman, Jan J Michiels, Christian Vrints. (2003) Comparison of turbidimetric aggregation and in vitro bleeding time (PFA-100) for monitoring the platelet inhibitory profile of antiplatelet agents in patients undergoing stent implantation. Thrombosis Research 111:3, 159-164
CrossRef312
Joseph Murphy, R Scott Wright, Ihor Gussak, Brent Williams, Robert N Daly, Valerie A Cain, Henry J Pieniaszek, Sherwin K B Sy, William Ebling, Kristen Simonson, Racehl A Wilcox, Stephen L Kopecky. (2003) The Use of Roxifiban (DMP754), a Novel Oral Platelet Glycoprotein IIb/IIIa Receptor Inhibitor, in Patients with Stable Coronary Artery Disease. American Journal of Cardiovascular Drugs 3:2, 101-112
CrossRef313
DF Muir, A Stevens, RO Napier-Hemy, F Fath-Ordoubadi, N Curzen. (2003) Recurrent stent thrombosis associated with lupus anticoagulant due to renal cell carcinoma. Acute Cardiac Care 5:1, 44-46
CrossRef314
Evangelia Karvouni, Demosthenes G Katritsis, John P.A Ioannidis. (2003) Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. Journal of the American College of Cardiology 41:1, 26-32
CrossRef315
Deepak L Bhatt, Benjamin I Lee, Peter J Casterella, Mark Pulsipher, Matthew Rogers, Marc Cohen, Victor E Corrigan, Thomas J Ryan, Jeffrey A Breall, Jeffrey W Moses, Gregory M Eaton, Mitchel A Sklar, A.Michael Lincoff. (2003) Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: Results of the coronary revascularization using integrilin and single bolus enoxaparin study. Journal of the American College of Cardiology 41:1, 20-25
CrossRef316
Branko Gligic, Radoslav Romanovic. (2003) Current treatment of cardiogenic shock. Vojnosanitetski pregled 60:6, 707-714
CrossRef317
(2002) Minimally Invasive Bypass Surgery. New England Journal of Medicine 347:26, 2165-2168
Full Text318
James C. Blankenship, Craig Balog, Shelly K. Sapp, Robert M. Califf, A. Michael Lincoff, James E. Tcheng, Eric J. Topol. (2002) Reduction in vascular access site bleeding in sequential abciximab coronary intervention trials. Catheterization and Cardiovascular Interventions 57:4, 476-483
CrossRef319
Upendra Kaul, Ripen K. Gupta, Kottaram K. Haridas, Saligrama S. Ramesh, Kamal K. Sethi, Balbir Singh, Rajiv Agarwal, Ram D. Yadave, Tapan Ghose, Rakesh R. Sapra, Rajiv Bajaj, Madhukar Shahi, Ajit Bhagwat, Pramod Kumar, Omen P. Mathews, Pratik K. Soni, . (2002) Platelet glycoprotein IIb/IIIa inhibition using eptifibatide with primary coronary stenting for acute myocardial infarction: A 30-day follow-up study. Catheterization and Cardiovascular Interventions 57:4, 497-503
CrossRef320
Holger Eggebrecht, Michael Haude, Uta Woertgen, Axel Schmermund, Clemens von Birgelen, Christoph Naber, Dietrich Baumgart, Christoph Kaiser, Olaf Oldenburg, Thomas Bartel, Knut Kroeger, Raimund Erbel. (2002) Systematic use of a collagen-based vascular closure device immediately after cardiac catheterization procedures in 1,317 consecutive patients. Catheterization and Cardiovascular Interventions 57:4, 486-495
CrossRef321
Mario Marzilli, Gianmario Sambuceti, Roberto Testa, Silvio Fedele. (2002) Platelet glycoprotein IIb/IIIa receptor blockade and coronary resistance in unstable angina. Journal of the American College of Cardiology 40:12, 2102-2109
CrossRef322
S Halfon, J Malinowski, U Sinha. (2002) Effect of anticoagulants and antiplatelet agents on platelet-mediated thrombin generation. Blood Coagulation& Fibrinolysis 13:8, 715-724
CrossRef323
W BRINKMAN, T TERRAMANI, S NAJIBI, E CHAIKOF. (2002) Platelets: Is aspirin sufficient or must we know how to pronounce abciximab?. Seminars in Vascular Surgery 15:4, 245-255
CrossRef324
R. K. Choi, N. H. Lee, D. S. Lim, S. K. Hong, H. K. Hwang. (2002) Pulmonary Hemorrhage After Percutaneous Coronary Intervention With Abciximab Therapy. Mayo Clinic Proceedings 77:12, 1340-1343
CrossRef325
Dietmar Seiffert, Donna L Pedicord, Cathy J Kieras, Bokang He, Andrew M Stern, Jeffrey T Billheimer. (2002) Regulation of clot retraction by glycoprotein IIb/IIIa antagonists. Thrombosis Research 108:2-3, 181-189
CrossRef326
Amar M Salam, Jassim Al Suwaidi. (2002) Platelet glycoprotein IIb/IIIa antagonists in clinical trials for the treatment of coronary artery disease. Expert Opinion on Investigational Drugs 11:11, 1645-1658
CrossRef327
Eric J. Topol. (2002) Economics and quality of care for patients with acute coronary syndromes: The impending crisis. Clinical Cardiology 25:S1, 9-15
CrossRef328
Steven P Sedlis, Douglass A Morrison, Jeffrey D Lorin, Rick Esposito, Gulshan Sethi, Jerome Sacks, William Henderson, Frederick Grover, K.B Ramanathan, Darryl Weiman, Jorge Saucedo, Tamim Antakli, Venki Paramesh, Stuart Pett, Sarah Vernon, Vladimir Birjiniuk, Frederick Welt, Mitchell Krucoff, Walter Wolfe, John C Lucke, Sundeep Mediratta, David Booth, Edward Murphy, Herbert Ward, LaWayne Miller, Stefan Kiesz, Charles Barbiere, Dan Lewis. (2002) Percutaneous coronary intervention versus coronary bypass graft surgery for diabetic patients with unstable angina and risk factors for adverse outcomes with bypass. Journal of the American College of Cardiology 40:9, 1555-1566
CrossRef329
Robert M. Califf. (2002) Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?. Statistics in Medicine 21:19, 2889-2897
CrossRef330
Rosaleen Chun, Beverley A. Orser, Mina Madan. (2002) Platelet Glycoprotein IIb/IIIa Inhibitors: Overview and Implications for the Anesthesiologist. Anesthesia & Analgesia 95:4, 879-888
CrossRef331
James W.H. Blake, Mark W.I. Webster, Rob Butler, John J. Edmond, Peter N. Ruygrok. (2002) Stent deployment with distal vascular protection for the culprit vein graft stenosis in a patient with an acute infarct and cardiogenic shock. Catheterization and Cardiovascular Interventions 57:2, 234-238
CrossRef332
Christian Seligmann, Yusuf Simsek, Mike Schimmer, Tobias Leitsch, Andreas Bock, Heinz-Peter Schultheiss. (2002) Human thrombocytes are able to induce a myocardial dysfunction in the ischemic and reperfused guinea pig heart mediated by free radicals-role of the GPIIb/IIIa-blocker tirofiban. Life Sciences 71:19, 2319-2329
CrossRef333
Laura S Fernandes, James E Tcheng, J.Conor O’Shea, Bonnie Weiner, Todd J Lorenz, Cindy Pacchiana, Lisa G Berdan, Kelly J Maresh, Diane Joseph, Mina Madan, Tift Mann, Rakhi Kilaru, Judith S Hochman, Neal S Kleiman. (2002) Is glycoprotein IIb/IIIa antagonism as effective in women as in men following percutaneous coronary intervention?. Journal of the American College of Cardiology 40:6, 1085-1091
CrossRef334
W. Cwikiel. (2002) Restenosis after balloon angioplasty and/or stent insertion - origin and prevention. A review of the literature. Acta Radiologica 43:5, 442-454
CrossRef335
James E Tcheng, J Conor O’Shea. (2002) Eptifibatide: a potent inhibitor of the platelet receptor integrin glycoprotein IIb/IIIa. Expert Opinion on Pharmacotherapy 3:8, 1199-1210
CrossRef336
Craig P. Juergens, Harvey D. White, Jorge A. Belardi, Carlos Macaya, Jordi Soler-Soler, Beat J. Meyer, Richard D. Levy, Ton Bunt, Joris Menten, Howard C. Herrmann, A.A.Jennifer Adgey, Georgia Tarnesby. (2002) A multicenter study of the tolerability of tirofiban versus placebo in patients undergoing planned intracoronary stent placement. Clinical Therapeutics 24:8, 1332-1344
CrossRef337
David J Moliterno, Steven J Yakubov, Peter M DiBattiste, Howard C Herrmann, Gregg W Stone, Carlos Macaya, Franz-Josef Neumann, Diego Ardissino, Jean-Pierre Bassand, Lynn Borzi, Alan C Yeung, Katherine A Harris, Laura A Demopoulos, Eric J Topol. (2002) Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. The Lancet 360:9330, 355-360
CrossRef338
Judy WM Cheng. (2002) Pharmacotherapeutic options for the management of myocardial infarction. Expert Opinion on Pharmacotherapy 3:8, 1153-1168
CrossRef339
Nasser Lakkis, Nada Lakiss, Jeremy Bobek, John Farmer. (2002) Platelet inhibition with tirofiban early during percutaneous coronary intervention: Dosing revisited. Catheterization and Cardiovascular Interventions 56:4, 474-477
CrossRef340
D HEELEE, K DEOGJO, H GAKKIM, S CHOI, S MUNJUNG, D SIKRYU, M SOOPARK. (2002) Local Intraarterial Urokinase Thrombolysis of Acute Ischemic Stroke with or without Intravenous Abciximab: A Pilot Study. Journal of Vascular and Interventional Radiology 13:8, 769-773
CrossRef341
Heidar Arjomand, Satish K. Surabhi, Marc Cohen. (2002) Unfractionated versus fractionated heparin for percutaneous coronary intervention. Current Cardiology Reports 4:4, 327-333
CrossRef342
Martin J. Quinn, Sorin J. Brener. (2002) Early invasive strategies for acute coronary syndromes. Current Cardiology Reports 4:4, 334-340
CrossRef343
Paul P. Dobesh, Jennifer B. Kasiar. (2002) Administration of Glycoprotein IIb-IIIa Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction. Pharmacotherapy 22:7, 864-888
CrossRef344
D. P. Chew, D. L. Bhatt. (2002) Optimizing glycoprotein IIb/IIIa inhibition: lessons from recent randomized controlled trials. Internal Medicine Journal 32:7, 338-345
CrossRef345
M. J. Claeys, M. G. Van der Planken, J. J. Michiels, F. Vertessen, D. Dilling, J. M. Bosmans, C. J. Vrints. (2002) Comparison of antiplatelet effect of loading dose of clopidogrel versus abciximab during coronary intervention. Blood Coagulation & Fibrinolysis 13:4, 283-288
CrossRef346
Hazar Shadid, Salim Aziz, Sarfraz Ahmad, Jawed Fareed, Debra Hoppensteadt, Harry Messmore, William Wehrmacher, Mahmut Tobu, Omer Iqbal. (2002) Antithrombotic agents in the treatment of severe sepsis. Expert Opinion on Emerging Drugs 7:1, 111-139
CrossRef347
Mandeep Singh, Daniel J. Tiede, Verghese Mathew, Kirk N. Garratt, Ryan J. Lennon, David R. Holmes, Charanjit S. Rihal. (2002) Rheolytic thrombectomy with Angiojet in thrombus-containing lesions. Catheterization and Cardiovascular Interventions 56:1, 1-7
CrossRef348
Ian C. Gilchrist, Michelle J. Nickolaus, Thierry Momplaisir. (2002) Same-day transradial outpatient stenting with a 6-hr course of glycoprotein IIb/IIIa receptor blockade: A feasibility study. Catheterization and Cardiovascular Interventions 56:1, 10-13
CrossRef349
Filip Jacobsson, Eva Swahn, Lars Wallentin, Mikael Dellborg. (2002) Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non—Q-wave myocardial infarction. Clinical Therapeutics 24:5, 752-765
CrossRef350
David C. Warltier, Peter C. A. Kam, Mark K. Egan. (2002) Platelet Glycoprotein IIb/IIIa Antagonists. Anesthesiology 96:5, 1237-1249
CrossRef351
Jacques R. Leclerc. (2002) Platelet glycoprotein IIb/IIIa antagonists: Lessons learned from clinical trials and future directions. Critical Care Medicine 30:Supplement, S332-S340
CrossRef352
JOEL P. REGINELLI, DEREK CHEW. (2002) Direct Thrombin Inhibitors for Percutaneous Coronary Intervention in the Current Era of Platelet Glycoprotein IIb/IIIa Inhibition. Journal of Interventional Cardiology 15:2, 141-146
CrossRef353
JAMES J. FERGUSON. (2002) Low Molecular Weight Heparins and Glycoprotein IIb/IIIa Antagonists. Journal of Interventional Cardiology 15:2, 147-154
CrossRef354
JOHN J. YOUNG, DEAN J. KEREIAKES. (2002) Cost Efficacy of Platelet Glycoprotein IIb/IIIa Antagonists in Clinical Trials and Clinical Practice. Journal of Interventional Cardiology 15:2, 115-120
CrossRef355
Shaker A. Mousa, James P. Abulencia, Owen J. T. McCarty, Nancy A. Turner, Konstantinos Konstantopoulos. (2002) Comparative Efficacy Between the Glycoprotein IIb/IIIa Antagonists Roxifiban and Orbofiban in Inhibiting Platelet Responses in Flow Models of Thrombosis. Journal of Cardiovascular Pharmacology 39:4, 552-560
CrossRef356
NEAL S. KLEIMAN. (2002) Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners?. Journal of Interventional Cardiology 15:2, 111-113
CrossRef357
Mats Eriksson, Kjeld Christensen, Tomas L Lindahl, Anders Larsson. (2002) Pharmaceutical thrombosis prevention in cardiovascular disease. Expert Opinion on Investigational Drugs 11:4, 553-563
CrossRef358
UMESH K. ARORA, IAN CONDE, NEAL S. KLEIMAN. (2002) Glycoprotein IIb/IIIa Antagonists in the Setting of Rescue Percutaneous Coronary Intervention. Journal of Interventional Cardiology 15:2, 155-162
CrossRef359
DAVID E. KANDZARI, KENNETH W. MAHAFFEY. (2002) Experience with Glycoprotein IIb/IIIa Antagonists in Patients with Acute Coronary Syndromes. Journal of Interventional Cardiology 15:2, 121-129
CrossRef360
D. A Moneret-Vautrin, M. Morisset, J. M Vignaud, G. Kanny. (2002) T cell mediated allergy to abciximab. Allergy 57:3, 269-270
CrossRef361
Adnan I. Qureshi, M. Fareed K. Suri, Zulfiqar Ali, Stanley H. Kim, Giuseppe Lanzino, Richard D. Fessler, Andrew J. Ringer, Lee R. Guterman, L. Nelson Hopkins. (2002) Carotid Angioplasty and Stent Placement: A Prospective Analysis of Perioperative Complications and Impact of Intravenously Administered Abciximab. Neurosurgery 50:3, 466-475
CrossRef362
Chantal Pharand, Donald A. Palisaitis, Denis Hamel. (2002) Potential Anaphylactic Shock with Abciximab Readministration. Pharmacotherapy 22:3, 380-383
CrossRef363
Brian L. Walton, Kim Mumm, Megumi Taniuchi, Howard I. Kurz, John M. Lasala. (2002) Diabetic patients treated with abciximab and intracoronary stenting. Catheterization and Cardiovascular Interventions 55:3, 321-325
CrossRef364
J. E. F. Zwart-van Rijkom, H. G. M. Leufkens, M. L. Simoons, A. W. Broekmans. (2002) Variability in abciximab (ReoPro
CrossRef365
Christopher P. Cannon. (2002) Critical Pathway for Unstable Angina and Non-ST Elevation Myocardial Infarction. Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine 1:1, 12-21
CrossRef366
R SHLANSKYGOLDBERG. (2002) Platelet Aggregation Inhibitors for Use in Peripheral Vascular Interventions: What Can We Learn from the Experience in the Coronary Arteries?. Journal of Vascular and Interventional Radiology 13:3, 229-246
CrossRef367
JONATHAN D. MARMUR, ERDAL CAVUSOGLU. (2002) The Use of the Glycoprotein IIb/IIIa Receptor Antagonists During Percutaneous Coronary Intervention. Journal of Interventional Cardiology 15:1, 71-84
CrossRef368
LISA K. JENNINGS, MARY V. JACOSKI, MELANIE McCABE WHITE. (2002) The Pharmacodynamics of Parenteral Glycoprotein IIb/IIIa Inhibitors. Journal of Interventional Cardiology 15:1, 45-60
CrossRef369
Guangyu An, Ningzheng Dong, Bojing Shao, Mingqing Zhu, Changgeng Ruan. (2002) Expression and characterization of the ScFv fragment of antiplatelet GPIIIa monoclonal antibody SZ-21. Thrombosis Research 105:4, 331-337
CrossRef370
CHRISTOPHER M. THOMPSON, STEVEN R. STEINHUBL. (2002) Monitoring of Platelet Function in the Setting of Glycoprotein IIb/IIIa Inhibitor Therapy. Journal of Interventional Cardiology 15:1, 61-70
CrossRef371
NEAL S. KLEIMAN. (2002) Antiplatelet Therapy and Coronary Interventions: Childhood Friends or Permanent Partners?. Journal of Interventional Cardiology 15:1, 41-42
CrossRef372
Richard Shlansky-Goldberg. (2002) Antiplatelet Medications. Journal of Vascular and Interventional Radiology 13:2, P223-P226
CrossRef373
Manesh R. Patel, Matthew T. Roe. (2002) Pharmacological Treatment of Elderly Patients with Acute Coronary Syndromes without Persistent ST Segment Elevation. Drugs & Aging 19:9, 633-646
CrossRef374
Joseph K. Choo, John J. Young, Dean J. Kereiakes. (2002) A Guide to Drug Use During Percutaneous Coronary Intervention. Drugs 62:18, 2589-2601
CrossRef375
Richard Shlansky-Goldberg. (2002) Combination therapy in peripheral vascular disease:. Journal of the American College of Surgeons 194:1, S103-S113
CrossRef376
Christophe Loubeyre, Marie-Claude Morice, Thierry Lefèvre, Jean-François Piéchaud, Yves Louvard, Pierre Dumas. (2002) A randomized comparison of direct stenting with conventional stent implantation in selected patients with acute myocardial infarction. Journal of the American College of Cardiology 39:1, 15-21
CrossRef377
Timothy D. Gladwell. (2002) Bivalirudin: A direct thrombin inhibitor. Clinical Therapeutics 24:1, 38-58
CrossRef378
Humberto A. Coto. (2002) Closure of the femoral vein puncture site after transcatheter procedures using Angio-Seal. Catheterization and Cardiovascular Interventions 55:1, 16-19
CrossRef379
Eric Boersma, Robert A Harrington, David J Moliterno, Harvey White, Pierre Théroux, Frans Van de Werf, Anneke de Torbal, Paul W Armstrong, Lars C Wallentin, Robert G Wilcox, John Simes, Robert M Califf, Eric J Topol, Maarten L Simoons. (2002) Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. The Lancet 359:9302, 189-198
CrossRef380
Jan Erik Otterstad, Keith A. A. Fox. (2002) Clinical Implications of CURE and PCI-CURE in Patients with the Acute Coronary Syndrome without Persistent ST-elevation. Scandinavian Cardiovascular Journal 36:5, 261-271
CrossRef381
Ken-ichi Suzuki, Kazuo Sato, Masazumi Kamohara, Seiji Kaku, Tomihisa Kawasaki, Shinya Yano, Yuichi Iizumi. (2002) Comparative Studies of a Humanized Anti-glycoprotein IIb/IIIa Monoclonal Antibody, YM337, and Abciximab on in Vitro Antiplatelet Effect and Binding Properties. Biological & Pharmaceutical Bulletin 25:8, 1006-1012
CrossRef382
Jay D. Schlaifer, William Horgan, Michael J. Malkowski. (2001) Acute thrombotic occlusion of the left main coronary artery in a hypercoagulable patient treated with intracoronary abciximab. Clinical Cardiology 24:12, 788-788
CrossRef383
A. Michael Lincoff. (2001) Anticoagulant and antiplatelet drugs. Catheterization and Cardiovascular Interventions 54:4, 514-520
CrossRef384
Peter J. Casterella, Dean J. Kereiakes, Steven R. Steinhubl, Russell E. Raymond, Kandice Kottke-Marchant, Karen Patel, Michelle Mueller, Monique Rosenthal, David J. Moliterno, Paul S. Teirstein. (2001) The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. Catheterization and Cardiovascular Interventions 54:4, 497-504
CrossRef385
K Boughalem, J.Y Pagny, T Demichéli, N Danchin. (2001) Les inhibiteurs de la glycoprotéine IIb IIIa dans l'angor instable. Annales de Cardiologie et d'Angéiologie 50:7-8, 377-384
CrossRef386
George J. Despotis, Michael S. Avidan, Charles W. Hogue. (2001) Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. The Annals of Thoracic Surgery 72:5, S1821-S1831
CrossRef387
Michael W. Rich. (2001) Treatment of Acute Myocardial Infarction. The American Journal of Geriatric Cardiology 10:6, 328-336
CrossRef388
Y Louvard. (2001) Traitement de l'angor instable : la stratégie invasive précoce. Annales de Cardiologie et d'Angéiologie 50:7-8, 385-396
CrossRef389
J.P Collet. (2001) Le traitement antithrombotique à la phase aiguë de l'angor instable. Annales de Cardiologie et d'Angéiologie 50:7-8, 366-376
CrossRef390
Martin J Quinn, Eric J Topol. (2001) Common variations in platelet glycoproteins: pharmacogenomic implications. Pharmacogenomics 2:4, 341-352
CrossRef391
William E. Boden. (2001) Clinical trials. Current Opinion in Cardiology 16:6, 361-363
CrossRef392
Wayne B. Batchelor, Kenneth W. Mahaffey, Peter B. Berger, Ezra Deutsch, Susan Meier, Vic Hasselblad, Edward T. Fry, Paul S. Teirstein, Allan M. Ross, Cynthia A. Binanay, James P. Zidar. (2001) A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial. Journal of the American College of Cardiology 38:6, E1608-E1613
CrossRef393
Stefano Sdringola, Abid R. Assali, Mohammed Ghani, Ali Moustapha, Hela Achour, S. Wamique Yusuf, Ken Fujise, Oscar Rosales, George W. Schroth, H. Vernon Anderson, Richard W. Smalling. (2001) Risk assessment of slow or no-reflow phenomenon in aortocoronary vein graft percutaneous intervention. Catheterization and Cardiovascular Interventions 54:3, 318-324
CrossRef394
Xavier Bosch, Pablo Loma-Osorio, Jaume Marrugat, Xavier Bosch. 2001. Platelet glycoprotein IIb/IIIa blockers for percutaneous coronary intervention and the initial treatment of non-ST segment elevation acute coronary syndromes. .
CrossRef395
Morton R. Rinder, Praveen K. Tamirisa, Megumi Taniuchi, Howard I. Kurz, Kimberly Mumm, John M. Lasala. (2001) Safety and efficacy of suture-mediated closure after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions 54:2, 146-151
CrossRef396
Prem K. Kittusamy, Robert A. Koenigsberg, Daniel J. McCormick. (2001) Abciximab for the treatment of acute distal embolization associated with internal carotid artery angioplasty. Catheterization and Cardiovascular Interventions 54:2, 221-233
CrossRef397
Bruce P Damiano, John A Mitchell, Edward Giardino, Thomas Corcoran, Barbara J Haertlein, Lawrence de Garavilla, Jack A Kauffman, William J Hoekstra, Bruce E Maryanoff, Patricia Andrade-Gordon. (2001) Antiplatelet and Antithrombotic Activity of RWJ-53308, A Novel Orally Active Glycoprotein IIb/IIIa Antagonist. Thrombosis Research 104:2, 113-126
CrossRef398
Harald Darius. (2001) Oral Glycoprotein IIb/IIa Antagonists for Unstable Angina — Is There Still a Chance for the Oral Substances?. Thrombosis Research 103, S117-S124
CrossRef399
Fran L. Paradiso-Hardy, Mina Madan, Sam Radhakrishnan, Susan Hurden, Eric A. Cohen. (2001) Severe thrombocytopenia possibly related to readministration of eptifibatide. Catheterization and Cardiovascular Interventions 54:1, 63-67
CrossRef400
Sheila A Doggrell. (2001) ReoPro rules: results from the ‘Do Tirofiban and ReoPro Give Similar Efficacy Trial’ (TARGET). Expert Opinion on Pharmacotherapy 2:9, 1507-1509
CrossRef401
Mandeep Singh, Guy S Reeder, E.Magnus Ohman, Verghese Mathew, William B Hillegass, R.David Anderson, Dianne S Gallup, Kirk N Garratt, David R Holmes. (2001) Does the presence of thrombus seen on a coronary angiogram affect the outcome after percutaneous coronary angioplasty? An angiographic trials pool data experience. Journal of the American College of Cardiology 38:3, 624-630
CrossRef402
Janette K. Burgess. (2001) Molecular mechanisms of drug-induced thrombocytopenia. Current Opinion in Hematology 8:5, 294-298
CrossRef403
Scott A. Harding, Darren L. Walters, Igor F. Palacios, Stephen N. Oesterle. (2001) Adjunctive pharmacotherapy for coronary stenting. Current Opinion in Cardiology 16:5, 293-299
CrossRef404
David J. Harnick, David A. Vorchheimer. (2001) Platelet glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: Initiate treatment early or wait for the catheterization laboratory?. Current Cardiology Reports 3:5, 355-361
CrossRef405
Jeffrey T. W. Pang, Stephen Fort, Anthony Delia Siega, Eric A. Cohen. (2001) Emergency Coronary Artery Bypass Surgery in the Era of Glycoprotein IIb/IIIa Receptor Antagonist Use. Journal of Cardiac Surgery 17:5, 425-431
CrossRef406
Marco L. Rossi, Piera Angelica Merlini, Diego Ardissino. (2001) Percutaneous Coronary Revascularisation in Women. Thrombosis Research 103, S105-S111
CrossRef407
Andreas Greinacher, Petra Eichler, Norbert Lubenow, Volker Kiefel. (2001) DRUG-INDUCED AND DRUG-DEPENDENT IMMUNE THROMBOCYTOPENIAS. Reviews in Clinical and Experimental Hematology 5:3, 166-200
CrossRef408
ANNIE V. COTE, PETER B. BERGER, DAVID R. HOLMES, CHRISTOPHER G. SCOTT, MALCOLM R. BELL. (2001) Hemorrhagic and Vascular Complications After Percutaneous Coronary Intervention With Adjunctive Abciximab. Mayo Clinic Proceedings 76:9, 890-896
CrossRef409
A V Cote, P B Berger, D R Holmes, C G Scott, M R Bell. (2001) Hemorrhagic and vascular complications after percutaneous coronary intervention with adjunctive abciximab.. Mayo Clinic Proceedings 76:9, 890-896
CrossRef410
Roman Kaliszan, Danuta Siluk, Zdzislaw Chilmonczyk. (2001) Hypolipidaemic and antiplatelet agents. Expert Opinion on Therapeutic Patents 11:8, 1301-1327
CrossRef411
Takamichi Miyamoto, Akihiro Niwa, Toshio Sinoda. (2001) State of Percutaneous Transluminal Coronary Artery Angioplasty and Effectiveness of Low-Density Lipoprotein Apheresis. Therapeutic Apheresis and Dialysis 5:4, 226-231
CrossRef412
Claudia Capozzolo, Federico Piscione, Giuseppe De Luca, Angelo Cioppa, Pietro Mazzarotto, Dario Leosco, Paolo Golino, Ciro Indolfi, Massimo Chiariello. (2001) Direct coronary stenting: Effect on coronary blood flow, immediate and late clinical results. Catheterization and Cardiovascular Interventions 53:4, 464-473
CrossRef413
A. Scott Mathis, Parag Meswani, Sarah A. Spinler. (2001) Risk Stratification in Non-ST Segment Elevation Acute Coronary Syndromes with Special Focus on Recent Guidelines. Pharmacotherapy 21:8, 954-987
CrossRef414
Sam S. Rebello, Charles J. Kasiewski, Wei Wang, Ross G. Bentley, Suzanne R. Morgan, Valeria Chu, Dennis Colussi, Karen Brown, Mark H. Perrone, Robert J. Leadley. (2001) Role of Short-Term Inhibition of Factor Xa by FXV673 in Arterial Passivation: A Study in a Chronic Model of Thrombosis in Conscious Dogs. Journal of Cardiovascular Pharmacology 38:2, 288-297
CrossRef415
Mandeep Singh, Gregory A. Nuttall, Karla V. Ballman, Charles J. Mullany, Peter B. Berger, David R. Holmes, Malcolm R. Bell. (2001) Effect of Abciximab on the Outcome of Emergency Coronary Artery Bypass Grafting After Failed Percutaneous Coronary Intervention. Mayo Clinic Proceedings 76:8, 784-788
CrossRef416
M Singh, G A Nuttall, K V Ballman, C J Mullany, P B Berger, D R Holmes, M R Bell. (2001) Effect of abciximab on the outcome of emergency coronary artery bypass grafting after failed percutaneous coronary intervention.. Mayo Clinic Proceedings 76:8, 784-788
CrossRef417
Gregg W. Stone. (2001) Glycoprotein IIb/IIIa inhibitors: More different than alike?. Catheterization and Cardiovascular Interventions 53:3, 304-307
CrossRef418
Nasser M. Lakkis, Sima George, Elson Thomas, Mohamad Ali, Kirk Guyer, David Carville. (2001) Use of ICHOR-platelet works to assess platelet function in patients treated with GP IIb/IIIa inhibitors. Catheterization and Cardiovascular Interventions 53:3, 346-351
CrossRef419
J BENENATI, R SHLANSKYGOLDBERG, A MEGLIN, E SEIDL. (2001) Thrombolytic and Antiplatelet Therapy in Peripheral Vascular Disease with Use of Reteplase and/or AbciximabThe SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Journal of Vascular and Interventional Radiology 12:7, 795-805
CrossRef420
Montalescot, Gilles, Barragan, Paul, Wittenberg, Olivier, Ecollan, Patrick, Elhadad, Simon, Villain, Philippe, Boulenc, Jean-Marc, Morice, Marie-Claude, Maillard, Luc, Pansiéri, Michel, Choussat, Rémi, Pinton, Philippe, . (2001) Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction. New England Journal of Medicine 344:25, 1895-1903
Full Text421
Boden, William E., McKay, Raymond G., . (2001) Optimal Treatment of Acute Coronary Syndromes — An Evolving Strategy. New England Journal of Medicine 344:25, 1939-1942
Full Text422
Topol, Eric J., Moliterno, David J., Herrmann, Howard C., Powers, Eric R., Grines, Cindy L., Cohen, David J., Cohen, Eric A., Bertrand, Michel, Neumann, Franz-Josef, Stone, Gregg W., DiBattiste, Peter M., Yakubov, Steven J., DeLucca, Paul T., Demopoulos, Laura, . (2001) Comparison of Two Platelet Glycoprotein IIb/IIIa Inhibitors, Tirofiban and Abciximab, for the Prevention of Ischemic Events with Percutaneous Coronary Revascularization. New England Journal of Medicine 344:25, 1888-1894
Full Text423
Ulrich Schmidt, Richard O Han, Thomas G DiSalvo, J.Luis Guerrero, Herman K Gold, Warren M Zapol, Kenneth D Bloch, Marc J Semigran. (2001) Cessation of platelet-mediated cyclic canine coronary occlusion after thrombolysis by combining nitric oxide inhalation with phosphodiesterase-5 inhibition. Journal of the American College of Cardiology 37:7, 1981-1988
CrossRef424
Warren J Cantor, Anne S Hellkamp, Eric D Peterson, James P Zidar, Patricia A Cowper, Michael H Sketch, James E Tcheng, Robert M Califf, E.Magnus Ohman. (2001) Achieving optimal results with standard balloon angioplasty: can baseline and angiographic variables predict stent-like outcomes?. Journal of the American College of Cardiology 37:7, 1883-1890
CrossRef425
Robert Anders, Jay Kleiman, Nancy Nicholson, Betty Wazowicz, Dan Burns. (2001) Xemilofiban/Orbofiban: Insight into Drug Development. Cardiovascular Drug Reviews 19:2, 116-132
CrossRef426
Keaven M Anderson, Robert M Califf, Gregg W Stone, Franz-Josef Neumann, Gilles Montalescot, Dave P Miller, James J Ferguson, James T Willerson, Harlan F Weisman, Eric J Topol. (2001) Long-term mortality benefit with abciximab in patients undergoing percutaneous coronary intervention. Journal of the American College of Cardiology 37:8, 2059-2065
CrossRef427
Daniel B. Fram, Satyendra Giri, Gohar Jamil, Joseph F. Mitchel, William E. Boden, Salah Din, Francis J. Kiernan. (2001) Suture closure of the femoral arteriotomy following invasive cardiac procedures: A detailed analysis of efficacy, complications, and the impact of early ambulation in 1,200 consecutive, unselected cases. Catheterization and Cardiovascular Interventions 53:2, 163-173
CrossRef428
(2001) Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. The Lancet 357:9272, 1915-1924
CrossRef429
Charles S Roberts, N.Ruben Bocanegra. (2001) Emergent operation for percutaneous coronary rupture after abciximab administration. The Annals of Thoracic Surgery 71:6, 2024-2026
CrossRef430
Josep Rod
CrossRef431
Sidney C. Smith, James T. Dove, Alice K. Jacobs, J. Ward Kennedy, Dean Kereiakes, Morton J. Kern, Richard E. Kuntz, Jeffery J. Popma, Hartzell V. Schaff, David O. Williams, Raymond J. Gibbons, Joseph P. Alpert, Kim A. Eagle, David P. Faxon, Valentin Fuster, Timothy J. Gardner, Gabriel Gregoratos, Richard O. Russell, Sidney C. Smith. (2001) ACC/AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines). Journal of the American College of Cardiology 37:8, 2239
CrossRef432
(2001) Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. The Lancet 357:9272, 1905-1914
CrossRef433
C FUSS, J PALMAZ, E SPRAGUE. (2001) Fibrinogen: Structure, Function, and Surface Interactions. Journal of Vascular and Interventional Radiology 12:6, 677-682
CrossRef434
Michael B. Holmes, Samer S. Kabbani, Christopher M. Terrien, Matthew W. Watkins, Burton E. Sobel, David J. Schneider. (2001) Quantification by flow cytometry of the efficacy of and interindividual variation of platelet inhibition induced by treatment with tirofiban and abciximab. Coronary Artery Disease 12:3, 245-253
CrossRef435
Adnan I. Qureshi, Zulfiqar Ali, M. Fareed K. Suri, Stanley H. Kim, Richard D. Fessler, Andrew J. Ringer, Lee R. Guterman, L. Nelson Hopkins. (2001) Open-label Phase I Clinical Study to Assess the Safety of Intravenous Eptifibatide in Patients Undergoing Internal Carotid Artery Angioplasty and Stent Placement. Neurosurgery 48:5, 998-1005
CrossRef436
Nancy S. Nicholson, Norman A. Abood, Susan G. Panzer-Knodle, Leo G. Frederick, Jimmy D. Page, Anita K. Salyers, Osman D. Suleymanov, James A. Szalony, Beatrice B. Taite, Robert J. Anders. (2001) Orbofiban: An orally active GPIIb/IIIa platelet receptor antagonist. Medicinal Research Reviews 21:3, 211-226
CrossRef437
José Alfón, Alberto Fernández de Arriba, Lluı́s A Gómez-Casajús, Manuel Merlos. (2001) Alternative Binding Assay of GP IIb/IIIa Antagonists With a Nonradioactive Labeling Method of Platelets. Thrombosis Research 102:3, 247-253
CrossRef438
Mohan S. Reddy, Thomas James Carmody, Dean J. Kereiakes. (2001) Severe delayed thrombocytopenia associated with abciximab (ReoPro) therapy. Catheterization and Cardiovascular Interventions 52:4, 486-488
CrossRef439
Sarfraz Ahmad, Walter P. Jeske, Qing Ma, Jeanine M. Walenga, Jawed Fareed. (2001) Inhibition of Tissue Factor-Activated Platelets by Low-Molecular-Weight Heparins and Glycoprotein IIb/IIIa Receptor Antagonist. Thrombosis Research 102:2, 143-151
CrossRef440
Omer Iqbal, Salim Aziz, Debra A Hoppensteadt, Sarfraz Ahmad, Jeanine M Walenga, Mamdouh Bakhos, Jawed Fareed. (2001) Emerging anticoagulant and thrombolytic drugs. Expert Opinion on Emerging Drugs 6:1, 111-135
CrossRef441
Franz-Josef Neumann, Willibald Hochholzer, Gisela Pogatsa-Murray, Albert Schömig, Meinrad Gawaz. (2001) Antiplatelet effects of abciximab, tirofiban and eptifibatide in patients undergoing coronary stenting. Journal of the American College of Cardiology 37:5, 1323-1328
CrossRef442
Daniel I. Simon, Christopher B. Liu, Peter Ganz, James M. Kirshenbaum, Robert N. Piana, Campbell Rogers MD, Andrew P. Selwyn MD, Jeffrey J. Popma. (2001) A comparative study of light transmission aggregometry and automated bedside platelet function assays in patients undergoing percutaneous coronary intervention and receiving abciximab, eptifibatide, or tirofiban. Catheterization and Cardiovascular Interventions 52:4, 425-432
CrossRef443
J. DAVIDTALLEY. (2001) Clinical Trials of Glycoprotein IIb/IIIa Inhibitors. Journal of Interventional Cardiology 14:2, 129-142
CrossRef444
R KELLY. (2001) NEW DEVELOPMENTS IN PERCUTANEOUS CORONARY INTERVENTION. Critical Care Clinics 17:2, 303-320
CrossRef445
J CALVIN, L KLEIN. (2001) THE USE OF ANTIPLATELET AGENTS IN ACUTE CARDIAC CARE. Critical Care Clinics 17:2, 365-377
CrossRef446
R SUNDRANI, L KLEIN. (2001) ANTITHROMBOTIC AND THROMBOLYTIC THERAPY IN ACUTE CARDIAC CARE. Critical Care Clinics 17:2, 379-390
CrossRef447
S HOLLENBERG. (2001) CARDIOGENIC SHOCK. Critical Care Clinics 17:2, 391-410
CrossRef448
F ALMEDA, R SNELL, J PARRILLO. (2001) The Contemporary Management of Acute Myocardial Infarction. Critical Care Clinics 17:2, 411-434
CrossRef449
Eli I Lev, Julio I Osende, Merwin F Richard, Jonathan A Robbins, Jenny A Delfin, Oswaldo Rodriguez, Samin K Sharma, Tim Jayasundera, Juan J Badimon, Jonathan D Marmur. (2001) Administration of abciximab to patients receiving tirofiban or eptifibatide: effect on platelet function. Journal of the American College of Cardiology 37:3, 847-855
CrossRef450
V Coen. (2001) Endovascular brachytherapy in coronary arteries: the Rotterdam experience. Cardiovascular Radiation Medicine 2:1, 42-50
CrossRef451
Phong Nguyen-Ho, Nasser M. Lakkis. (2001) Platelet glycoprotein IIb/IIIa receptor antagonists and coronary artery disease. Current Atherosclerosis Reports 3:2, 139-148
CrossRef452
Baskaran Chandrasekar, Serge Doucet, Luc Bilodeau, Jacques Crepeau, Pierre deGuise, Jean Gregoire, Richard Gallo, Gilles Cote, Raoul Bonan, Michel Joyal, Gilbert Gosselin, Jean-Fran
CrossRef453
Barbara S. Wiggins, Ann K. Wittkowsky, Jean M. Nappi. (2001) Clinical Use of New Antithrombotic Therapies for Medical Management of Acute Coronary Syndromes. Pharmacotherapy 21:3, 320-337
CrossRef454
Eric J. Dippel, Dean J. Kereiakes, Daniel A. Tramuta, Thomas M. Broderick, Thomas M. Shimshak, Eli M. Roth, Charles R. Hattemer, John P. Runyon, David D. Whang, John F. Schneider, Charles W. Abbottsmith. (2001) Coronary perforation during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade: An algorithm for percutaneous management. Catheterization and Cardiovascular Interventions 52:3, 279-286
CrossRef455
Manish S Chauhan, Richard E Kuntz, Kalon K.L Ho, David J Cohen, Jeffrey J Popma, Joseph P Carrozza, Donald S Baim, Donald E Cutlip. (2001) Coronary artery stenting in the aged. Journal of the American College of Cardiology 37:3, 856-862
CrossRef456
Joel S. Bennett. (2001) N
OVEL PLATELET INHIBITORS . Annual Review of Medicine 52:1, 161-184
CrossRef457
David P. Lee, Sidney Lo, Niall A. Herity, Michael Ward, Alan C. Yeung. (2001) Utility of mechanical rheolysis as an adjunct to rescue angioplasty and platelet inhibition in acute myocardial infarction and cardiogenic shock: A case report. Catheterization and Cardiovascular Interventions 52:2, 220-225
CrossRef458
Antonis S. Manolis. (2001) Reduced incidence of clinical restenosis with newer generation stents, stent oversizing, and high-pressure deployment: Single-operator experience. Clinical Cardiology 24:2, 119-126
CrossRef459
Adam B Greenbaum, Robert A Harrington, Michael P Hudson, Cynthia M MacAulay, Robert G Wilcox, Maarten L Simoons, Lisa G Berdan, Alan Guerci, Dennis V Cokkinos, Michael M Kitt, A.Michael Lincoff, Eric J Topol, Robert M Califf, E.Magnus Ohman. (2001) Therapeutic value of eptifibatide at community hospitals transferring patients to tertiary referral centers early after admission for acute coronary syndromes. Journal of the American College of Cardiology 37:2, 492-498
CrossRef460
Seiya Horisawa, Munekiyo Kaneko, Teruo Sakurama. (2001) Protective Effects of SM-20302, an Orally Active GPIIb/IIIa Antagonist, in an ADP/Epinephrine-Induced Guinea Pig Model of Transient Cerebral Ischemia. Thrombosis Research 101:3, 119-126
CrossRef461
Shuji KITAMURA, Hideto FUKUSHI, Toshio MIYAWAKI, Masaki KAWAMURA, Zen-ichi TERASHITA, Hirosada SUGIHARA, Takehiko NAKA. (2001) Novel Non-Peptide GPIIb/IIIa Antagonists. Synthesis and Biological Activities of 2-[4-[2-(4-Amidinobenzoylamino)-2-(substituted)acetyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic Acids.. CHEMICAL & PHARMACEUTICAL BULLETIN 49:3, 258-267
CrossRef462
Shuji KITAMURA, Hideto FUKUSHI, Toshio MIYAWAKI, Masaki KAWAMURA, Zen-ichi TERASHITA, Takehiko NAKA. (2001) Orally Active GPIIb/IIIa Antagonists. Synthesis and Biological Activities of Masked Amidines as Prodrugs of 2-[(3S)-4-[(2S)-2-(4-Amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3-(2-methoxy-2-oxoethyl)-2-oxopiperazinyl] acetic Acid.. CHEMICAL & PHARMACEUTICAL BULLETIN 49:3, 268-277
CrossRef463
DJA Price, PG Campbell, AGC Sutton, ED. (2001) Selective use of abciximab in coronary stenting: overall outcomes can still be equivalent to those in the EPISTENT treatment group. Acute Cardiac Care 4:1, 15-20
CrossRef464
William B. Hillegass, Anne R. Newman, Dominic L. Raco. (2001) Glycoprotein IIb/IIIa Receptor Therapy in Percutaneous Coronary Intervention and Non???ST-Segment Elevation Acute Coronary Syndromes. PharmacoEconomics 19:1, 41-55
CrossRef465
Carlo Di Mario, Nico HJ Pijls. (2001) An introduction to provisional stenting. Acute Cardiac Care 4:2, 59-65
CrossRef466
Abdulhay Albirini, Sorin J Brener. (2001) Platelet glycoprotein IIb/IIIa receptor inhibition in primary angioplasty for acute myocardial infarction: The new paradigm of direct revascularization. Acute Cardiac Care 4:1, 7-14
CrossRef467
Masroor A. Khan, Ming W. Liu, Francisco L. Chio, Virginia B. Yates, Gregory D. Chapman, Vijay K. Misra, Araceli Sweeney, Larry S. Dean. (2001) Effect of Abciximab on cardiac enzyme elevation after transluminal extraction atherectomy (TEC) in high-risk saphenous vein graft lesions: Comparison with a historical control group. Catheterization and Cardiovascular Interventions 52:1, 40-44
CrossRef468
Derek P. Chew, Deepak L. Bhatt, Eric J. Topol. (2001) Oral Glycoprotein IIb/IIIa Inhibitors. American Journal of Cardiovascular Drugs 1:6, 421-428
CrossRef469
Noriyasu Nagaoka, Tatsuaki Matsubara, Katsuo Okazaki, Naomichi Masuda, Kyoko Shikaura, Nigishi Hotta. (2001) Comparison of Ticlopidine and Cilostazol for the Prevention of Restenosis after Percutaneous Transluminal Coronary Angioplasty.. Japanese Heart Journal 42:1, 43-54
CrossRef470
Robert F. Storey. (2001) Clinical experience with antithrombotic drugs acting on purine receptor pathways. Drug Development Research 52:1-2, 202-212
CrossRef471
Derek P. Chew, Deepak L. Bhatt. (2001) Oral glycoprotein IIb/IIIa antagonists in coronary artery disease. Current Cardiology Reports 3:1, 63-71
CrossRef472
Fumiyuki Ishibashi, Taro Saito, Seiji Hokimoto, Katsuo Noda, Yasushi Moriyama, Shuichi Oshima. (2001) Combined Revascularization Strategy for Acute Myocardial Infarction in Patients With Intracoronary Thrombus. Japanese Circulation Journal 65:4, 251-256
CrossRef473
John A. Ormiston, Bridget Dixon, Mark W.I. Webster, Peter N. Ruygrok. (2001) 5 French guide catheters for percutaneous coronary intervention: A feasibility study in 100 consecutive patients. Catheterization and Cardiovascular Interventions 52:1, 45-48
CrossRef474
Charles R. Cannan. (2001) Antithrombotic therapy in cardiac stent patients. Current Cardiology Reports 3:1, 78-84
CrossRef475
Antonio Colombo. (2001) Experience is important; progress makes the difference!. Acute Cardiac Care 4:3, 123-125
CrossRef476
Richard Shlansky-Goldberg. (2001) Antiplatelet Medications: Use of Glycoprotein IIb/IIIa Receptor Inhibitors in Interventional Procedures. Journal of Vascular and Interventional Radiology 12:1, P26-P29
CrossRef477
James F. Benenati. (2001) Use of Thrombolytics in Interventional Procedures. Journal of Vascular and Interventional Radiology 12:1, P18-P21
CrossRef478
Paul Harrison. (2000) Progress in the assessment of platelet function. British Journal of Haematology 111:3, 733-744
CrossRef479
Alejandra Scazziota, Raul Altman, Jorge Rouvier, Claudio Gonzalez, Zulfiqar Ahmed, Walter P. Jeske, Jeanine M. Walenga, Jawed Fareed. (2000) Abciximab treatment in vitro after aspirin treatment in vivo has additive effects on platelet aggregation, ATP release, and P-selectin expression. Thrombosis Research 100:6, 479-488
CrossRef480
Derek P Chew, David J Moliterno. (2000) A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. Journal of the American College of Cardiology 36:7, 2028-2035
CrossRef481
S. Sdringola, A. Assali, M. Ghani, A. Yepes, O. Rosales, G.W. Schroth, Ken Fujise, H.V. Anderson, R.W. Smalling. (2000) Adenosine use during aortocoronary vein graft interventions reverses but does not prevent the slow-no reflow phenomenon. Catheterization and Cardiovascular Interventions 51:4, 394-399
CrossRef482
(2000) Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. The Lancet 356:9247, 2037-2044
CrossRef483
Chaim Lotan, Dong Shaohong. (2000) The no-reflow phenomenon: A light at the end of the tunnel?. Catheterization and Cardiovascular Interventions 51:4, 400-401
CrossRef484
R CALIFF. (2000) Critical concepts in cost-effectiveness for cardiovascular specialists. American Heart Journal 140:6, s143-s147
CrossRef485
R LI. (2000) Facilitated percutaneous coronary intervention: A novel concept in expediting and improving acute myocardial infarction care. American Heart Journal 140:6, s125-s135
CrossRef486
A LINCOFF. (2000) GUSTO IV: Expanding therapeutic options in acute coronary syndromes. American Heart Journal 140:6, s103-s114
CrossRef487
D YAMADA. (2000) Importance of microembolization and inflammation in atherosclerotic heart disease. American Heart Journal 140:6, s90-s102
CrossRef488
K CAMPBELL. (2000) Glycoprotein IIb/IIIa inhibitors: Therapeutic applications in acute ST-segment elevation myocardial infarction. American Heart Journal 140:6, s115-s124
CrossRef489
Eric J. Topol. (2000) The Future of Antiplatelet Therapy: Optimizing Management in Patients with Acute Coronary Syndrome. Clinical Cardiology 23:S6, 23-28
CrossRef490
S. B. King III. (2000) Optimizing Antiplatelet Therapy in Coronary Interventions. Clinical Cardiology 23:S6, 8-13
CrossRef491
Christopher P. Cannon. (2000) Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials. Clinical Cardiology 23:S6, 14-17
CrossRef492
Cheuk-Kit Wong, Harvey D. White. (2000) Medical treatment for acute coronary syndromes. Current Opinion in Cardiology 15:6, 441-462
CrossRef493
Fengqi Liu, Robert M Craft, Steve A Morris, Roger C Carroll. (2000) Lotrafiban: an oral platelet glycoprotein IIb/IIIa blocker. Expert Opinion on Investigational Drugs 9:11, 2673-2687
CrossRef494
Jeffrey A. Brinker. (2000) ?IIb or Not IIb or Maybe IIb?? Is that the question? Or is it ?Which IIb and to Whom??. Catheterization and Cardiovascular Interventions 51:2, 145-146
CrossRef495
Heinz Brock. (2000) Cardiovascular therapies in the critically ill: economic and cost-effectiveness evaluations. Current Opinion in Critical Care 6:5, 354-358
CrossRef496
Mark I. Furman, Andrew L. Frelinger, Alan D. Michelson. (2000) Antithrombotic therapy in the cardiac catheterization laboratory: Focus on antiplatelet agents. Current Cardiology Reports 2:5, 386-394
CrossRef497
Sidney A. Cohen, Mohit Trikha, Mary A. Mascelli. (2000) Potential future clinical applications for the GPIIb/IIIa antagonist, abciximab in thrombosis, vascular and oncological indications. Pathology & Oncology Research 6:3, 163-174
CrossRef498
Cornelius M Dyke, Devinder Bhatia, Todd J Lorenz, Steven P Marso, Barbara E Tardiff, Charissa Hogeboom, Robert A Harrington. (2000) Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. The Annals of Thoracic Surgery 70:3, 866-871
CrossRef499
Ian Conde-Pozzi, Neal S. Kleiman. (2000) Platelet activation in acute myocardial infarction and the rationale for combination therapy. Current Cardiology Reports 2:5, 378-385
CrossRef500
David Hasdai, Robert A. Harrington, Judith S. Hochman, Robert M. Califf, Alexander Battler, James W. Box, Maarten L. Simoons, Jaap Deckers, Eric J. Topol, David R. Holmes. (2000) Platelet glycoprotein IIb/IIIa blockade and outcome of cardiogenic shock complicating acute coronary syndromes without persistent ST-segment elevation. Journal of the American College of Cardiology 36:3, 685-692
CrossRef501
Dawn M. Bell, Jean Nappi. (2000) Myocardial Infarction in Women: A Critical Appraisal of Gender Differences in Outcomes. Pharmacotherapy 20:9, 1034-1044
CrossRef502
Leslie Cho, Steve P. Marso, Deepak L. Bhatt, Eric J. Topol. (2000) Optimizing Percutaneous Coronary Revascularization in Diabetic Women: Analysis from the EPISTENT Trial. Journal of Women's Health & Gender-Based Medicine 9:7, 741-746
CrossRef503
Leslie Cho, Eric J Topol, Craig Balog, Joanne M Foody, Joan E Booth, Catherine Cabot, Neal S Kleiman, James E Tcheng, Robert Califf, A.Michael Lincoff. (2000) Clinical benefit of glycoprotein IIb/IIIa blockade with abciximab is independent of gender. Journal of the American College of Cardiology 36:2, 381-386
CrossRef504
William C. Dillon, George J. Eckert, James C. Dillon, Michael E. Ritchie. (2000) Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine. Catheterization and Cardiovascular Interventions 50:4, 426-430
CrossRef505
A.Michael Lincoff, LeRoy A LeNarz, George J Despotis, Peter K Smith, Joan E Booth, Russell E Raymond, Shelly K Sapp, Catherine F Cabot, James E Tcheng, Robert M Califf, Mark B Effron, Eric J Topol. (2000) Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials
A complete list of the principal investigators and study coordinators of the EPILOG (Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade) Study Group and the EPISTENT (Evaluation of Platelet IIb/IIIa Inhibition in STENTing) Study Group can be found in the Appendices.. The Annals of Thoracic Surgery 70:2, 516-526
CrossRef506
J. DAVID TALLEY. (2000) Pharmacology of GP IIb-IIIa Platelet Inhibitors, Part IV. Journal of Interventional Cardiology 13:4, 243-254
CrossRef507
Scott C Silvestry, Peter K Smith. (2000) Current status of cardiac surgery in the abciximab-treated patient. The Annals of Thoracic Surgery 70:2, S12-S19
CrossRef508
Anitha Pothula, Victor L Serebruany, PaulA Gurbel, Marcus E McKenzie, Dan Atar. (2000) Pathophysiology and therapeutic modification of thrombin generation in patients with coronary artery disease. European Journal of Pharmacology 402:1-2, 1-10
CrossRef509
Talal Hammoud, Jean-François Tanguay, Martial G Bourassa. (2000) Management of coronary artery disease: therapeutic options in patients with diabetes. Journal of the American College of Cardiology 36:2, 355-365
CrossRef510
M. Koestenberger, S. Gallistl, G. Cvirn, B. Roschitz, W. Muntean. (2000) Effects of the glycoprotein IIb/IIIa receptor antagonist c7E3 Fab and anticoagulants on platelet aggregation and thrombin potential under high coagulant challenge in vitro. Blood Coagulation and Fibrinolysis 11:5, 425-432
CrossRef511
David C Sane, Lakshmi V Damaraju, Eric J Topol, Catherine F Cabot, Mary Ann Mascelli, Robert A Harrington, Maarten L Simoons, Robert M Califf. (2000) Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. Journal of the American College of Cardiology 36:1, 75-83
CrossRef512
Adnan Kastrati, Werner Koch, Meinrad Gawaz, Julinda Mehilli, Corinna Böttiger, Kathrin Schömig, Nicolas von Beckerath, Albert Schömig. (2000) PlA polymorphism of glycoprotein IIIa and risk of adverse events after coronary stent placement. Journal of the American College of Cardiology 36:1, 84-89
CrossRef513
Sokrates Korovesis, Salim Fredericks, David Holt, Pavlos Toutouzas, Juan Carlos Kaski, Michael M. Webb-Peploe, Demosthenes Katritsis. (2000) Release of platelet activation markers during coronary angioplasty. Coronary Artery Disease 11:5, 391-398
CrossRef514
Spiros G Frangos, Alan H Chen, Bauer Sumpio. (2000) Vascular drugs in the new millennium11No competing interests declared.. Journal of the American College of Surgeons 191:1, 76-92
CrossRef515
Vicens Mart
CrossRef516
Guido Belli, Antonio Pezzano, Anna Maria De Biase, Edgardo Bonacina, Pedro Silva, Paolo Salvad
CrossRef517
Matthias Hollmann, Hans Dieter Lehmann, Hans P. Albrecht, Marco Thyes. 2000. Cardiovascular Drugs. .
CrossRef518
Michael B. Horowitz, Phillip D. Purdy. (2000) The Use of Stents in the Management of Neurovascular Disease: A Review of Historical and Present Status. Neurosurgery 46:6, 1335-1343
CrossRef519
Adnan I. Qureshi, Andreas R. Luft, Mudit Sharma, Lee R. Guterman, L. Nelson Hopkins. (2000) Prevention and Treatment of Thromboembolic and Ischemic Complications Associated with Endovascular Procedures: Part I???Pathophysiological and Pharmacological Features. Neurosurgery 46:6, 1344-1359
CrossRef520
Herbert Hirsch, Jason Lazar, Kevin P. Marzo, Richard M. Steingart. (2000) Percutaneous revascularization for unstable angina in the elderly. Coronary Artery Disease 11:4, 315-322
CrossRef521
Adnan I. Qureshi, M. Fareed K. Suri, Jehanzeb Khan, Richard D. Fessler, Lee R. Guterman, L. Nelson Hopkins. (2000) Abciximab as an Adjunct to High-risk Carotid or Vertebrobasilar Angioplasty: Preliminary Experience. Neurosurgery 46:6, 1316-1325
CrossRef522
(2000) Antithrombotic Therapy in Non???ST-Segment Elevation Acute Coronary Syndromes. Clinical Drug Investigation 19:6, 409-420
CrossRef523
Ya-Ting Chen, Edward R. Tuohy, Harlan M. Krumholz. (2000) Anti-thrombotic therapy for elderly patients with acute coronary syndromes. Coronary Artery Disease 11:4, 323-330
CrossRef524
O'Neill, William W., Serruys, Patrick, Knudtson, Merrill, van Es, Gerrit-Anne, Timmis, Gerald C., van der Zwaan, Coen, Kleiman, Jay, Gong, Jianjian, Roecker, Ellen B., Dreiling, Roger, Alexander, John, Anders, Robert, . (2000) Long-Term Treatment with a Platelet Glycoprotein-Receptor Antagonist after Percutaneous Coronary Revascularization. New England Journal of Medicine 342:18, 1316-1324
Full Text525
Michael R. Mooney, Stephen G. Ellis, Gary Gershony, Kais J. Yehyawi, Barbara Kummer, Marsha Lowrie. (2000) Immediate sealing of arterial puncture sites after cardiac catheterization and coronary interventions: Initial U.S. feasibility trial using the Duett vascular closure device. Catheterization and Cardiovascular Interventions 50:1, 96-102
CrossRef526
Juan C. Kaski, David A. Smith. (2000) The Management of Chronic Ischemic Heart Disease in the Elderly. The American Journal of Geriatric Cardiology 9:3, 145-151
CrossRef527
Christopher Heeschen, Christian W Hamm, Jens Bruemmer, Maarten L Simoons. (2000) Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. Journal of the American College of Cardiology 35:6, 1535-1542
CrossRef528
Tatsuro Yomo, Dan L. Serna, Ledford L. Powell, Da Wang, Samuel E. Wilson, Shin Ishimaru, John C. Chen. (2000) Glycoprotein IIb/IIIa Receptor Inhibitor Attenuates Platelet Aggregation Induced by Thromboxane A2 During In Vitro Nonpulsatile Ventricular Assist Circulation. Artificial Organs 24:5, 355-361
CrossRef529
René G. Favaloro. (2000) Surgical treatment of acute myocardial infarction. Journal of the American College of Cardiology 35:5, 18B-24B
CrossRef530
Shaker A Mousa. (2000) Integrins as novel drug discovery targets: potential therapeutic and diagnostic implications. Expert Opinion on Therapeutic Targets 4:2, 143-153
CrossRef531
A.Michael Lincoff, Robert M Califf, Eric J Topol. (2000) Platelet glycoprotein IIb/IIIa receptor blockade in coronary artery disease. Journal of the American College of Cardiology 35:5, 1103-1115
CrossRef532
EFRAIN GAXIOLA, RONALD E. VLIETSTRA, ALAN S. BRENNER, KEVIN F. BROWNE, DOUGLAS G. EBERSOLE, LYDIA ROMAN, RICHARD A. KERENSKY. (2000) Diabetes and Multiple Stents Independently Double the Risk of Short-term Revascularization. Journal of Interventional Cardiology 13:2, 87-91
CrossRef533
Shaker A. Mousa. (2000) Potential Role of Platelet Glycoprotein IIb/IIIa Antagonists in Cerebrovascular Disorders. CNS Drugs 13:3, 155-160
CrossRef534
Jens Jensen, Sven V. Eriksson, Bo Lindvall, Peter Lundin, Christer Sylvén. (2000) On-line vectorcardiography during elective coronary angioplasty indicates procedure-related myocardial infarction. Coronary Artery Disease 11:2, 161-169
CrossRef535
Nicholas A. Watkins, Willem H. Ouwehand. (2000) Introduction to Antibody Engineering and Phage Display. Vox Sanguinis 78:2, 72-79
CrossRef536
Baskaran Chandrasekar, Jean-François Tanguay. (2000) Platelets and restenosis. Journal of the American College of Cardiology 35:3, 555-562
CrossRef537
Deepak L Bhatt, Steven P Marso, A.Michael Lincoff, Katherine E Wolski, Stephen G Ellis, Eric J Topol. (2000) Abciximab reduces mortality in diabetics following percutaneous coronary intervention. Journal of the American College of Cardiology 35:4, 922-928
CrossRef538
Koon-Hou Mak, Mark B. Effron, David J. Moliterno. (2000) Platelet Glycoprotein IIb/IIIa Receptor Antagonists And Their Use In Elderly Patients. Drugs & Aging 16:3, 179-187
CrossRef539
Bärbel Wittke, Hilary Ensor, Jain Chung, Herbert Birnböck, Berthold Lausecker, Sylvie I. Ertel, Ian J. Mackie, Samuel J. Machin. (2000) Pharmacokinetics and pharmacodynamics of sibrafiban alone or in combination with ticlopidine and aspirin. British Journal of Clinical Pharmacology 49:3, 231-239
CrossRef540
Ulrich Kintscher, Kai Kappert, Gunther Schmidt, Gesine Doerr, Matthias Grill, Brigitte Wollert-Wulf, Michael Graefe, Eckart Fleck, Kristof Graf. (2000) Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells. European Journal of Pharmacology 390:1-2, 75-87
CrossRef541
Aamer B. Ahmed, Ray D. Latimer, Alain Vuylsteke. (2000) Cardiovascular pharmacology: new drugs and new indications. Current Opinion in Anaesthesiology 13:1, 5-13
CrossRef542
RAJIV MARAJ, PAIROJ RERKPATTANAPIPAT, NATTAWUT WONGPRAPARUT, MOISES FRAIFELD, GARY S. LEDLEY, LARRY E. JACOBS, SHAHRIAR YAZDANFAR, MORRIS N. KOTLER. (2000) Iatrogenic Cardiovascular Complications: Part IV: Interventional Procedures. Journal of Interventional Cardiology 13:1, 59-70
CrossRef543
Balram Bhargava, Ran Kornowski, Roxana Mehran, Kenneth M Kent, Mun K Hong, Alexandra J Lansky, Ron Waksman, Augusto D Pichard, Lowell F Satler, Martin B Leon. (2000) Procedural results and intermediate clinical outcomes after multiple saphenous vein graft stenting. Journal of the American College of Cardiology 35:2, 389-397
CrossRef544
Bruno Vahdat, Isabelle Canavy, Laurent Fourcade, Eric Garcia, Jacques Quilici, Jean-Louis Bonnet, Michel Bory. (2000) Fatal cerebral hemorrhage and severe thrombocytopenia during abciximab treatment. Catheterization and Cardiovascular Interventions 49:2, 177-180
CrossRef545
Arshad Ali, Sandish Patil, Kevin J. Grady, Theodore L. Schreiber. (2000) Diffuse alveolar hemorrhage following administration of tirofiban or abciximab: A nemesis of platelet glycoprotein IIb/iIIa inhibitors. Catheterization and Cardiovascular Interventions 49:2, 181-184
CrossRef546
J.J. Connors. (2000) Intracranial Atherosclerosis: Natural History, Therapy, and Results. Journal of Vascular and Interventional Radiology 11:2, 140-146
CrossRef547
Richard Shlansky-Goldberg. (2000) Antiplatelet Agents in Vascular Disease. Journal of Vascular and Interventional Radiology 11:2, 388-391
CrossRef548
J.J. Connors, Joan C. Wojak. (2000) Intracranial Angioplasty for Atherosclerotic Disease. Journal of Vascular and Interventional Radiology 11:2, 331-334
CrossRef549
Yeghiazarians, Yerem, Braunstein, Joel B., Askari, Arman, Stone, Peter H., . (2000) Unstable Angina Pectoris. New England Journal of Medicine 342:2, 101-114
Full Text550
Lars Grip. (2000) Appropriateness of Percutaneous Transluminal Coronary Angioplasty in Stable and Unstable Angina Pectoris. A review. Scandinavian Cardiovascular Journal 34:5, 454-460
CrossRef551
John H Lemmer, Mark T Metzdorff, Albert H Krause, M.Alan Martin, J.Edward Okies, Jon G Hill. (2000) Emergency coronary artery bypass graft surgery in abciximab-treated patients. The Annals of Thoracic Surgery 69:1, 90-95
CrossRef552
Peter H Grewe, Thomas Deneke, Abderrahman Machraoui, Jürgen Barmeyer, Klaus-Michael Müller. (2000) Acute and chronic tissue response to coronary stent implantation: pathologic findings in human specimen. Journal of the American College of Cardiology 35:1, 157-163
CrossRef553
Iyad Rashdan, Eliot Schechter. (2000) Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty. Catheterization and Cardiovascular Interventions 49:1, 113-116
CrossRef554
Upendra Kaul, Rakesh Sapra, Balbir Singh, D. (2000) Reversal of slow flow phenomenon during primary stenting by bail-out administration of abciximab. Acute Cardiac Care 3:1, 35-39
CrossRef555
Gail Richardson, Nicholas P Curzen, Mela. (2000) Failure to monitor ticlopidine: the case for clopidogrel. Acute Cardiac Care 3:1, 29-33
CrossRef556
ND Palmer, S Fort, IR Starkey, TRD Shaw, DB Northridge. (2000) In-hospital resource utilization in coronary angioplasty: the impact of increased coronary stenting rates and antiplatelet therapy. Acute Cardiac Care 3:3, 161-165
CrossRef557
David R. Holmes. (2000) Platelet glycoprotein receptor site blockade in coronary artery disease. Current Cardiology Reports 2:1, 69-73
CrossRef558
Eric Van De Graaff, Steven R Steinhubl. (2000) Antiplatelet medications and their indications in preventing and treating coronary thrombosis. Annals of Medicine 32:8, 561-571
CrossRef559
Jacobs, Alice K., . (1999) Coronary Stents — Have They Fulfilled Their Promise?. New England Journal of Medicine 341:26, 2005-2006
Full Text560
THIERRY LEFÈVRE, MARIE-CLAUDE MORICE. (1999) Interventional Treatment of Acute Myocardial Infarction: Is The Thrombolysis Era Coming to an End?. Journal of Interventional Cardiology 12:6, 477-486
CrossRef561
Shaker A. Mousa. (1999) Antiplatelet therapies: from aspirin to GPIIb/IIIa-receptor antagonists and beyond. Drug Discovery Today 4:12, 552-561
CrossRef562
On Topaz, Nelson Bernardo, Pratik Desai, Yves Janin. (1999) Acute thrombotic-ischemic coronary syndromes: The usefulness of TEC. Catheterization and Cardiovascular Interventions 48:4, 406-420
CrossRef563
Raj Makkar, Ben Goff, Neal Eigler, Martin Sebastian, Tim Fischell, Lawrence Barr, Chris D'Haem, Prediman K. Shah, Mark B. Effron, Frank Litvack. (1999) Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. Catheterization and Cardiovascular Interventions 48:4, 430-434
CrossRef564
Holger Eggebrecht, Michael Haude, Dietrich Baumgart, Olaf Oldenburg, Jörg Herrmann, Christian Bruch, Peter Hunold, Claus Neurohr, Clemens Birgelen, Dirk Welge, Marc -Alexander Katz, Raimund Erbel. (1999) Hämostatischer Verschluß der arteriellen Punktionsstelle mittels Angio-Seal™ nach diagnostischer Herzkatheteruntersuchung oder Koronarintervention. Herz 24:8, 607-613
CrossRef565
Gary Gershony, Todd Jensen. (1999) The duett™ closure device: Concept and experimental results. Herz 24:8, 614-619
CrossRef566
Gérard Helft, Paolo Bartolomeo, Azfar G Zaman, Stephen G Worthley, Sylvie Chokron, Claude Le Pailleur, Farzyn Beygui, Claude Le Feuvre, Jean-Philippe Metzger, André Vacheron, Michel M Samama. (1999) The Heparin Management Test. Thrombosis Research 96:6, 481-485
CrossRef567
Jean-Marc Masse, Katy Perlemuter, Najet Debili, Remi Letestu, Alain Castaigne, Elisabeth M. Cramer. (1999) Intracellular trafficking of the alphaIIbbeta3 receptor antagonist, abciximab, in normal and Glanzmann's disease megakaryocytes. British Journal of Haematology 107:4, 720-730
CrossRef568
Jean-Marc Idée, Claire Corot. (1999) Thrombotic risk associated with the use of iodinated contrast media in interventional cardiology: pathophysiology and clinical aspects. Fundamental & Clinical Pharmacology 13:6, 613-623
CrossRef569
James M. Wilson, James J. Ferguson. (1999) Platelet-endothelial interactions in atherothrombotic disease: Therapeutic implications. Clinical Cardiology 22:11, 687-698
CrossRef570
Christopher P Cannon. (1999) Overcoming thrombolytic resistance. Journal of the American College of Cardiology 34:5, 1395-1402
CrossRef571
Raimund Erbel, Gerd Heusch. (1999) Coronary Microembolization—Its Role in acute coronary syndromes and interventions. Herz 24:7, 558-575
CrossRef572
J Conor O’Shea, James E Tcheng. (1999) Eptifibatide: a potent inhibitor of the platelet receptor integrin, glycoprotein IIb/IIIa. Expert Opinion on Investigational Drugs 8:11, 1893-1905
CrossRef573
Luis Branco, Philip Barren, Su-Yau Mao, David Pfarr, Ruth Kaplan, Christina Postema, Solomon Langermann, Scott Koenig, Syd Johnson. (1999) SELECTIVE DELETION OF ANTIGEN-SPECIFIC, ACTIVATED T CELLS BY A HUMANIZED MAB TO CD2 (MEDI-507) IS MEDIATED BY NK CELLS. Transplantation 68:10, 1588-1596
CrossRef574
Young Keun Ahn, Myung Ho Jeong, Joon Woo Kim, Seong Hee Kim, Jang Hyun Cho, Jeong Gwan Cho, Chang Soo Park, Sang Woo Juhng, Jong Chun Park, Jung Chaee Kang. (1999) Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheterization and Cardiovascular Interventions 48:3, 324-330
CrossRef575
Lloyd W. Klein. (1999) Significance of creatine kinase release after coronary interventions. Catheterization and Cardiovascular Interventions 48:2, 130-132
CrossRef576
STEVEN B.H. TIMMIS. (1999) Stents Aren't the Answer for Everything: The Lasting Relevance of Balloon Angioplasty. Journal of Interventional Cardiology 12:5, 327-328
CrossRef577
NICHOLAS KIPSHIDZE, PARAMJITH S. CHAWLA. (1999) Role of Autoperfusion Balloon in Endovascular Interventions. Journal of Interventional Cardiology 12:5, 329-337
CrossRef578
Verghese Mathew, Diane E Grill, Christopher G Scott, J.Aaron Grantham, Henry H Ting, Kirk N Garratt, David R Holmes. (1999) The influence of abciximab use on clinical outcome after aortocoronary vein graft interventions. Journal of the American College of Cardiology 34:4, 1163-1169
CrossRef579
Antonio L. Bartorelli, Daniela Trabattoni, Stefano Galli, Luca Grancini, Sergio Cozzi, Paolo Ravagnani. (1999) Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA. Catheterization and Cardiovascular Interventions 48:2, 211-213
CrossRef580
William S Weintraub, Steven Culler, Stephen J Boccuzzi, John R Cook, Andrzej S Kosinski, David J Cohen, Joy Burnette. (1999) Economic impact of GPIIB/IIIA blockade after high-risk angioplasty. Journal of the American College of Cardiology 34:4, 1061-1066
CrossRef581
Jörg Geiger. (1999) Anti-aggregatory drugs: I. Platelet receptor antagonists. Expert Opinion on Therapeutic Patents 9:10, 1389-1414
CrossRef582
FELIPE A. CECEÑA, DAVID H. HOELZINGER, JESS A. MILLER, SAWSAN ABU-SHAKRA. (1999) The Platelet IIb/IIIa Inhibitor Abciximab as Adjunctive Therapy in Carotid Stenting of Potential Thrombotic Lesions. Journal of Interventional Cardiology 12:5, 355-361
CrossRef583
Annapoorna Kini, Subhash Kini, Jonathan D. Marmur, Tudor Bertea, George Dangas, Thomas P. Cocke, Samin K. Sharma. (1999) Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. Catheterization and Cardiovascular Interventions 48:2, 123-129
CrossRef584
M. Cohen, J. J. Ferguson, R. A. Harrington. (1999) Trials of glycoprotein IIb-IIIa inhibitors in non-st-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the united states. Clinical Cardiology 22:S6, VI-2-VI-12
CrossRef585
Thaddeus R. Tolleson, Robert A. Harrington. (1999) Recent clinical trials in acute coronary syndromes without persistent ST elevation. Current Opinion in Cardiology 14:5, 403
CrossRef586
Dawn M. Bell. (1999) Analysis of Number Needed to Treat and Cost of Platelet Glycoprotein IIb/IIIa Inhibitors in Percutaneous Coronary Interventions and Acute Coronary Syndromes. Pharmacotherapy 19:9, 1086-1093
CrossRef587
Mina Madan, James C. Blankenship, Scott D. Berkowitz. (1999) Bleeding complications with platelet glycoprotein IIb/IIIa receptor antagonists. Current Opinion in Hematology 6:5, 334-341
CrossRef588
Thomas J Ryan, Elliott M Antman, Neil H Brooks, Robert M Califf, L.David Hillis, Loren F Hiratzka, Elliot Rapaport, Barbara Riegel, Richard O Russell, Earl E Smith, W.Douglas Weaver, Raymond J Gibbons, Joseph S Alpert, Kim A Eagle, Timothy J Gardner, Arthur Garson, Gabriel Gregoratos, Richard O Russell, Thomas J Ryan, Sidney C Smith. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 34:3, 890-911
CrossRef589
Annapoorna Kini, Jonathan D Marmur, Subhash Kini, George Dangas, Thomas P Cocke, Sylvan Wallenstein, Eppie Brown, John A Ambrose, Samin K Sharma. (1999) Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course. Journal of the American College of Cardiology 34:3, 663-671
CrossRef590
Paul D. McGrath, David J. Malenka, David E. Wennberg, Samuel J. Shubrooks, William A. Bradley, John F. Robb, Mirle A. Kellett, Thomas J. Ryan, Michael J. Hearne, Bruce Hettleman, John R. O’Meara, Peter VerLee, Matthew W. Watkins, Winthrop D. Piper, Gerald T. O’Connor. (1999) Changing outcomes in percutaneous coronary interventions. Journal of the American College of Cardiology 34:3, 674-680
CrossRef591
Jacquelynn J. Cook, Bohumil Bednar, Joseph J. Lynch, Robert J. Gould, Melissa S. Egbertson, Wasyl Halczenko, Mark E. Duggan, George D. Hartman, Man-Wai Lo, Gail M. Murphy, Lawrence I. Deckelbaum, Frederick L. Sax, Eliav Barr. (1999) Tirofiban (Aggrastat®). Cardiovascular Drug Reviews 17:3, 199-224
CrossRef592
Koon Hou Mak, David J. Moliterno. (1999) Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Current Cardiology Reports 1:3, 199-205
CrossRef593
Joseph A. Guzzo, Timothy C. Nichols. (1999) Possible anaphylactic reaction to abciximab. Catheterization and Cardiovascular Interventions 48:1, 71-73
CrossRef594
Clinton T Lloyd, Antonio M Calafiore, Peter Wilde, Raimondo Ascione, Leonardo Paloscia, Christopher R Monk, Gianni D Angelini. (1999) Integrated left anterior small thoracotomy and angioplasty for coronary artery revascularization. The Annals of Thoracic Surgery 68:3, 908-911
CrossRef595
J. J. Connors, Joan C. Wojak. (1999) Percutaneous transluminal angioplasty for intracranial atherosclerotic lesions: evolution of technique and short-term results. Journal of Neurosurgery 91:3, 415-423
CrossRef596
Maher Rabah, Denise Mason, David W.M Muller, Randal Hundley, Aaron D Kugelmass, Bonnie Weiner, Louis Cannon, William W O’Neill, Robert D Safian. (1999) Heparin after percutaneous intervention (HAPI): a prospective multicenter randomized trial of three heparin regimens after successful coronary intervention. Journal of the American College of Cardiology 34:2, 461-467
CrossRef597
Ian Fisher, Paul Robinson, James M. Ritter. (1999) Platelet glycoprotein IIb/IIIa blockade with tirofiban: effect on aggregation caused by P256, an antibody to human IIb/IIIa receptors. British Journal of Clinical Pharmacology 48:2, 197-199
CrossRef598
Christopher P. Cannon. (1999) Incorporating platelet glycoprotein iib/iiia inhibition in critical pathways: Unstable angina/non-st-segment elevation myocardial infarction. Clinical Cardiology 22:S4, 30-36
CrossRef599
James T. Willerson, Pierre Zoldhelyi. (1999) Future directions in thrombolysis. Clinical Cardiology 22:S4, 44-53
CrossRef600
Christopher P. Cannon. (1999) Combination therapy for acute myocardial infarction: Glycoprotein ilb/iiia inhibitors plus thrombolysis. Clinical Cardiology 22:S4, 37-43
CrossRef601
Richard Gallo, James H Chesebro, Juan J Badimon. (1999) Treatment of Unstable Angina. Thrombosis Research 95:3, V15-V31
CrossRef602
(1999) Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. The Lancet 354:9180, 708-715
CrossRef603
Markus Borries, Yuriko Fischer, Hugo Stiegler, Ansgar Peters, Bodo E. Strauer, Matthias Leschke, Michael Heins, Hans Reinauer, Frank C. Schoebel. (1999) Changes of hemostasis, endogenous fibrinolysis, platelet activation and endothelins after percutaneous transluminal coronary angioplasty in patients with stable angina. Journal of the American College of Cardiology 34:2, 486-493
CrossRef604
Vijay D. Subbarao, Jason Phillips, George A. Stouffer. (1999) Cardiology Grand Rounds from The University of Texas Medical Branch. The American Journal of the Medical Sciences 318:2, 107
CrossRef605
Lincoff, A. Michael, Califf, Robert M., Moliterno, David J., Ellis, Stephen G., Ducas, John, Kramer, Jeffrey H., Kleiman, Neal S., Cohen, Eric A., Booth, Joan E., Sapp, Shelly K., Cabot, Catherine F., Tcheng, James E., Talley, J. David, Caramori, Paul O., Burton, Jeffrey R., Kelly, Thomas A., Ivanc, Tom B., Topol, Eric J., . (1999) Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors. New England Journal of Medicine 341:5, 319-327
Full Text606
Steven J. Jubelirer, Beth A. Koenig, Mark C. Bates. (1999) Acute profound thrombocytopenia following C7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy. American Journal of Hematology 61:3, 205-208
CrossRef607
Heidar Arjomand, Zafar M. Magsi, Khai S. Chang, Daniel A.N. Mascarenhas. (1999) Abciximab readministration: A single-operator community-hospital experience. Catheterization and Cardiovascular Interventions 47:3, 294-296
CrossRef608
Alain Coiffic, Eric Cazes, Gérard Janvier, François Forestier, François Lanza, Alan Nurden, Paquita Nurden. (1999) Inhibition of Platelet Aggregation by Abciximab but Not by Aspirin Can Be Detected by a New Point-of-Care Test, the Hemostatus. Thrombosis Research 95:2, 83-91
CrossRef609
Yutaka Matsumoto, Keiko Marukawa, Hiromi Okumura, Tomoya Adachi, Takeshi Tani, Yukio Kimura. (1999) Comparative Study of Antiplatelet Drugs in Vitro. Thrombosis Research 95:1, 19-29
CrossRef610
D. Williamson, S. Giuliano, S. P. Jackson. (1999) Platelet adhesion receptors: novel targets for anti-thrombotic therapy. Australian and New Zealand Journal of Medicine 29:3, 452-461
CrossRef611
Jack R. Chamberlin, Amy B. Lardi, Louis S. McKeever, Ming H. Wang, Govind Ramadurai, Paul Grunenwald, William P. Towne, Eric D. Grassman, Fred S. Leya, Bruce E. Lewis, Lowell H. Stein. (1999) Use of vascular sealing devices (VasoSeal and Perclose) versus assisted manual compression (Femostop) in transcatheter coronary interventions requiring Abciximab (ReoPro). Catheterization and Cardiovascular Interventions 47:2, 143-147
CrossRef612
DOUGLAS YUN, JODI MOONEY, MICHAEL R. MOONEY. (1999) Possis Angiojet Rapid Thrombectomy System: A New Device for the Definitive Treatment of Thrombotic Coronary Lesions. Journal of Interventional Cardiology 12:3, 209-214
CrossRef613
Toshiaki Aoki, Kayoko Harada, Jiro Seki, Akito Tanaka, Hisashi Takasugi, Yukio Motoyama. (1999) FK633: A Potent and Selective Platelet GPIIb/IIIa Antagonist. Cardiovascular Drug Reviews 17:2, 147-159
CrossRef614
Joseph E Prince, Christie M Ballantyne. (1999) Adhesion molecules in cardiovascular disease. Expert Opinion on Therapeutic Targets 3:2, 263-277
CrossRef615
P. Priollet. (1999) Artériopathie des membres inférieurs: Vers une prise en charge globale. La Revue de Médecine Interne 20:6, 473-475
CrossRef616
Ganesh Manoharan, Suzanne J Maynard, AA Jennifer Adgey. (1999) The therapeutic use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. Expert Opinion on Investigational Drugs 8:5, 555-566
CrossRef617
Luis R.P. Scott, Jose A. Silva, Christopher White, Tyrone J. Collins. (1999) Rheolytic thrombectomy: A new treatment for stent thrombosis. Catheterization and Cardiovascular Interventions 47:1, 97-101
CrossRef618
Bärbel Wittke, Ian J. Mackie, Samuel J. Machin, Uwe Timm, Manfred Zell, Timothy Goggin. (1999) Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers. British Journal of Clinical Pharmacology 47:5, 521-530
CrossRef619
Seiya Horisawa, Munekiyo Kaneko, Yoshiharu Ikeda, Yasuyuki Ueki, Teruo Sakurama. (1999) Antithrombotic Effect of SM-20302, a Nonpeptide GPIIb/IIIa Antagonist, in a Photochemically Induced Thrombosis Model in Guinea Pigs. Thrombosis Research 94:4, 227-234
CrossRef620
Lilian McGregor, Michel Bellangeon, Elsa Chignier, Laurence Lerond, Cecile Rousselle, John L McGregor. (1999) Effect of a Micronized Purified Flavonoid Fraction on in Vivo Platelet Functions in the Rat. Thrombosis Research 94:4, 235-240
CrossRef621
WILLIAM W. O'NEILL, PATRICK SERRUYS, MERRILL KNUDTSON, GERRIT-ANN ES, GERALD C. TIMMIS, COEN ZWAAN, JAY KLEIMAN, KERRY BARKER, ROGER DREILING, RICHARD HUBBARD, JOHN ALEXANDER, ROBERT ANDERS. (1999) Design and Objectives of the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events (EXCITE) Study. Journal of Interventional Cardiology 12:2, 109-116
CrossRef622
A. A. Jennifer Adgey, T. P. Mathew, M. T. Harbinson. (1999) Periprocedural creatine kinase-mb elevations: Long-term impact and clinical implications. Clinical Cardiology 22:4, 257-265
CrossRef623
Jack Hirsh, Jeffrey I Weitz. (1999) New antithrombotic agents. The Lancet 353:9162, 1431-1436
CrossRef624
J. DAVID TALLEY. (1999) Interventional Management of Acute Coronary Syndromes. Journal of Interventional Cardiology 12:2, 117-132
CrossRef625
Chumpol Piamsomboon, Peter M.T. Wong, Atul Mathur, Davinderjit Singh, Ming W. Liu, William A. Baxley, Sriram S. Iyer, Larry S. Dean, Gary S. Roubin. (1999) Does platelet glycoprotein IIb/IIIa receptor antibody improve in-hospital outcome of coronary stenting in high-risk thrombus containing lesions?. Catheterization and Cardiovascular Interventions 46:4, 415-420
CrossRef626
GREGG W. STONE, BRUCE R. BRODIE, JOHN J. GRIFFIN, MARIE CLAUDE MORICE, COSTANTINO COSTANTINI, PAUL A. OVERLIE, THOMAS J. LINNEMEIER, JEFFREY MOSES, WILLIAM W. O'NEILL, CINDY L. GRINES, . (1999) Improved Short-Term Outcomes of Primary Coronary Stenting Compared to Primary Balloon Angioplasty in Acute Myocardial Infarction at Experienced Centers: The PAMI Study Group Experience. Journal of Interventional Cardiology 12:2, 101-108
CrossRef627
John A. Bittl. (1999) Creatine kinase leaks, myocardial necrosis, and prognosis after percutaneous coronary interventions. Catheterization and Cardiovascular Interventions 46:3, 303-304
CrossRef628
Jeffrey L Anderson, Gretchen J King, Tami L Bair, Sidney P Elmer, Joseph B Muhlestein, Jessica Habashi, John F Carlquist. (1999) Associations between a polymorphism in the gene encoding glycoprotein IIIa and myocardial infarction or coronary artery disease. Journal of the American College of Cardiology 33:3, 727-733
CrossRef629
Warren J. Cantor, Kori Leblanc, Bernadette Garvey, K. Randal Watson, Al Rasymas, Bradley H. Strauss. (1999) Combined use of orgaran and reopro during coronary angioplasty in patients unable to receive heparin. Catheterization and Cardiovascular Interventions 46:3, 352-355
CrossRef630
Craig R Narins, Dave P Miller, Robert M Califf, Eric J Topol. (1999) The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization. Journal of the American College of Cardiology 33:3, 647-653
CrossRef631
Kenneth A Ault, Christopher P Cannon, Jane Mitchell, John McCahan, Russell P Tracy, William F Novotny, James D Reimann, Eugene Braunwald. (1999) Platelet activation in patients after an acute coronary syndrome: results from the TIMI-12 trial. Journal of the American College of Cardiology 33:3, 634-639
CrossRef632
Dennis Kelly, Rohit Arora. (1999) Prognostic significance of myocardial enzyme release after coronary interventions. Catheterization and Cardiovascular Interventions 46:3, 292-302
CrossRef633
Hitoshi Banno, Hiroshi Kawazura, Takanori Yutaka, Noriko Sakuma, Takashi Kitamori, Junko Hosoya, Kenji Kibayashi, Hiroyuki Yamashita, Kazuo Umemura, Mitsuyoshi Nakashima. (1999) Antiaggregatory, antithrombotic effects of MS-180, a novel platelet glycoprotein IIb/IIIa receptor antagonist. European Journal of Pharmacology 367:2-3, 275-282
CrossRef634
John D Folts, Andrew I Schafer, Joseph Loscalzo, James T Willerson, James E Muller. (1999) A perspective on the potential problems with aspirin as an antithrombotic agent: a comparison of studies in an animal model with clinical trials. Journal of the American College of Cardiology 33:2, 295-303
CrossRef635
Jinbao Huang, Sam S. Rebello, Lewis A. Rosenberg, Munekiyo Kaneko, Teruo Sakurama, Benedict R. Lucchesi. (1999) Temporary and partial inhibition of platelets by SM-20302 prevents coronary artery thrombosis in a chronic canine model. European Journal of Pharmacology 366:2-3, 203-213
CrossRef636
Richard Shlansky-Goldberg. (1999) Beyond Heparin, the “Newer” Antiplatelet Drugs. Journal of Vascular and Interventional Radiology 10:2, 123-126
CrossRef637
J.J. Connors, Joan C. Wojak. (1999) Intracranial Angioplasty for Atherosclerotic Disease. Journal of Vascular and Interventional Radiology 10:2, 43-47
CrossRef638
J.J. Connors, J.C. Wojak. (1999) Development of a Safer Technique for Intracranial Angioplasty for Atherosclerosis by Analysis of 9 Years’ Experience in 68 Patients. Journal of Vascular and Interventional Radiology 10:2, 181-183
CrossRef639
E.-P. Strecker, I. Boos. (1999) Iliac and femoral arterial stents — an overview. Minimally Invasive Therapy & Allied Technologies 8:3, 145-151
CrossRef640
Stephen M Zaacks, Philip R Liebson, James E Calvin, Joseph E Parrillo, Lloyd W Klein. (1999) Unstable angina and non-Q wave myocardial infarction: does the clinical diagnosis have therapeutic implications?. Journal of the American College of Cardiology 33:1, 107-118
CrossRef641
(1999) Point - Counterpoint: The wide use of IIb/IIIa inhibitors in interventional cardiology - is it justified?. Acute Cardiac Care 2:1, 61-70
CrossRef642
Eric J Topol, Tatiana V Byzova, Edward F Plow. (1999) Platelet GPIIb-IIIa blockers. The Lancet 353:9148, 227-231
CrossRef643
Shuichi Oshima, Taro Saito, Shota Nakamura, Katsuo Noda, Haruhiko Date, Seiji Hokimoto, Izumi Taniguchi, Nobuyasu Yamamoto. (1999) Percutaneous Transluminal Coronary Angioplasty, Alone or in Combination With Urokinase Therapy, During Acute Myocardial Infarction. Japanese Circulation Journal 63:2, 91-96
CrossRef644
TM Reilly, SA Mousa, AL Racanelli. (1999) New antiplatelet drugs. Expert Opinion on Emerging Drugs 4:1, 197-208
CrossRef645
Victor A Umans, Jan H Cornel, Stella Schrijver-van Velthoven, Paul Kloeg, Piet Bartels, Jean Bronzwaer. (1999) Safety and efficacy of treatment with platelet GPIIb/IIIa receptor blockade in unstable angina patients awaiting PTCA at a referring clinic. Acute Cardiac Care 2:4, 223-230
CrossRef646
Barbara E Tardiff, Robert M Califf, James E Tcheng, A.Michael Lincoff, Kristina N Sigmon, Robert A Harrington, Kenneth W Mahaffey, E.Magnus Ohman, Paul S Teirstein, James C Blankenship, Michael M Kitt, Eric J Topol. (1999) Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. Journal of the American College of Cardiology 33:1, 88-96
CrossRef647
Muredach P. Reilly, Niamh Moran, Emma Meagher, Norman Delanty, Andrew E. Cucchiara, John A. Lawson, Francesca Catella-Lawson. (1999) A Randomized, Placebo-Controlled, Crossover Study of E5510 and Aspirin in Healthy Volunteers. Journal of Cardiovascular Pharmacology 33:1, 12-18
CrossRef648
Khatereh Moshfegh, Walter A Wuillemin, Maurice Redondo, Bernhard Lämmle, Jürg H Beer, Sabina Liechti-Gallati, Beat J Meyer. (1999) Association of two silent polymorphisms of platelet glycoprotein la/lla receptor with risk of myocardial infarction: a case-control study. The Lancet 353:9150, 351-354
CrossRef649
Donald L Drakeman, Paul K Wallace. (1999) Monoclonal antibodies. Expert Opinion on Emerging Drugs 4:1, 355-365
CrossRef650
Mahomed Y Salame, Ranjit S More, Stefan Verheye, Mark E Leimbach, Spencer B King III, Nicolas AF Chronos. (1999) The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. Acute Cardiac Care 2:4, 207-215
CrossRef651
Noel M Caplice, Robert D Simari, David R Holmes. (1999) Molecular biology and gene transfer in atherosclerosis in the stenting era. Acute Cardiac Care 2:3, 141-152
CrossRef652
Upendra Kaul, Balbir Singh, Dinesh Sudan, Rakesh Sapra, Ram Dev Yadav, Tapan Ghose, N.S. Dixit. (1999) Primary stenting in acute myocardial infarction: A 30-day follow up study. Catheterization and Cardiovascular Interventions 46:1, 4-10
CrossRef653
Ron JG Peters, Hans JRM Bonnier, Jaap J Bredee. (1999) Guidelines for indications for coronary revascularization in The Netherlands. Acute Cardiac Care 2:3, 153-162
CrossRef654
Todd J. Lorenz, Fraser Macdonald, Michael M. Kitt. (1999) Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb–IIIa. Clinical Therapeutics 21:1, 128-137
CrossRef655
(1998) Abciximab and Alveolar Hemorrhage. New England Journal of Medicine 339:25, 1861-1863
Full Text656
JOACHIM SCHOFER. (1998) Risk Assessment for Coronary Interventions. Journal of Interventional Cardiology 11:6, 633-640
CrossRef657
W.Brian Gibler, Robert G Wilcox, Christoph Bode, Alain D Castaigne, Herman Delooz, Dirk Elich, Keith A Fox, Dean J Kereiakes, Hans Rupprecht, Eric J Topol. (1998) Prospective Use of Glycoprotein IIb/IIIa Receptor Blockers in the Emergency Department Setting. Annals of Emergency Medicine 32:6, 712-722
CrossRef658
J. L. Mehta. (1998) Salutary effects of aspirin in coronary artery disease are not limited to its platelet inhibitory effects. Clinical Cardiology 21:12, 879-884
CrossRef659
URI ROSENSCHEIN. (1998) Ultrasound Thrombolysis: An Alternative to the Pharmacological Approach. Journal of Interventional Cardiology 11:6, 603-607
CrossRef660
Masakiyo Nobuyoshi, Yoshihisa Nakagawa. (1998) AngioJet thrombectomy catheter for the thrombus-laden lesions. Catheterization and Cardiovascular Diagnosis 45:4, 394-395
CrossRef661
(1998) Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) Trial. Journal of the American College of Cardiology 32:7, 2003-2010
CrossRef662
David C. Calverley, Gerald J. Roth. (1998) ANTIPLATELET THERAPY. Hematology/Oncology Clinics of North America 12:6, 1231-1249
CrossRef663
L. A. HOURIGAN, A. J. RAINBIRD, M. DOORIS. (1998) Intracoronary stenting for acute myocardial infarction (AMI) in a 24-year-old man using anabolic androgenic steroids.. Australian and New Zealand Journal of Medicine 28:6, 838-839
CrossRef664
Rabih R Azar, Raymond G McKay, Paul D Thompson, Jeffrey A Hirst, Joseph F Mitchell, Daniel B Fram, David D Waters, Francis J Kiernan. (1998) Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes. Journal of the American College of Cardiology 32:7, 1996-2002
CrossRef665
Mariano Sentí, Clara Aubó, Mireia Bosch, Marco Pavesi, Araceli Pena, Rafel Masiá, Jaume Marrugat. (1998) Platelet glycoprotein IIb/IIIa genetic polymorphism is associated with plasma fibrinogen levels in myocardial infarction patients. Clinical Biochemistry 31:8, 647-651
CrossRef666
Steven R Steinhubl, Michael S Lauer, Debabrata P Mukherjee, David J Moliterno, A. Michael Lincoff, Stephen G Ellis, Eric J Topol. (1998) The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non–Q-wave myocardial infarctions. Journal of the American College of Cardiology 32:5, 1366-1370
CrossRef667
L. Paulette Hale, Karen Smith, Gregory A. Braden, John Owen. (1998) Orgaran during rotational atherectomy in the setting of heparin-induced thrombocytopenia. Catheterization and Cardiovascular Diagnosis 45:3, 318-322
CrossRef668
DavidR Holmes, John Hirshfeld, David Faxon, RonaldE Vlietstra, Alice Jacobs, SpencerB King, ThomasM Bashore, NancyD Bridges, CharlesB Higgins, LorenF Hiratzka, WilliamC Little, RaymondD Magorien, MichaelA Nocero, Stephen Oesterle, RobertA Vogel, JamesS Forrester, PamelaS Douglas, DavidP Faxon, JohnD Fisher, RaymondJ Gibbons, JonathanL Halperin, AdolphM Hutter, JudithS Hochman, Sanjiv Kaul, WilliamS Weintraub, WilliamL Winters, MichaelJ Wolk. (1998) ACC expert consensus document on coronary artery stents. Journal of the American College of Cardiology 32:5, 1471-1482
CrossRef669
Duane C. Berkompas. (1998) Abciximab combined with angioplasty in a patient with renal artery stent subacute thrombosis. Catheterization and Cardiovascular Diagnosis 45:3, 272-274
CrossRef670
T. Joseph, J. Marco, L. Gregorint. (1998) Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty. Clinical Cardiology 21:11, 851-852
CrossRef671
Susan P. Etheridge, Lloyd Y. Tani, L. LuAnn Minich, James R. Revenaugh. (1998) Platelet glycoprotein IIb/IIIa receptor blockade therapy for large coronary aneurysms and thrombi in Kawasaki disease. Catheterization and Cardiovascular Diagnosis 45:3, 264-268
CrossRef672
Cherian Sebastian, Michael Scherlag, Aaron Kugelmass, Eliot Schechter. (1998) Primary stent implantation for acute myocardial infarction during pregnancy: Use of abciximab, ticlopidine, and aspirin. Catheterization and Cardiovascular Diagnosis 45:3, 275-279
CrossRef673
Gérard Helft, Sylvie Choktron, Farzyn Beygui, Claude Le Feuvre, Ismail Elalamy, Jean-Philippe Metzger, André Vacheron, Michel Meyer Samama. (1998) Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty. Catheterization and Cardiovascular Diagnosis 45:3, 329-331
CrossRef674
Stephen G Ellis, A.Michael Lincoff, Dave Miller, James E Tcheng, Neal S Kleiman, Dean Kereiakes, Robert Califf, Eric J Topol. (1998) Reduction in complications of angioplasty with abciximab occurs largely independently of baseline lesion morphology. Journal of the American College of Cardiology 32:6, 1619-1623
CrossRef675
MA de Belder, AGC Sutton. (1998) Abciximab (Reopro): a clinically effective glycoprotein IIb/IIIa receptor blocker. Expert Opinion on Investigational Drugs 7:10, 1701-1717
CrossRef676
R. P. Steeds, K. S. Channer. (1998) Recent advances in the management of unstable angina and non-Q-wave myocardial infarction. British Journal of Clinical Pharmacology 46:4, 335-341
CrossRef677
Ulrich E. Heidland, Waldemar J. Klimek, Christoph J. Michel, Matthias P. Heintzen, Bodo E. Strauer. (1998) Einfluß einer intrakoronaren Dipyridamol-Applikation auf die Inzidenz der Restenose nach PTCA. Medizinische Klinik 93:10, 579-584
CrossRef678
John M Alvarez. (1998) Coronary stenting and use of abciximab. The Lancet 352:9136, 1311
CrossRef679
KHOI M. LE. (1998) Update on Glycoprotein IIb/IIIa Blockade in Endovascular Interventions. Journal of Interventional Cardiology 11:s5, S18-S28
CrossRef680
MASAKIYO NOBUYOSHI, SATOSHI SHIZUTA. (1998) Update on Percutaneous Management of Chronic Total Occlusion. Journal of Interventional Cardiology 11:s5, S42-S45
CrossRef681
THACH NGUYEN, DAYI HU, JAMES NGUYEN, SHIGERU SAITO, VIJAY DAVE. (1998) The Challenges of Today's Endovascular Interventions. Journal of Interventional Cardiology 11:s5, S1-S8
CrossRef682
Eric J Topol, A Michael Lincoff, Shelly Sapp. (1998) Coronary stenting and use of abciximab. The Lancet 352:9136, 1311-1312
CrossRef683
Jorge Joven, José M Simó, Elisabet Vilella, Jordi Camps, Luis Masana, Gabriel de Febrer, Mercè Camprubı́, Cristobal Richart, Alfredo Bardaji, Elena Casao, Miguel Pocovi, Fernando Civeira. (1998) Lipoprotein(a) and the significance of the association between platelet glycoprotein IIIa polymorphisms and the risk of premature myocardial infarction. Atherosclerosis 140:1, 155-159
CrossRef684
Tift Mann, Gabriela Cubeddu, Josie Bowen, Joel E Schneider, Michael Arrowood, William N Newman, Michael J Zellinger, Gregory C Rose. (1998) Stenting in acute coronary syndromes: a comparison of radial versus femoral access sites. Journal of the American College of Cardiology 32:3, 572-576
CrossRef685
Gary Gershony, John M. Brock, Jerry S. Powell. (1998) Novel vascular sealing device for closure of percutaneous vascular access sites. Catheterization and Cardiovascular Diagnosis 45:1, 82-88
CrossRef686
Sam S. Rebello, Jinbao Huang, Wayne J. Shiu, Kumi Saito, Munekiyo Kaneko, Yoshikazu Saitoh, Benedict R. Lucchesi. (1998) Pharmacokinetics and Pharmacodynamics of SM-20302, a GPIIb/IIIa Receptor Antagonist, in Anesthetized Dogs. Journal of Cardiovascular Pharmacology 32:3, 485-494
CrossRef687
The PURSUIT Trial Investigators. (1998) Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes. New England Journal of Medicine 339:7, 436-443
Full Text688
N. Curzen, R. Haque, A. Timmis. (1998) Applications of thrombolytic therapy. Intensive Care Medicine 24:8, 756-768
CrossRef689
J. M. Alvarez, R. W. Harper, R. E. Peverill. (1998) Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention - caution regarding the combined use of aspirin, ticlopidine and abciximab. Australian and New Zealand Journal of Medicine 28:4, 463-464
CrossRef690
Leo Lunney, Khalid Karim, Thomas Little. (1998) Vasoseal hemostasis following coronary interventions with Abciximab. Catheterization and Cardiovascular Diagnosis 44:4, 405-406
CrossRef691
Scott D. Berkowitz, David C. Sane, Kristina N. Sigmon, Jane H. Shavender, Robert A. Harrington, James E. Tcheng, Eric J. Topol, Robert M. Califf. (1998) Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Journal of the American College of Cardiology 32:2, 311-319
CrossRef692
Harvey D. White, John K. French, Christopher J. Ellis. (1998) New antiplatelet agents. Australian and New Zealand Journal of Medicine 28:4, 558-564
CrossRef693
Surender K Vaswani, Robert G Hamilton. (1998) Humanized Antibodies as Potential Therapeutic Drugs. Annals of Allergy, Asthma & Immunology 81:2, 105-119
CrossRef694
Konstantinos Konstantopoulos, Sharad Kukreti, Larry V McIntire. (1998) Biomechanics of cell interactions in shear fields. Advanced Drug Delivery Reviews 33:1-2, 141-164
CrossRef695
G. Hornstra, C. A. Barth, C. Galli, R. P. Mensink, M. Mutanen, R. A. Riemersma, M. Roberfroid, K. Salminen, G. Vansant, P. M. Verschuren. (1998) Functional food science and the cardiovascular system. British Journal of Nutrition 80:S1, S113
CrossRef696
Hans Domanovits, Karin Janata, Anton N. Laggner, Stephan Hornykewycz, Mariam Nikfardjam, Gerald Maurer, Kurt Huber. (1998) Restoration of coronary blood flow by single bolus injection of the gpiib/iiia receptor antagonist c7e3 fab in a patient with acute myocardial infarction of recent onset. Clinical Cardiology 21:7, 525-528
CrossRef697
C.Michael Gibson, Mukesh Goel, David J. Cohen, Robert N. Piana, Lawrence I. Deckelbaum, Katherine E. Harris, Spencer B. King. (1998) Six-month angiographic and clinical follow-up of patients prospectively randomized to receive either tirofiban or placebo during angioplasty in the RESTORE trial. Journal of the American College of Cardiology 32:1, 28-34
CrossRef698
RH Stables. (1998) Routine use of abciximab in coronary stenting?. The Lancet 352:9122, 81-82
CrossRef699
Homayoun Khanlou, Sotirios Tsiodras, Glenn Eiger, Khalid Abousy, Steven Goldberg, Fred Nakhjavan, Shahriar Yazdanfar. (1998) Fatal alveolar hemorrhage and Abciximab (ReoProTM) therapy for acute myocardial infarction. Catheterization and Cardiovascular Diagnosis 44:3, 313-316
CrossRef700
Eric J Topol. (1998) Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The Lancet 352:9122, 87-92
CrossRef701
Donna L. Pedicord, Beth E. Thomas, Shaker A. Mousa, Ira B. Dicker. (1998) Glycoprotein IIb/IIIa Receptor Antagonists Inhibit the Development of Platelet Procoagulant Activity. Thrombosis Research 90:6, 247-258
CrossRef702
Steven A. Kagan, Stuart I. Myers. (1998) MEDIATORS OF RESTENOSIS. Surgical Clinics of North America 78:3, 481-500
CrossRef703
Andre Uzan. (1998) Antithrombotic agents. Expert Opinion on Emerging Drugs 3:1, 189-208
CrossRef704
Jeffrey S. Mandak, James C. Blankenship, Laura H. Gardner, Scott D. Berkowitz, Frank V. Aguirre, Kristina N. Sigmon, Gerald C. Timmis, Ian C. Gilchrist, Michael McIvor, Jon Resar, Bonnie H. Weiner, Barry S. George, J.David Talley, A.Michael Lincoff, James E. Tcheng, Robert M. Califf, Eric J. Topol. (1998) Modifiable Risk Factors for Vascular Access Site Complications in the IMPACT II Trial of Angioplasty With Versus Without Eptifibatide. Journal of the American College of Cardiology 31:7, 1518-1524
CrossRef705
The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. (1998) A Comparison of Aspirin plus Tirofiban with Aspirin plus Heparin for Unstable Angina. New England Journal of Medicine 338:21, 1498-1505
Full Text706
The Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. (1998) Inhibition of the Platelet Glycoprotein IIb/IIIa Receptor with Tirofiban in Unstable Angina and Non–Q-Wave Myocardial Infarction. New England Journal of Medicine 338:21, 1488-1497
Full Text707
Chesebro, James H., Badimon, Juan J., . (1998) Platelet Glycoprotein IIb/IIIa Receptor Blockade in Unstable Coronary Disease. New England Journal of Medicine 338:21, 1539-1541
Full Text708
Hilla Knobler, Naphtali Savion, Boris Shenkman, Shlomo Kotev-Emeth, David Varon. (1998) Shear-Induced Platelet Adhesion and Aggregation on Subendothelium Are Increased in Diabetic Patients. Thrombosis Research 90:4, 181-190
CrossRef709
R. W. F. Campbell, L. Wallentin, F. W. A. Verheugt, A. G. G. Turpie, A. Maseri, W. Klein, J. G. F. Cleland, C. Bode, R. Becker, J. Anderson, M. E. Bertrand, C. R. Conti. (1998) Management Strategies for a Better Outcome in Unstable Coronary Artery Disease. Clinical Cardiology 21:5, 314-322
CrossRef710
Hans Ulrich Stilz, Wolfgang Guba, Bernd Jablonka, Melitta Just, Otmar Klingler, Wolfgang König, Volkmar Wehner, Gerhard Zoller. (1998) From a peptide lead to an orally active peptidomimetic fibrinogen receptor antagonist. Letters in Peptide Science 5:2-3, 215-221
CrossRef711
Hans-Jürgen Rupprecht. (1998) Neue Konzepte in der Prävention der Atherothrombose. Herz 23:3, 205-207
CrossRef712
Ivan T Straznicky, Andrew Zambanini, Harvey D White. (1998) Ongoing clinical trials of anti-platelet agents in the management of acute ischaemic coronary syndromes. Expert Opinion on Investigational Drugs 7:5, 811-821
CrossRef713
Anil K. Goklaney, Joshua D. Murphy, William B. Hillegass. (1998) Abciximab therapy in percutaneous intervention: Economic issues in the United States. American Heart Journal 135:4, s90-s97
CrossRef714
Timothy J Shetler, Blanche D Bailey, Joseph A Jakubowski, Charles V Jackson. (1998) Intravenous Administration of the Glycoprotein IIb-IIIa Receptor Antagonist 7E3 Induces Reperfusion of an Acute Thrombotic Occlusion of the Canine Coronary Artery. Thrombosis Research 90:2, 95-100
CrossRef715
Elizabeth G. Quinn, David J.G. Fergusson. (1998) Coronary embolism following aortic and mitral valve replacement: Successful management with abciximab and urokinase. Catheterization and Cardiovascular Diagnosis 43:4, 457-459
CrossRef716
James J. Ferguson, Dean J. Kereiakes, A.A.Jennifer Adgey, Keith A.A. Fox, William B. Hillegass, Matthias Pfisterer, Corrado Vassanelli. (1998) Safe use of platelet GP IIb/IIIa inhibitors. American Heart Journal 135:4, s77-s89
CrossRef717
Eugene Braunwald, Attilio Maseri, Paul W. Armstrong, Robert M. Califf, W.Brian Gibler, Christian W. Hamm, Maarten L. Simoons, Frans Van de Werf. (1998) Rationale and clinical evidence for the use of GP IIb/IIIa inhibitors in acute coronary syndromes. American Heart Journal 135:4, s56-s66
CrossRef718
Y. M. Cheong, R. Dick, B. Sia, Y. L. Lim. (1998) Percutaneous transluminal coronary angioplasty (PTCA) without on-site surgical facilities. Australian and New Zealand Journal of Medicine 28:2, 165-172
CrossRef719
Ben A. van Hout, Lee Bowman, David J. Zelinger, Maarten L. Simoons. (1998) Costs and effects in therapy for acute coronary syndromes: The case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. American Heart Journal 135:4, s98-s106
CrossRef720
Nicolas Chronos, Alec Vahanian, Amadeo Betriu, Håkan Emanuelsson, Sheldon Goldberg, Dietrich Gulba, Ben A. van Hout. (1998) Use of abciximab in interventional cardiology. American Heart Journal 135:4, s67-s76
CrossRef721
A.A.Jennifer Adgey. (1998) An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. American Heart Journal 135:4, s43-s55
CrossRef722
James J. Ferguson, Hesham M. Waly, J.Michael Wilson. (1998) Fundamentals of coagulation and glycoprotein IIb/IIIa receptor inhibition. American Heart Journal 135:4, s35-s42
CrossRef723
Michael Haude, Christoph Altmann, Beate Eick, Fengqi Liu, Barbara Schwippert, Diethelm Tschöpe, Raimund Erbel. (1998) Analysis of vessel wall morphology, blood flow velocity, and the hemostatic system in a patient with a large intracoronary thrombus. Catheterization and Cardiovascular Diagnosis 43:3, 298-305
CrossRef724
RenÉ G. Favaloro. (1998) Critical Analysis of Coronary Artery Bypass Graft Surgery: A 30-Year Journey. Journal of the American College of Cardiology 31:4, 1B-63B
CrossRef725
Shaker A. Mousa, John Wityak. (1998) Orally Active Isoxazoline GPIIb/IIIa Antagonists. Cardiovascular Drug Reviews 16:1, 48-61
CrossRef726
Spencer B King. (1998) The Development of Interventional Cardiology. Journal of the American College of Cardiology 31:4, 64B-88B
CrossRef727
Cathy A. Sila. (1998) NEUROLOGIC COMPLICATIONS OF VASCULAR SURGERY. Neurologic Clinics 16:1, 9-20
CrossRef728
Robert M. Califf, Alaa E. Abdelmeguid, Richard E. Kuntz, Jeffrey J. Popma, Charles J. Davidson, Eric A. Cohen, Neal S. Kleiman, Kenneth W. Mahaffey, Eric J. Topol, Carl J. Pepine, Ray J. Lipicky, Christopher B. Granger, Robert A. Harrington, Barbara E. Tardiff, Brian S. Crenshaw, Robert P. Bauman, Bram D. Zuckerman, Bernard R. Chaitman, John A. Bittl, E.Magnus Ohman. (1998) Myonecrosis After Revascularization Procedures. Journal of the American College of Cardiology 31:2, 241-251
CrossRef729
John M. Alvarez. (1998) Emergency coronary bypass grafting for failed percutaneous coronary artery stenting: increased costs and platelet transfusion requirements after the use of abciximab. The Journal of Thoracic and Cardiovascular Surgery 115:2, 472-473
CrossRef730
James S Gammie, Marco Zenati, Robert L Kormos, Brack G Hattler, Lawrence M Wei, Ronald V Pellegrini, Bartley P Griffith, Cornelius M Dyke. (1998) Abciximab and Excessive Bleeding in Patients Undergoing Emergency Cardiac Operations. The Annals of Thoracic Surgery 65:2, 465-469
CrossRef731
Andrew D. Michaels, Brian Whisenant, John S. Macgregor. (1998) Multivessel coronary thrombosis treated with abciximab (reopro®) in a patient with essential thrombocythemia. Clinical Cardiology 21:2, 134-138
CrossRef732
Toshiaki Aoki, Dermot Cox, Kayoko Senzaki, Jiro Seki, Akito Tanaka, Hisashi Takasugi, Yukio Motoyama. (1998) Comparison of the Antithrombotic Effects of FK633, GPIIb/IIIa Antagonist, and Aspirin in a Guinea Pig Thrombosis Model. Thrombosis Research 89:3, 129-136
CrossRef733
Anoop Chauhan, Erik Vu, Donald R. Ricci, Christopher E. Buller, Michael D. Moscovich, Stephanie Monkman, Ian M. Penn. (1998) Multiple coronary stenting in unstable angina: Early and late clinical outcomes. Catheterization and Cardiovascular Diagnosis 43:1, 11-16
CrossRef734
M.Musa Khan, Stephen G. Ellis, Frank V. Aguirre, Harlan F. Weisman, Nancy M. Wildermann, Robert M. Califf, Eric J. Topol, Neal S. Kleiman. (1998) Does Intracoronary Thrombus Influence the Outcome of High Risk Percutaneous Transluminal Coronary Angioplasty? Clinical and Angiographic Outcomes in a Large Multicenter Trial. Journal of the American College of Cardiology 31:1, 31-36
CrossRef735
Edgar R. Gonzalez. (1998) Antiplatelet therapy in atherosclerotic cardiovascular disease. Clinical Therapeutics 20, B18-B41
CrossRef736
Patrick Henry, Kamel Boughalem, Jean-Paul Rinaldi, Serge Makowski, Kalife Khalife, Jean-Léon Guermonprez, Didier Blanchard. (1998) Use of anti-GP IIb-IIIa in acute thrombosis after intracoronary stent implantation. Catheterization and Cardiovascular Diagnosis 43:1, 105-107
CrossRef737
Koon-Hou Mak, Arthur T. H. Tan, Charles Chan, Tian-Hai Koh, Eric J. Topol. (1998) The Clinical Impact of Platelet Glycoprotein IIb/IIIa Receptor Blockade in Cardiovascular Medicine. Japanese Circulation Journal 62:4, 233-243
CrossRef738
Rien Vander Zee, Toyoaki Murohara, Jonathan Passeri, Marianne Kearney, David A. Cheresh, Jeffrey M. Isner. (1998) Reduced Intimal Thickening Following αvβ 3 Blockade is Associated with Smooth Muscle Cell Apoptosis. Cell Communication and Adhesion 6:5, 371-379
CrossRef739
Uttam C Garg, Donna K Arnett, Aaron R Folsom, Michael A Province, Roger R Williams, John H Eckfeldt. (1998) Lack of Association between Platelet Glycoprotein IIb/IIIa Receptor PlA Polymorphism and Coronary Artery Disease or Carotid Intima-Media Thickness. Thrombosis Research 89:2, 85-89
CrossRef740
William W. O'Neill. (1998) Rails, reopro™, and the real world. Catheterization and Cardiovascular Diagnosis 43:1, 7-8
CrossRef741
Gregg W. Stone, Bruce R. Brodie, John J. Griffin, Marie Claude Morice, Costantino Costantini, Frederick G. St. Goar, Paul A. Overlie, Jeffrey J. Popma, JoAnn McDonnell, Denise Jones, William W. O’Neill, Cindy L. Grines. (1998) Prospective, Multicenter Study of the Safety and Feasibility of Primary Stenting in Acute Myocardial Infarction: In-Hospital and 30-Day Results of the PAMI Stent Pilot Trial. Journal of the American College of Cardiology 31:1, 23-30
CrossRef742
Randolph L. Geary, Seppo T. Nikkari, William D. Wagner, J.Koudy Williams, Michael R. Adams, Richard H. Dean. (1998) Wound healing: A paradigm for lumen narrowing after arterial reconstruction. Journal of Vascular Surgery 27:1, 96-108
CrossRef743
P. Macke Consigny. (1998) Pharmacologic Manipulation of Restenosis. Journal of Vascular and Interventional Radiology 9:1, 291-294
CrossRef744
J. N. Hamburger, P. W. Serruys. (1997) Treatment of thrombus containing lesions in diseased native coronary arteries and saphenous vein bypass grafts using the angioJet rapid thrombectomy system. Herz 22:6, 318-321
CrossRef745
J.E. Joseph, S.J. Machin. (1997) New antiplatelet drugs. Blood Reviews 11:4, 178-190
CrossRef746
Glenn C. Hunter. (1997) The clinical and pathologic spectrum of recurrent carotid stenosis. The American Journal of Surgery 174:6, 583-588
CrossRef747
Davees Joseph, V. V. Bashi, Soma Guhathakurtha, H. Harilal, Aju Jacob, Thomas George, S. Suguna. (1997) Saphenous vein covered stenting for right coronary artery lesion containing thrombus. Catheterization and Cardiovascular Diagnosis 42:4, 427-429
CrossRef748
C Cannon. (1997) Clinical perspectives on the use of composite endpoints. Controlled Clinical Trials 18:6, 517-529
CrossRef749
Joseph B Muhlestein, Labros A Karagounis, Sanjeev Treehan, Jeffrey L Anderson. (1997) “Rescue” Utilization of Abciximab for the Dissolution of Coronary Thrombus Developing as a Complication of Coronary Angioplasty. Journal of the American College of Cardiology 30:7, 1729-1734
CrossRef750
H. Darius, M. Buerke, J. P. Boissel, T. Grosser, K. Veit, K. Zacharowski, J. Meyer. (1997) Lokale Medikamentengabe und Gentherapie. Herz 22:6, 347-354
CrossRef751
Braunwald, Eugene, . (1997) Cardiovascular Medicine at the Turn of the Millennium: Triumphs, Concerns, and Opportunities. New England Journal of Medicine 337:19, 1360-1369
Full Text752
Bernhard R Winkelmann, Ralf Zahn, Hans Ulrich Stilz. (1997) Overview of clinical trials with glycoprotein IIb-IIIa receptor antagonists in the prevention and management of coronary. Expert Opinion on Investigational Drugs 6:11, 1623-1642
CrossRef753
Nigel Wheeldon, David Cumberland. (1997) Pharmacologic prevention of acute ischemic complications of coronary angioplasty. Catheterization and Cardiovascular Diagnosis 42:3, 249-256
CrossRef754
Karen M. Brashear, Jacquelynn J. Cook, Bohumil Bednar, Rodney A. Bednar, Robert J. Gould, Wasyl Halczenko, Marie A. Holahan, Robert J. Lynch, George D. Hartman, John.H. Hutchinson. (1997) Nonpeptide glycoprotein IIb/IIIa inhibitors: 18. Indole alpha-sulfonamide acids are potent inhibitors of platelet aggregation. Bioorganic & Medicinal Chemistry Letters 7:21, 2793-2798
CrossRef755
J.Sheppard Mondy, J.Koudy Williams, Michael R. Adams, Richard H. Dean, Randolph L. Geary. (1997) Structural determinants of lumen narrowing after angioplasty in atherosclerotic nonhuman primates. Journal of Vascular Surgery 26:5, 875-883
CrossRef756
Pinak B Shah, Waqar H Ahmed, Peter Ganz, John A Bittl. (1997) Bivalirudin Compared With Heparin During Coronary Angioplasty for Thrombus-Containing Lesions. Journal of the American College of Cardiology 30:5, 1264-1269
CrossRef757
Carl L. Tommaso, Bruce A. Bergelson. (1997) Diminishing impact of in-lab complications. Catheterization and Cardiovascular Diagnosis 42:3, 257-258
CrossRef758
(1997) Platelet Glycoprotein IIb/IIIa Receptor Blockade after Coronary Angioplasty. New England Journal of Medicine 337:17, 1243-1245
Full Text759
J. David Talley. (1997) Progress in Interventional Cardiology. Journal of Interventional Cardiology 10:5, 387-390
CrossRef760
Boulos Toursarkissian, David Schwartz, Paul R. Eisenberg, Brian G. Rubin. (1997) Arterial thrombosis induces early upregulation of intercellular adhesion molecule in the media. Journal of Vascular Surgery 26:4, 663-669
CrossRef761
Steven R. Bailey, Edward O'Leary, Robert Chilton. (1997) Angioscopic evaluation of site-specific administration of ReoPro. Catheterization and Cardiovascular Diagnosis 42:2, 181-184
CrossRef762
David Rawitscher, Thomas N. Levin, Ian Cohen, Ted Feldman. (1997) Rapid reversal of no-reflow using abciximab after coronary device intervention. Catheterization and Cardiovascular Diagnosis 42:2, 187-190
CrossRef763
David K. Murdock, Timothy Logemann, Mark T. Hoffmann, Karen J. Olson, Richard S. Engelmeier. (1997) Feature topic: Clinical use of abciximab: Coronary artery stenting for suboptimal PTCA results in acute myocardial infarction in patients treated with abciximab: Early and six-month outcome. Catheterization and Cardiovascular Diagnosis 42:2, 173-179
CrossRef764
GERALD C. TIMMIS, SANDEEP KHURANA. (1997) Advances in Antiplatelet Therapy in Coronary Artery Disease: Importance of the Platelet GPIIb/IIIa Receptor. Journal of Interventional Cardiology 10:5, 327-333
CrossRef765
Paul T. Vaitkus, William T. Witmer, Richard G. Brandenburg, Susannah K. Wells, Jonathan B. Zehnacker. (1997) Economic Impact of Angioplasty Salvage Techniques, With an Emphasis on Coronary Stents: A Method Incorporating Costs, Revenues, Clinical Effectiveness and Payer Mix. Journal of the American College of Cardiology 30:4, 894-900
CrossRef766
MERVYN S. GOTSMAN, A. TEDDY WEISS, YOSEPH ROZENMAN, CHAIM LOTAN, DORON ZAHGER, MORRIS MOSSERI. (1997) Prehospital Thrombolysis in Acute Myocardial Infarction Salvages Myocardium. Journal of Interventional Cardiology 10:5, 315-325
CrossRef767
Dirk H Walter, Volker Schächinger, Mathias Elsner, Stefanie Dimmeler, Andreas M Zeiher. (1997) Platelet glycoprotein Illa polymorphisms and risk of coronary stent thrombosis. The Lancet 350:9086, 1217-1219
CrossRef768
Ken-ichi Suzuki, Yumiko Sakai, Nami Hisamichi, Yuta Taniuchi, Kazuo Sato, Chinami Terazaki, Seiji Kaku, Tomihisa Kawasaki, Shinya Yano, Osamu Inagaki, Yasuhiko Masuho. (1997) Comparison of the antiplatelet effect of YM337 and abciximab in rhesus monkeys. European Journal of Pharmacology 336:2-3, 169-176
CrossRef769
(1997) More on “Hybrid Revascularization”. New England Journal of Medicine 337:12, 861-862
Full Text770
M Qayyum. (1997) Glycoprotein IIb/IIIa Receptor Blockers in Acute Coronary Syndromes. ACC Current Journal Review 6:5, 15-19
CrossRef771
Ajith Kumar, Howard C Herrmann. (1997) Tirofiban: an investigational plateletglycoprotein IIb/IIIa receptor antagonist. Expert Opinion on Investigational Drugs 6:9, 1257-1267
CrossRef772
P. Robbins, M. Forrest, S. von Kier, D. Royston. (1997) A454 THROMBELASTOGRAPHIC EVALUATION OF THE INTERACTION BETWEEN REOPRO [trademark symbol] (C7E3 FAB) AND HEMOSTATIC DRUGS. Anesthesiology 87:Supplement, 454A
CrossRef773
PETER B. AMSTERDAM, JAMES E. TCHENG. (1997) Platelet and Thrombin Inhibitors as Adjuncts to Thrombolytic Therapy and Percutaneous Coronary Interventions: A Review. Journal of Interventional Cardiology 10:4, 249-263
CrossRef774
Victor A Umans, Paul H Kloeg, Jean Bronzwaer. (1997) The CAPTURE trial. The Lancet 350:9075, 445
CrossRef775
R. J. Gumina, P. J. Newman, D. Kenny, D. C. Warltier, G. J. Gross. (1997) The leukocyte cell adhesion cascade and its role in myocardial ischemia-reperfusion injury. Basic Research in Cardiology 92:4, 201-213
CrossRef776
Arnoud WJ van't Hof, Aylee Liem, Menko-Jan de Boer, Felix Zijlstra. (1997) Clinical value of 12-lead electrocardiogram after successful reperfusion therapy for acute myocardial infarction. The Lancet 350:9078, 615-619
CrossRef777
Con N. Aroney. (1997) Improving the results of coronary angioplasty. Australian and New Zealand Journal of Medicine 27:4, 510-514
CrossRef778
Kenneth G Lehmann, Scott T Ferris, Samantha J Heath-Lange. (1997) Maintenance of Hemostasis After Invasive Cardiac Procedures: Implications for Outpatient Catheterization. Journal of the American College of Cardiology 30:2, 444-451
CrossRef779
Sorin J. Brener, Floyd D. Loop, Bruce W. Lytle, Stephen G. Ellis, Delos M. Cosgrove, Eric J. Topol. (1997) A profile of candidates for repeat myocardial revascularization: Implications for selection of treatment. The Journal of Thoracic and Cardiovascular Surgery 114:2, 153-161
CrossRef780
A.Michael Lincoff, Robert M. Califf, Keaven M. Anderson, Harlan F. Weisman, Frank V. Aguirre, Neal S. Kleiman, Robert A. Harrington, Eric J. Topol. (1997) Evidence for Prevention of Death and Myocardial Infarction With Platelet Membrane Glycoprotein IIb/IIIa Receptor Blockade by Abciximab (c7E3 Fab) Among Patients With Unstable Angina Undergoing Percutaneous Coronary Revascularization. Journal of the American College of Cardiology 30:1, 149-156
CrossRef781
James J. Glazier, Jeffrey A. Hirst, Francis J. Kiernan, Daniel B. Fram, Adel M. Eldin, Charles A. Primiano, Joseph F. Mitchel, Raymond G. McKay. (1997) Site-specific intracoronary thrombolysis with urokinase-coated hydrogel balloons: Acute and follow-up studies in 95 patients. Catheterization and Cardiovascular Diagnosis 41:3, 246-253
CrossRef782
The EPILOG Investigators. (1997) Platelet Glycoprotein IIb/IIIa Receptor Blockade and Low-Dose Heparin during Percutaneous Coronary Revascularization. New England Journal of Medicine 336:24, 1689-1697
Full Text783
Holmes, David R. Jr., . (1997) Preventing Coronary Restenosis and Complications. New England Journal of Medicine 336:24, 1748-1749
Full Text784
The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. (1997) A Clinical Trial Comparing Primary Coronary Angioplasty with Tissue Plasminogen Activator for Acute Myocardial Infarction. New England Journal of Medicine 336:23, 1621-1628
Full Text785
TM Reilly, SA Mousa, AL Racanelli. (1997) New antiplatelet drugs. Expert Opinion on Emerging Drugs 2:1, 73-92
CrossRef786
Peter P. de Jaegere, Frank D. Eefting, Pieter R. Stella, Huub W. Meijburg, Pieter W. Westerhof, Etienne Robles de Medina. (1997) Revascularization of patients with coronary artery disease: The interventional cardiologist's perspective. The Annals of Thoracic Surgery 63:6, S23-S27
CrossRef787
SA Douglas, GZ Feuerstein. (1997) Pharmacological treatments for restenosis. Expert Opinion on Emerging Drugs 2:1, 29-72
CrossRef788
EULOGIO GARCÍA. (1997) In-Hospital Results of the Wiktor Stent in Acute Myocardial Infarction. Journal of Interventional Cardiology 10:3, 231-235
CrossRef789
Atsushi Kato. (1997) The biologic and clinical spectrum of Glanzmann's Thrombasthenia: implications of integrin αIIbβ3 for its pathogenesis. Critical Reviews in Oncology/Hematology 26:1, 1-23
CrossRef790
(1997) Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. The Lancet 349:9063, 1429-1435
CrossRef791
Freek WA Verheugt. (1997) In search of a superaspirin for the heart. The Lancet 349:9063, 1409-1410
CrossRef792
(1997) Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. The Lancet 349:9063, 1422-1428
CrossRef793
Takashi Sugimori, Diana L Griffith, M Amin Arnaout. (1997) Emerging paradigms of integrin ligand binding and activation. Kidney International 51:5, 1454-1462
CrossRef794
Randy K. Bottner, Kenneth R. Hardigan. (1997) Cardiac tamponade following stent implantation with adjuvant platelet IIb/IIIa receptor inhibitor administration. Catheterization and Cardiovascular Diagnosis 40:4, 380-382
CrossRef795
KOON-HOU MAK, ERIC J. TOPOL. (1997) Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization. Annals of the New York Academy of Sciences 811:1 Atheroscleros, 255-288
CrossRef796
I. Nyamekye, D. Costa, M. Raphael, C.C.R. Bishop. (1997) Thrombosis and restenosis after peripheral angioplasty: Does acute 111indium-platelet accumulation predict angioplasty outcome?. European Journal of Vascular and Endovascular Surgery 13:4, 388-393
CrossRef797
JAMES J. FERGUSON. (1997) New Pharmacological Adjuncts for Coronary Stenting: Can New Anticoagulants Improve Outcomes?. Journal of Interventional Cardiology 10:2, 155-159
CrossRef798
J. David Talley, Thomas D. Conley. (1997) Progress in Interventional Cardiology. Journal of Interventional Cardiology 10:2, 163-169
CrossRef799
Fernando Alfonso, Pedro Rodriguez, Paul Phillips, Javier Goicolea, Rosana Hernández, Maria-José Pérez-Vizcayno, Antonio Fernández-Ortiz, Javier Segovia, Camino Bañuelos, Paloma Aragoncillo, Carlos Macaya. (1997) Clinical and Angiographic Implications of Coronary Stenting in Thrombus-Containing Lesions. Journal of the American College of Cardiology 29:4, 725-733
CrossRef800
Georg Kottirsch, Hans-Günther Zerwes, Nigel S. Cook, Carlo Tapparelli. (1997) Beta-amino acid derivatives as orally active non-peptide fibrinogen receptor antagonists. Bioorganic & Medicinal Chemistry Letters 7:6, 727-732
CrossRef801
Suraj G. Kamat, Nancy A. Turner, Konstantinos Konstantopoulos, J. David Hellums, Larry V. McIntire, Neal S. Kleiman, Joel L. Moake. (1997) Effects of Integrelin on Platelet Function in Flow Models of Arterial Thrombosis. Journal of Cardiovascular Pharmacology 29:2, 156-163
CrossRef802
Randy K. Bottner, Kenneth R. Hardigan. (1997) High-speed rotational ablation for in-stent restenosis. Catheterization and Cardiovascular Diagnosis 40:2, 144-149
CrossRef803
Paul M Ridker, Charles H Hennekens, Christian Schmitz, Meir J Stampfer, Klaus Lindpaintner. (1997) PIA1/A2 polymorphism of platelet glycoprotein IIIa and risks of myocardial infarction, stroke, and venous thrombosis. The Lancet 349:9049, 385-388
CrossRef804
(1997) Bypass Angioplasty Revascularization Investigation. New England Journal of Medicine 336:2, 136-138
Full Text805
Timothy K. Liem, Rosemary Teel, Shivendra Shukla, Donald Silver. (1997) The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodies. Journal of Vascular Surgery 25:1, 124-130
CrossRef806
Kenneth R. Chien, Mitsuyuki Shimizu, Masahiko Hoshijima, Susumu Minamisawa, Andrew A. Grace. (1997) Toward Molecular Strategies for Heart Disease. Japanese Circulation Journal 61:2, 91-118
CrossRef807
Philip E. Greilich, Barbara M. Alving, Kathleen L. OʼNeill, Audrey S. Chang, Thomas J. Reid. (1997) A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized Patients. Anesthesia & Analgesia 84:1, 31-38
CrossRef808
Shigeyuki Takada, Tomofumi Kurokawa, Keiko Miyazaki, Susumu Iwasa, Yasuaki Ogawa. (1997) Sustained release of a water-soluble GP IIb/IIIa antagonist from copoly(dl-lactic/glycolic)acid microspheres. International Journal of Pharmaceutics 146:2, 147-157
CrossRef809
Herve Le Breton, Edward F. Plow, Eric J. Topol. (1996) Role of Platelets in Restenosis After Percutaneous Coronary Revascularization. Journal of the American College of Cardiology 28:7, 1643-1651
CrossRef810
Kumar Sridhar, David Fischman, Sheldon Goldberg, Andrew Zalewski, Paul Walinsky, Doranne Porter, Sarah Fenton, Bhavdeep Gupta, Randal Rake, Sharon Gebhardt, Michael Savage. (1996) Peripheral vascular complications after intracoronary stent placement: Prevention by use of a pneumatic vascular compression device. Catheterization and Cardiovascular Diagnosis 39:3, 224-229
CrossRef811
Pascal J. Goldschmidt-Clermont, Steven P. Schulman, Nisha C. Chandra, Dmitriy Grigoryev, Kirk R. Dise, Manish Sagar, Robert J. Fox, Lindsay D. Coleman, Pamela Ouyang, Kenneth L. Baughman, Gary Gerstenblith, Paul F. Bray, Christine Richardson, Frank C. Dorsey, Charles Du Mee, Michael M. Kitt, . (1996) Refining the treatment of women with unstable angina-A randomized, double-blind, comparative safety and efficacy evaluation of integrelin™ versus aspirin in the management of unstable angina. Clinical Cardiology 19:11, 869-874
CrossRef812
Bruce F. Waller, Edward T.A. Fry, Thomas F. Peters, James B. Hermiller, Charles M. Orr, James Vantassel, Cass A. Pinkerton. (1996) Abrupt (<1 day), acute (<1 week), and early (<1 month) vessel closure at the angioplasty site. Morphologic observations and causes of closure in 130 necropsy patients undergoing coronary angioplasty. Clinical Cardiology 19:11, 857-868
CrossRef813
Karl R. Karsch, Melitta B. Preisack, Rainer Baildon, Volker Eschenfelder, David Foley, Eulogio J. Garcia, Martin Kaltenbach, Christoph Meisner, Hans K. Selbmann, Patrick W. Serruys, Man F. Shiu, Martin Sujatta, Raoul Bonan. (1996) Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Journal of the American College of Cardiology 28:6, 1437-1443
CrossRef814
Committee Members, Thomas J. Ryan, Jeffrey L. Anderson, Elliott M. Antman, Blaine A. Braniff, Neil H. Brooks, Robert M. Califf, L. David Hillis, Loren F. Hiratzka, Elliott Rapaport, Barbara J. Riegel, Richard O. Russell, Earl E. Smith, W. Douglas Weaver, James L. Ritchie, Melvin D. Cheitlin, Kim A. Eagle, Timothy J. Gardner, Arthur Garson, Raymond J. Gibbons, Richard P. Lewis, Robert A. O'Rourke, Thomas J. Ryan. (1996) ACC/AHA guidelines for the management of patients with acute myocardial infarction. Journal of the American College of Cardiology 28:5, 1328-1419
CrossRef815
Bittl, John A., . (1996) Advances in Coronary Angioplasty. New England Journal of Medicine 335:17, 1290-1302
Full Text816
JEFFREY LEFKOVITS, JAMES C. BLANKENSHIP, KEAVEN M. ERSON, GAIL L. STONER, J.DAVID TALLEY, SETH J. WORLEY, HARLAN F. WEISMAN, ROBERT M. CALIFF, ERIC J. TOPOL. (1996) Increased Risk of Non-Q Wave Myocardial Infarction After Directional Atherectomy Is Platelet Dependent: Evidence From the EPIC Trial. Journal of the American College of Cardiology 28:4, 849-855
CrossRef817
Mohamed El Setiha, Mamdouh El Gamal, Jacques Koolen, Nico Pijls, Hans Bonnier, Rolf Michels. (1996) Coronary stenting for failed angioplasty in acute myocardial infarction. Catheterization and Cardiovascular Diagnosis 39:2, 149-154
CrossRef818
Richard D. Schultz, Richard R. Heuser, Carol Hatler, Dianne Frey. (1996) Use of c7E3 Fab in conjunction with primary coronary stenting for acute myocardial infarctions complicated by cardiogenic shock. Catheterization and Cardiovascular Diagnosis 39:2, 143-148
CrossRef819
Samuel Rodriguez, Warren K. Laskey. (1996) Editorial comment: Primary DCA for MI: An exception to the “bigger is better” hypothesis?. Catheterization and Cardiovascular Diagnosis 39:2, 166-167
CrossRef820
J. David Talley. (1996) Progress in Interventional Cardiology. Journal of Interventional Cardiology 9:5, 413-419
CrossRef821
JEFFREY L. ANDERSON, SANJEEV TREHAN. (1996) The TEAM Studies: A Review. Journal of Interventional Cardiology 9:5, 361-372
CrossRef822
James H. O'Keefe, Robert D. Conn, Carl J. Lavie, Timothy M. Bateman. (1996) The New Paradigm for Coronary Artery Disease: Altering Risk Factors, Atherosclerotic Plaques, and Clinical Prognosis. Mayo Clinic Proceedings 71:10, 957-965
CrossRef823
The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb Investigators. (1996) A Comparison of Recombinant Hirudin with Heparin for the Treatment of Acute Coronary Syndromes. New England Journal of Medicine 335:11, 775-782
Full Text824
Lowell F. Satler, Gary S. Mintz. (1996) Editorial comment: Analysis of intracoronary thrombus prior to coronary stenting using the dispatch infusion catheter. Catheterization and Cardiovascular Diagnosis 38:4, 415-416
CrossRef825
Simoons, Maarten L., . (1996) Myocardial Revascularization — Bypass Surgery or Angioplasty?. New England Journal of Medicine 335:4, 275-277
Full Text826
David R. Boston, William H. Barry, Assaad Malouf. (1996) Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty. Clinical Cardiology 19:7, 536-542
CrossRef827
Akito Tanaka, Hiroyoshi Sakai, Takatoshi Ishikawa, Isao Nakanishi, Mitsuru Ohkubo, Toshiaki Aoki, Yukio Motoyama, Hisashi Takasugi. (1996) Design, synthesis, and evaluation of fibrinogen inhibitors, ω-(p-amidinophenoxy) alkanoylaspartic acid derivatives. Bioorganic & Medicinal Chemistry Letters 6:13, 1443-1448
CrossRef828
Jeffrey S. Bostwick, Charles J. Kasiewski, Valeria Chu, Scott I. Klein, Ralph D. Sabatino, Mark H. Perrone, Christopher T. Dunwiddie, Jacquelynn J. Cook, Robert J. Leadley. (1996) Anti-thrombotic activity of RG13965, a novel platelet fibrinogen receptor antagonist. Thrombosis Research 82:6, 495-507
CrossRef829
D. J. Amos, A. M. Tonkin, H. D. White. (1996) New insights into the pathogenesis, prevention and management of acute coronary syndromes. Australian and New Zealand Journal of Medicine 26:3, 344-348
CrossRef830
David J. Moliterno, Eric J. Topol. (1996) Another step toward resolving the contrast controversy. Journal of the American College of Cardiology 27:6, 1387-1389
CrossRef831
Cindy L. Grines, Theodore L. Schreiber, Vicky Savas, Denise E. Jones, Frank J. Zidar, Vellappillil Gangadharan, Marc Brodsky, Robert Levin, Robert Safian, Sylvia Puchrowicz-Ochocki, Mark D. Castellani, William W. O'Neill. (1996) A randomized trial of low osmolar ionic versus nonionic contrast media in patients with myocardial infarction or unstable angina undergoing percutaneous transluminal coronary angioplasty. Journal of the American College of Cardiology 27:6, 1381-1386
CrossRef832
Michael Gottsauner-Wolf, David J. Moliterno, A. Michael Lincoff, Eric J. Topol. (1996) Restenosis-an open file. Clinical Cardiology 19:5, 347-356
CrossRef833
Cleveland M Moore, Mohammad Ehlayel, Lily E Leiva, Ricardo U Sorensen. (1996) New Concepts in the Immunology of Sickle Cell Disease. Annals of Allergy, Asthma & Immunology 76:5, 385-403
CrossRef834
Gregory T. Almony, Jeffrey Lefkovits, Eric J. Topol. (1996) Antiplatelet and anticoagulant use after myocardial infarction. Clinical Cardiology 19:5, 357-365
CrossRef835
Jane Phillips-Hughes, Krishna Kandarpa. (1996) Restenosis: Pathophysiology and Preventive Strategies
. Journal of Vascular and Interventional Radiology 7:3, 321-333
CrossRef836
Handin, Robert I., . (1996) Platelets and Coronary Artery Disease. New England Journal of Medicine 334:17, 1126-1128
Full Text837
Weiss, Ethan J., Bray, Paul F., Tayback, Matthew, Schulman, Steven P., Kickler, Thomas S., Becker, Lewis C., Weiss, James L., Gerstenblith, Gary, Goldschmidt-Clermont, Pascal J., . (1996) A Polymorphism of a Platelet Glycoprotein Receptor as an Inherited Risk Factor for Coronary Thrombosis. New England Journal of Medicine 334:17, 1090-1094
Full Text838
J. Kereiakes, Neal S. Kleiman, John Ambrose, Marc Cohen, Samuel Rodriguez, Theresa Palabrica, Howard C. Herrmann, Joseph M. Sutton, W.Douglas Weaver, Donna B. McKee, Virginia Fitzpatrick, Frederic L. Sax. (1996) Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. Journal of the American College of Cardiology 27:3, 536-542
CrossRef839
Barbara Marie Alving, Andrew J. Carter. (1996) Newer antithrombotic agents: Potential for clinical use in venous and arterial thrombosis. Journal of Thrombosis and Thrombolysis 2:4, 285-288
CrossRef840
Eric Eeckhout, Lukas Kappenberger, Jean-Jacques Goy. (1996) Stents for intracoronary placement: Current status and future directions. Journal of the American College of Cardiology 27:4, 757-765
CrossRef841
Toshiaki Aoki, Dermot Cox, Kayoko Senzaki, Jiro Seki, Akihito Tanaka, Hisashi Takasugi, Yukio Motoyama. (1996) The anti-platelet and anti-thrombotic effects of FK633, a peptide-mimetic antagonist. Thrombosis Research 81:4, 439-450
CrossRef842
Lloyd W. Klein, Jai B. Agarwal. (1996) Editorial comment: When we “act” on ACT levels: Activated clotting time measurements to guide heparin administration during and after interventional procedures. Catheterization and Cardiovascular Diagnosis 37:2, 154-157
CrossRef843
Hugo Cate, Michael T. Nurmohamed, Jan W. Cate. (1996) Developments in antithrombotic therapy: state of the art anno 1996. Pharmacy World and Science 18:6, 195-203
CrossRef844
R. Voss, T. Scarlat, A. Matzdorff, H. Tillmanns. (1996) Flow cytometric detection of platelet activation in patients undergoing diagnostic and interventional coronary angiography. Platelets 7:4, 237-241
CrossRef845
Franz-Josef Neumann, Meinrad Gawaz, Ilka Ott, Andreas May, Georg Mössmer, Albert Schömig. (1996) Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary palmaz-schatz stenting. Journal of the American College of Cardiology 27:1, 15-21
CrossRef846
Gustaaf A. Dekker, Herman P. van Geijn. (1996) Endothelial dysfunction in preeclampsia. Part II: Reducing the adverse consequences of endothelial cell dysfunction in preeclampsia; therapeutic perspectives. Journal of Perinatal Medicine 24:2, 119-139
CrossRef847
Neal S. Kleiman, Albert E. Raizner, Robert Jordan, Ann L. Wang, Daniel Norton, Kenneth F. Mace, Alaknanda Joshi, Barry S. Coller, Harlan F. Weisman. (1995) Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors. Journal of the American College of Cardiology 26:7, 1665-1671
CrossRef848
Shinya Yano, Seiji Kaku, Ken-Ichi Suzuki, Chinami Terazaki, Toshiko Sakayori, Tomihisa Kawasaki, Koji Kawamura, Yuji Sugita, Kenji Hoshino, Yasuhiko Masuho. (1995) Natural antibodies against the immunoglobulin F(ab′)2 fragment cause elimination of antigens recognized by the F(ab′)2 from the circulation. European Journal of Immunology 25:11, 3128-3133
CrossRef849
D CUTLER, C BODE, M RUNGE. (1995) The Promise of New Genetically Engineered Plasminogen Activators
CrossRef850
Bittl, John A., Strony, John, Brinker, Jeffrey A., Ahmed, Waqar H., Meckel, Clyde R., Chaitman, Bernard R., Maraganore, John, Deutsch, Ezra, Adelman, Burt, . (1995) Treatment with Bivalirudin (Hirulog) as Compared with Heparin during Coronary Angioplasty for Unstable or Postinfarction Angina. New England Journal of Medicine 333:12, 764-769
Full Text851
Serruys, Patrick W., Herrman, Jean-Paul R., Simon, Rudiger, Rutsch, Wolfgang, Bode, Christoph, Laarman, Gert-Jan, van Dijk, Rene, van den Bos, Arjan A., Umans, Victor A.W.M., Fox, Keith A.A., Close, Philip, Deckers, Jaap W., . (1995) A Comparison of Hirudin with Heparin in the Prevention of Restenosis after Coronary Angioplasty. New England Journal of Medicine 333:12, 757-764
Full Text852
PREDIMAN K. SHAH. (1995) New Antithrombotic Drugs for Systemic and Local Delivery for Coronary Artery Disease. Journal of Interventional Cardiology 8:4, 427-437
CrossRef853
Enrique P. Gurfinkel, Eustaquio J. Manos, Ricardo I. Mejaíl, Miguel A. Cerdá, Ernesto A. Duronto, Claudio N. García, Ana M. Daroca, Branco Mautner. (1995) Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. Journal of the American College of Cardiology 26:2, 313-318
CrossRef854
Joseph A. Puma, Michael H. Sketch, James E. Tcheng, Robert A. Harrington, Harry R. Phillips, Richard S. Stack, Robert M. Califf. (1995) Percutaneous revascularization of chronic coronary occlusions: An overview. Journal of the American College of Cardiology 26:1, 1-11
CrossRef855
Epstein, Franklin H., , Lefkovits, Jeffrey, Plow, Edward F., Topol, Eric J., . (1995) Platelet Glycoprotein IIb/IIIa Receptors in Cardiovascular Medicine. New England Journal of Medicine 332:23, 1553-1559
Full Text856
Seiji Kaku, Tomihisa Kawasaki, Yumiko Sakai, Yuta Taniuchi, Shinya Yano, Ken-ichi Suzuki, Chinami Terazaki, Koji Kawamura, Yasuhiko Masuho, Noboru Satoh, Toichi Takenaka, Kennichi Yanagi, Norio Ohshima. (1995) Antithrombotic effect of a humanized anti-GPIIb/IIIa monoclonal antibody, YM207, in a photochemically induced thrombosis model in monkeys. European Journal of Pharmacology 279:2-3, 115-121
CrossRef857
R.G. Humphries, M.J. Robertson, P. Leff. (1995) A novel series of P2T purinoceptor antagonists: definition of the role of ADP in arterial thrombosis. Trends in Pharmacological Sciences 16:6, 179-181
CrossRef858
Lesle Oleksowicz, Janice P. Dutcher. (1995) Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies. Medical Oncology 12:2, 95-102
CrossRef859
Christopher P. Cannon, Eugene Braunwald. (1995) Hirudin: Initial results in acute myocardial infarction, unstable angina and angioplasty. Journal of the American College of Cardiology 25:7, S30-S37
CrossRef860
M. A. Bettmann. (1995) Future directions in vascular interventional radiology. European Radiology 5:S2, S99-S102
CrossRef861
Jingbo Gao, Sanford J. Shattil. (1995) An enzyme-linked immunosorbent assay to identify inhibitors of activation of platelet integrin αIIbβ3. Journal of Immunological Methods 181:1, 55-64
CrossRef862
Iwao Ojima, Subrata Chakravarty, Qing Dong. (1995) Antithrombotic agents: From RGD to peptide mimetics. Bioorganic & Medicinal Chemistry 3:4, 337-360
CrossRef863
Steven Coutré, M.D, Lawrence Leung, M.D. (1995) NOVEL ANTITHROMBOTIC THERAPEUTICS TARGETED AGAINST PLATELET GLYCOPROTEIN IIb/IIIa. Annual Review of Medicine 46:1, 257-265
CrossRef864
J. David Talley. (1995) NEWS & VIEWS. Journal of Interventional Cardiology 8:1, 102-106
CrossRef865
Robert A. Harrington. (1995) Antithrombotic therapy during percutaneous coronary intervention. Journal of Thrombosis and Thrombolysis 2:1, 21-28
CrossRef866
Christopher P. Cannon, Russell Tracy. (1995) Clotting for the clinician: An overview of thrombosis and antithrombotic therapy. Journal of Thrombosis and Thrombolysis 2:2, 95-106
CrossRef867
Paul R. Eisenberg. (1995) Novel antithrombotic strategies for the treatment of coronary artery thrombosis: A critical appraisal. Journal of Thrombosis and Thrombolysis 1:3, 237-249
CrossRef868
S. G. Panzer-Knodle, P. Jacqmin, J. D. Page, N. S. Nicholson, J. A. Zablocki, V. W. Engleman, L. P. Feigen. (1995) Characterization of Binding of an RGD Mimetic, [ 3 H]-SC-52012, to Platelet GPIIb/IIIa. Platelets 6:5, 288-295
CrossRef869
B. Rocca, R. De Cristofaro, M. Della Ventura, B. Bizzi, R. Landolfi. (1995) Kinetics of Free Platelet Decrease After ADP: Effect of Fibrinogen Binding Inhibitors. Platelets 6:3, 152-159
CrossRef870
Yangsoo Jang, A.Michael Lincoff, Edward F. Plow, Eric J. Topol. (1994) Cell adhesion molecules in coronary artery disease. Journal of the American College of Cardiology 24:7, 1591-1601
CrossRef871
C. Bode, T. K. Nordt, M. S. Runge. (1994) Thrombolytic therapy in acute myocardial infarction—Selected recent developments. Annals of Hematology 69:4, S35-S40
CrossRef872
D. C. Gulba, R. Dechend. (1994) Thrombolysis in thromboembolic diseases. Annals of Hematology 69:4, S41-S57
CrossRef873
C. CHRISTOPOULOS. (1994) Platelet surface IgG in patients receiving infusions of Fab fragments of a chimaeric monoclonal antibody to glycoprotein IIb-IIIa. Clinical & Experimental Immunology 98:1, 6-11
CrossRef874
M. G. Davies, P.-O. Hagen. (1994) Pathobiology of intimal hyperplasia. British Journal of Surgery 81:9, 1254-1269
CrossRef875
DANIEL B. MARK. (1994) Costs of Interventional Cardiac Procedures. Journal of Interventional Cardiology 7:4, 369-378
CrossRef876
J. David Talley, Frank V. Aguirre. (1994) Progress in Interventional Cardiology. Journal of Interventional Cardiology 7:4, 389-394
CrossRef877
MaryR. Cahill, M.G. Macey, J.R. Dawson, A.C. Newland. (1994) Prevention of restenosis after angioplasty. The Lancet 343:8909, 1361
CrossRef878
Harker, Laurence A., . (1994) Platelets and Vascular Thrombosis. New England Journal of Medicine 330:14, 1006-1007
Full Text
- Letters
